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Introduction: Randomised controlled trials (RCT) have supplemented standard data 
collection with routine healthcare data. However, no RCTs in the United Kingdom have 
been conducted solely using routine data in oncology or secondary care. This thesis was 
undertaken to assess methods to enable the replacement or supplementation of 
standard RCT data. I present examples of routine data follow-up in two clinical settings: 
prostate and bladder cancer. 
 
Methods: Routine healthcare datasets were validated against reference patient data 
(for example, trial data and clinical noting), for their ability to identify trial outcomes of 
interest. Models were developed to algorithmically identify these outcomes from the 
routine data. Outcomes included: toxicity (serious adverse events), disease progression, 
treatments and the last known follow-up interaction.   
 
Results: Models were developed enabling the identification of outcomes of interest 
from the routine data, for example sepsis admissions and trial non-survival endpoints, 
for example, progression. This enabled the estimation of uncollected trial case report 
form (CRF) events, which subsequently have become of interest. I developed a novel 
routine data-derived endpoint, which correlated with standard trial endpoints, enabling 
estimation of treatment effects from routine data. I also developed a method to validate 
the feasibility of using routine data as the basis for oncology trial follow-up. 
 
Discussion: The nature of the routine data meant that models had to be developed to 
enable identification of some events of interest indirectly. Although routine data quality 
was shown to be improving, techniques had to be implemented, for example, through 
data querying, to ensure integrity, accuracy and relevance. Routine data can provide a 
robust method of trial data collection but needs to be used in combination with other 
data sources, such as, standard trial data or clinical noting. 
 
Conclusion: I propose that routine data are a feasible source of trial outcomes; however, 





1 CHAPTER ONE: Introduction 
1.1 Routinely collected data in healthcare 
There remains a clear therapeutic need for improved interventions in the field of 
oncology (2-4). Clinical trials, however, can be complex, resource intensive, expensive to 
perform and funding from the government and other sources is limited (5). It has been 
proposed that randomised controlled trials (RCT) are experiencing ‘increasingly 
prohibitive costs of conducting adequately powered studies’ (6). There are also other 
limitations, including lack of research into rare diseases (7) and often an inability to 
retrospectively answer new research questions due to inadequate case report form 
(CRF) outcomes reported for the new hypotheses. Therefore, clinical progress is 
restricted, and the rate of therapeutic advances has reduced. An article published in a 
series from the journal Nature (2014, (8)) investigated the success rates for 
interventional drugs in trials; they identified that drug productivity may be lower than 
previous estimates and concluded that, ‘adaptive clinical trial designs and improved 
methodologies and greater flexibility with alternative surrogate endpoints are areas in 
which this productivity can be improved’ (8). 
 
There are many methods to enhance trial design, for example, the use of a Multi-Arm-
Multi-Stage (MAMS) platform, whereby a simultaneous assessment of many different 
interventions can be undertaken against a single control arm (9). In addition, pre-
existing dataset analysis is another potential way to provide an enhanced framework to 
establish results (9). Routinely collected healthcare data may therefore, offer an 
efficient alternative for trials (10). 
 
Back in 2000 it was recognised that despite RCTs being widely accepted as the optimum 
method to assess outcomes, sometimes they have limited use. For example, if the RCT is 
not feasible (11). It was thus proposed in 2000 that routinely collected data could be 
used to alleviate these problems. However, it was also stated that there was ‘insufficient 
information on patients’ conditions [in the routine data] at discharge to enable a 
comparison of outcomes’ (11). Eleven years on from 2000 (2011), an article, 





are increasing (12) and alongside this increase in data, it has been proposed that 
healthcare data may now ‘resemble extremely closely the unknown distribution of the 
clinical phenomenon of interest’ (13). Over the last few decades there has been an 
increase in the size and complexity of data and its value in healthcare is increasingly 
being comprehended and accepted. It has been stated that, ‘the secret of human 
disease may lurk under the vast ocean of big data, waiting [for] us to decode and 
understand them’ (14).  
 
However, as initially identified in 2000, insufficient outcomes remain a limitation of such 
resources and therefore, analyses often require data mining techniques, or indirect 
identification through the use of alternative coding. Insufficiently reported routine data 
outcomes include, treatment and disease events such as non-survival endpoints, for 
example, disease progression (see further details in 1.5.3) and patient reported 
outcomes, such as quality of life data. One definition of data mining is the use of 
methods to analyse large volumes of data (15), but often these models do not get 
adapted for clinical use. In addition, coding errors and missing data are limitations (15). 
There are further challenges in harvesting these data (12), both practical and regulatory. 
Further practical issues include the difficulty of extracting useful information from a 
large, un-cleaned, exponentially growing, raw dataset with a potential lag between data 
collection and processing (16) and regulatory issues include, safeguarding, privacy, 
ownership and governance. These issues are discussed further below in section 1.3. 
 
Despite these limitations, the overriding opinion is that there is vast potential for these 
data to lead to improved patient outcomes. For example, leading to a longer and 
improved quality of life, through enhancing research and development with tools and 
algorithms to improve trial design (16). This potential can be seen with the timely set-up 
of the Health Data Research UK (HDR UK) initiative. HDR UK was established in April 
2018 (17) and one of its aims is to develop better, faster and more efficient clinical trials 
(18) using health data, to aid recruitment and follow-up.  
 
Hence, this thesis aimed to extract trial outcomes from routine healthcare data, by 
establishing methods to create and evaluate models, whilst ensuring feasibility for 





1.2 Types of routine clinical healthcare data 
Although the terminology is often used interchangeably, the following are the main 
types of routine healthcare data; 1) electronic healthcare records (EHR), 2) 
administrative data (collected for a primary function other than research) or claims data 
(for example, health insurance claims, particularly common in the United States of 
America (USA)) and 3) registry data (figure 1) (19).  
 
EHRs (20) are the electronic version of the patient clinical noting, which often are used 
to create the other datasets (both the administrative and the registry data). EHRs 
contain unstructured and structured data. Structured data are derived from defined 
fields and coding schemes, whereas unstructured data can be derived from sources such 
as free-text clinical noting which may be scanned (21). Free-text may be searchable, for 
example, a word document. However, scanned noting may be non-searchable and 
therefore it is difficult to extract data (22). Clinical noting data are now largely electronic 
but unstructured and often electronically unsearchable.  
 
Administrative or claims data are collected primarily for non-research uses, for example, 
for reimbursement service purposes. In contrast, registry data are collected to evaluate 
specific populations, usually upon diagnosis of a disease. Clinical registry data can also 
be derived from other sources, including manual clinician input into a website-based 
interface, patient reporting systems, or these data can be derived from medical devices 
and services (23). For example, the National Radiotherapy Dataset (RTDS), which derives 
data from the radiotherapy treatment machine, through an oncology management 





















Figure 1: A simplified data flow for the three main types of routine healthcare data.  
Dashed line = flow of data. 
 
The nomenclature for these data sources is complex, due to the varying data derivation 
sources and interchangeable definitions used within the literature. Thus, this thesis will 
refer to routinely collected healthcare data as, 1) administrative and 2) registry data 
(figure 1).  
1.2.1 Administrative data  
There are many different administrative datasets in the United Kingdom (UK). Examples 
include, datasets collected in both primary care (general practice (GP)-derived) and 
secondary care (hospital-derived). A primary care example is, the Clinical Practice 
Research Datalink (CPRD) (25, 26) which collects primary care patient interactions 
throughout the UK. The secondary care data are managed by National Health Service 
(NHS) Digital (NHSD) in England (the Hospital Episode Statistics (HES)) (27), the Secure 
Anonymised Information Linkage (SAIL) Databank in Wales (enabling linkage of multiple 
primary and secondary care datasets) (28, 29) and the Information Service Division (ISD) 
in Scotland (30, 31). In the UK, all non-private care occurs through the NHS and due to 
this, NHS secondary healthcare interactions are documented by NHSD, SAIL or ISD data.  
 
Patient healthcare interaction e.g. 
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Due to this research being undertaken in a secondary care setting in England, the 
administrative database investigated here was the Hospital Episode Statistics (HES). In 
addition, a local dataset was used during the non-trial analyses. These local data are the 
hospital data that are returned to form the HES data (figure 2), so can be assumed to be 
a HES equivalent. In addition, a registry dataset was utilised, which is discussed below 
(section 1.2.2). 
1.2.1.1 The Hospital Episode Statistics (HES) 
HES data are collected for every NHS inpatient, outpatient and accident and emergency 
(A&E) visit in England. The database contains disease and procedure fields populated by 
International Statistical Classification of Diseases (ICD) (32) and Office of Population 
Censuses and Surveys (OPCS) Classification of Interventions and Procedures (33) codes 
respectively.  
 
The HES contain clinical, patient, administrative and geographical information but 
contain no data on disease or treatment outcomes. For example, the date that a 
patient’s disease has worsened (disease progression) or that the treatment is no longer 
working (treatment failure) is not documented. Taking the example of progression, 
whilst subsequent treatments for a progression event (for example, chemotherapy) 
should be reported in the HES, this progression outcome would not be reported. This 
means that often clinical trial outcomes cannot be directly isolated from these data. 
 
Although not documented in the HES data, time to cancer progression is often a key trial 
endpoint, which functions as a surrogate for overall survival (OS) (time to death) (34). OS 
is often the preferred indicator of clinical benefit. It is possible to collect death data 
using NHSD collected sources and many RCTs currently use such data sources (35). 
However, other endpoints (non-survival) are reached prior to OS (34) and are therefore 
desirable. Delaying the time to these endpoints being reached is often of clinical benefit 
to patients and therefore these events are documented in trials (34) (details on cancer 
outcomes can be seen in section 1.5.3 and 1.5.4). 
 
The HES dataset is vast; data collection began in 1987 with the collection of admitted 





were collected from 2003 and A&E data from 2007. In addition, methods of collecting 
these data have changed dramatically since 1987; initially annual data collection was 
undertaken, but currently HES are released monthly and undergoes a two week cleaning 
process, meaning more processed data can be accessed more frequently (27). 
 
As shown (figure 1), data from the EHR are used to form the administrative data, hence 
clinical HES data are derived from EHR coding (figure 2). Data from the EHR are 
formulated into an administrative system (the hospital Patient Administration System 
(PAS)), through translation of events into the diagnosis and procedure codes. Translation 
of the unstructured clinical event data into the PAS is undertaken manually by clinical 
coding staff at a single healthcare provider level, in contrast to structured data which 
can be automatically incorporated into datasets. This manual translation can lead to 
errors (37) and systematic differences in the coding between hospital trusts (for 
example, see section 3.3.2.2).   
 
Extracts of these data are sent on a frequent basis to the Secondary Uses Service (SUS), 
where these data are stored and processed (outside of the NHS trust that these data 
were derived from) to become the HES data, or where they are prepared for secondary 
uses. One major use of these data is, Payment by Results (PbR) (38); these data can be 
prepared to contain financial information so hospitals can be paid for the care they 
provide (figure 2) (27). These data are also used for audit purposes, for benchmarking 
and policy making for service improvement. Users include national bodies and 
regulators, such as the Department of Health and the National Institute for Clinical 
Excellence (NICE), governmental departments and researchers (39).  
 
Processed HES data are frequently used for research, including, to estimate costs (40, 
41), epidemiology (42, 43), to identify risk factors (44, 45) and in validation studies of 
data quality (46). In addition, these data are less frequently used to identify non-survival 





















Figure 2: A simplified flow of data (dashed lines) from the patient event occurring at the individual 
healthcare provider level, through to the creation of the multi-provider HES data. 
 
The process of cleaning the SUS data is vast and involves four main steps, including, 
editing organisation codes (provider code mapping), identifying clear data errors (data 
cleaning), deriving extra information such as geographical data from the coding 
(derivations) and removing duplicates (duplicate removal) (48). 
1.2.2 Registry data 
There are many different disease registries, however, the National Cancer Registry in the 
UK collects data for all NHS patients (through an opt-out regime) diagnosed with cancer. 
It is managed by the National Cancer Registration and Analysis Service (NCRAS) which is 
part of Public Health England (PHE) (49). The NCRAS is involved in various projects, for 
example, the Cancer Outcomes and Services Dataset (COSD) (50), the RTDS (24) and the 
Systemic Anti-Cancer Therapy (SACT) dataset (51, 52). The main registry data used in this 






















1.2.2.1 The Systemic Anti-Cancer Therapy (SACT) dataset 
From May 2014, all NHS trusts that deliver anti-cancer regimens were required to 
document data in the SACT registry. SACT collects therapy data for all adult and 
paediatric haematological or solid tumours (51). For example, oral chemotherapy, 
standard chemotherapy, immunotherapy and steroid regimens are required to be 
collected (53).  
1.2.3 Administrative data vs. registry data 
The main difference between registry and administrative data is the purpose of 
collection. Registry data are collected for research/audit purposes, whereas 
administrative data are often collected for other purposes (for example, payment). This 
has implications on the quality and completeness of these data. Hospitals can be fined 
for incorrect reporting of administrative data, as inaccurate measures of performance 
can be generated and the hospitals may not get paid for the care they provide (37). In 
contrast, because the primary function of registry data is not for administrative 
purposes, this can lead to sporadic reporting. An example of this is the method of data 
collection for recurrence, in the COSD. These data are manually collated, often in 
multiple disciplinary meetings (MDT), which is labour intensive (54) and results in missed 
cases (23).  
1.3 Healthcare data challenges 
There are many practical and regulatory challenges that accompany using routine 
healthcare data. All of these challenges needed to be considered during the conduct of 
this thesis (table 1). 
1.3.1 Regulatory issues 
Regulatory concerns arise when using routine data in trials (table 1). Issues include, 
privacy, security and consent. In parallel to the evolution of electronic medical record 
usage alongside the dawn of valuable data repositories, there was a rise in privacy and 
security concerns (55, 56). Hence, in 1996 it was acknowledged that a universal security 
policy was lacking in the healthcare industry (57). Therefore, the following year, the 





rules (58). In addition, on the 25th May 2018 the General Data Protection Regulation 
(GDPR) was initiated to strengthen data protection (59). It applies to all personal data, 
defined as, data with the ability to identify any individual by identifiers (directly or 
indirectly). The GDPR documents seven key principles: 1) lawfulness, fairness and 
transparency, 2) purpose limitation, 3) data minimisation, 4) accuracy, 5) storage 
limitation, 6) integrity and confidentiality (security) and 7) accountability (60). The 
studies in this thesis were undertaken during the implementation of the GDPR.  
 
Although all of these regulations are absolutely necessary to protect patient privacy, it 
has since been proposed that these regulations, that were created to protect us, have 
now created large, valuable but inaccessible data repositories or ‘silos’ (61). Such 
regulations are thus proposed to have halted innovation and these regulations 
previously created to protect us from harm, are actually now leading to harm (61). The 
Times 2017 stated that, ‘the NHS could transform diagnosis and treatment if only we 
overcame our distrust and let it share patient data’ (62).  
1.3.2 Practical issues 
Practical issues with utilising routinely collected data for trials, include, data accuracy 
(quality), outcome availability (limited outcomes), cost (63), linkage, timeliness of 
collection and bias (table 1). Routine healthcare data are often seen to have quality 
issues, where the coding is incorrect or missing (46, 64, 65). Consideration of this is of 
utmost importance during these studies, as trial data integrity is vital. For example, 
estimates of treatment effects may be changed upon loss to follow-up, leading to biased 
and invalid results (66). Despite these routine data inadequacies, such data have been 
seen to be improving (46).  
 
As discussed above (section 1.2.1.1), clinical variables of interest are often not available 
in routine healthcare datasets, for example, progression outcomes (10) (see section 
1.5.3 and 1.5.4 for further details on cancer outcomes). Thus, it has been stated that for 
trials that need strictly defined endpoints, standard dedicated follow-up is required for 
patient safety and quality endpoint reporting (10). Hence, it was proposed that routine 
healthcare data (registry data) can be used for collecting baseline variables only, and 





The Academy of Medical Sciences and the Association of the British Pharmaceutical 
Industry released a report in 2017 expressing the need for new trial endpoints (2). The 
report stated that new endpoints seek to ‘accelerate the development of anti-cancer 
treatments’ whilst aiming for a strong overall survival association but also reflecting 
patient priorities (2). It was here proposed that routine clinical data could be used to 
identify or validate existing endpoints or for long-term tracking of responses. However, 
it was also highlighted that prior to this, considerable work is required to develop useful 
and reliable outcomes that are compatible across different datasets (2).  
 
Another potential limitation is data timeliness; data are required that are timely in order 
to use such a resource for clinical trial analyses (63). Data must be available with a 
suitable delay from when the event occurred but also available at frequent intervals 
from the data provider. Consideration of the frequency of data transfers from routine 
data providers and the delay in event collection in the routine data are both vital for trial 
design. Costs also have to be considered; it is believed that routine data follow-up 
techniques will reduce costs (63). However, assessments of the routine data methods 
compared to the standard trial follow-up techniques are required to confirm this. 
Linkage rates are also a concern, if trial data cannot be linked to the routine sources, 
then loss to follow-up will occur and outcomes will be missed. Another limitation is that 
the routine data studies can also be biased impacting the study integrity (see section 
2.6) (table 1).  
 
 Aspect Notes 
Practical 
Outcome availability Can the outcome required by the trial be identified in the routine data? 
Accuracy Is data quality high enough, compared to standard trial data? 
Linkage Can these data be linked to the trial identification numbers (ID) or loss to follow-up will occur? 
Cost Does using a routine data framework reduce the costs compared to standard follow-up? 
Timeliness Are these data recent enough to perform trial analyses? Are recent events accessible? 
Bias Does the use of routine data lead to biased studies; for example, ascertainment, design, selection and temporal issues? 
Regulatory 
Privacy, security and 
consent 
Are all regulatory aspects in place to enable access and use of 
the routine data? 
Data retention Can the routine data be kept long enough for an adequate audit trail for the trial? 
 





Despite these concerns, in addition to the timely HDR UK initiation (section 1.1), the 
National Institute for Health Research (NIHR) are currently calling out for ‘data-enabled 
trials’ (deadline September 2019). Grants are being offered for projects, such as those 
within this thesis. This highlights the timeliness of this research (67), despite the 
practical and regulatory issues.  
 
Due to these data practicality and regulatory concerns, this thesis aimed to assess if 
feasible methods could be developed to 1) replace/supplement existing clinical follow-
up within the well-established prostate cancer RCT, STAMPEDE (section 1.5.1) and 2) if 
feasible, enable routine data to be used as the basis of follow-up for the new bladder 
cancer RCT, BladderPath (section 1.5.2). The background behind the trials and outcomes 
of interest are documented below. 
1.4 The clinical need 
Cardiovascular disease has been the leading cause of death worldwide; however, it was 
predicted that by 2020 cancer would become the leading cause of death (68). In fact, 
many countries already record more deaths from cancer (69) and therefore, strategies 
need to be developed to reduce this incidence. This thesis investigated two different 
urological malignancies, prostate and bladder cancer, both resulting in high morbidity 
(the amount of disease in a population) and mortality worldwide (70, 71).  
1.5 Clinical trials and routine data 
Routine data are increasingly being used in RCTs (chapter 5, section 5.4). The routine 
data can be linked by unique patient identifiers, such as the NHS number, to the trial ID 
to enable patient level data to be analysed (63). The STAMPEDE trial (72) and the 
BladderPath (73) trial are exemplar RCTs used within the studies presented in this thesis.  
1.5.1 Prostate cancer and the STAMPEDE trial 
Prostate cancer is the most common male cancer in the UK (74) and in 2008 it was 
suggested to be the ‘sixth leading cause of cancer death among men worldwide’ (70). In 
2008 there were 899,000 new cases and 258,000 deaths due to prostate cancer, 
worldwide (70). Due to the ageing of the population and growth, by 2030 these figures 





However, it was estimated that in 2012 prostate cancer already accounted for 1.1 
million cases and 307,000 deaths, so is fast out-growing its projected estimates (70, 75). 
 
Prostate cancer can progress (worsen) from the confines of the prostate gland (non-
metastatic (M0) with or without the local lymph nodes of the pelvis) to distant 
(metastatic, M1) lymph nodes out of the pelvis or to other distant M1 sites (76, 77). 
These distant M1 sites can include the viscera (organs) and the bone (78). Skeletal 
related events (SRE) may occur if the cancer has progressed to the bone. An example of 
an SRE is spinal cord compression, a complication of bone cancer; SREs are discussed in 
detail in section 1.5.4. The cancer may also be recurrent, where the disease can return, 
when there was previously a response to treatment (79). This can result in the need for 
treatment change (79).  
 
The STAMPEDE (72) (Systemic Therapy for Advancing or Metastatic Prostate cancer: 
Evaluation of Drug Efficacy) trial is the largest interventional prostate cancer trial 
worldwide and is testing multiple treatments in advancing or metastatic disease, in 
comparison to a single control treatment (the standard-of-care, SOC). The STAMPEDE 
trial uses a MAMS design (9, 80, 81) to allow simultaneous assessment of multiple 
treatments against the SOC (9, 82) (figure 3).  The STAMPEDE SOC is currently hormone 
therapy (Androgen Deprivation Therapy, ADT), with or without radiotherapy (RT) in 







Figure 3: The STAMPEDE MAMS trial, currently with treatment arms A-L.  
This figure was extracted and edited from the STAMPEDE protocol (72). 
 
STAMPEDE has recruited over 11,000 patients with high-risk disease localised to the 
prostate gland, the lymph nodes or metastatic sites, or relapsing disease after initial 
treatment to the prostate (72). If a patient is diagnosed with this, they may be eligible to 
enter the STAMPEDE trial (figure 3) (72). 
 
STAMPEDE has so far evaluated or is evaluating: the SOC (arm A) (see description 
above); SOC plus zoledronic acid bisphosphonate treatment (83) (arm B); docetaxel (83) 
(arm C); celecoxib (84) (arm D); zoledronic acid plus docetaxel (83) (arm E); zoledronic 
acid plus celecoxib (84) (arm F); abiraterone (85) (arm G); M1 radiotherapy (86) (arm H); 
enzalutamide hormone therapy plus abiraterone (arm J); metformin (arm K) and a 
hormone therapy patch (72) (arm L). The STAMPEDE treatment arms investigated during 








A STAMPEDE eligibility criterion (arms A-K, not arm L), includes the intention to treat 
with long-term hormone therapy (androgen deprivation therapy, ADT). Hence, when 
patients enter the trial, they have not had prior exposure to long-term hormone therapy 
and therefore, the patients on these arms are assumed to be recruited with hormone 
sensitive prostate cancer (HSPC) (72). This means that the prostate cancer should 
respond to hormone therapy. Patients can be administered the STAMPEDE SOC 
treatments (arm A, control arm) or be recruited to the other experimental arms which 
includes various treatments (arm B-L) (figure 3). 
 
The patients can develop recurrent disease after initial treatment. At this point, if the 
patient is no longer responding to hormone therapy, castrate resistant prostate cancer 
has developed (CRPC) (87) (see section 3.3.2.3 for further details). In the order of 
severity (most severe, to least severe), this progression to the CRPC state can include: 
visceral metastases (internal organs), bone metastases including an SRE, bone 
metastases without an SRE, CRPC disease without metastases or lymph-node 
metastases alone (including, the non-metastatic local lymph nodes of the pelvis or 
distant metastatic lymph nodes) (88). Continual progression can occur and death from 
prostate cancer or non-prostate cancer causes is possible in any state, regardless of the 
severity (88). Subsequent treatments may be suitable and the recurrent and non-
recurrent groups are continually followed-up by the trial until death. An example of a 
STAMPEDE trial patient pathway can be seen in section 1.5.2.1. 
1.5.2 Bladder cancer and the BladderPath trial 
In 2012 it was estimated that bladder cancer was the 9th most common cause of cancer 
worldwide when combining both sexes (75). The aim of the study presented within this 
thesis was to determine the feasibility of using routine data for follow-up for the 
BladderPath trial for bladder cancer (ISRCTN35296862) (73). However, the initial data 
analyses were conducted in a non-trial patient cohort.  
 
When a patient is newly diagnosed with bladder cancer they may be eligible to enter the 
BladderPath trial (73). In summary, the rationale for the trial is as follows: the outcomes 
for patients with bladder cancer have not changed significantly for many decades and 





(the first management intervention) in the more severe disease subgroup, muscle 
invasive bladder cancer (MIBC) (73). The BladderPath trial (Image Directed Redesign of 
Bladder Cancer Treatment Pathway) is an RCT assessing a redesigned patient pathway, 
with the aim to fast track the correct patients to the most appropriate treatment, to 
reduce delays and improve outcomes (73, 89). 
 
The standard pathway is that patients have a flexible cystoscopy to diagnose bladder 
cancer, which is followed by rigid cystoscopy under general anaesthetic during which 
piecemeal excision of tumour can be undertaken - the transurethral resection of bladder 
tumour (TURBT) (73). Diagnosis can include non-muscle invasive bladder cancer 
(NMIBC), where the cancer has not invaded the muscle layer, or the more severe form, 
MIBC, where the cancer has invaded the muscle layer (90). TURBT not only acts as a 
diagnostic tool, but it is also used for NMIBC treatment, as the tumour can be potentially 
completely excised during the investigative process. However, if MIBC is present, further 
treatment is necessary: typically cystectomy, chemotherapy, or radiotherapy or 
combinations of all three, or palliative care (73). In addition, both NMIBC and MIBC can 
become recurrent and if so, further treatment is additionally required; NMIBC can also 
progress to MIBC disease. Multiple recurrences can occur and hence, where 
appropriate, additional treatments can be given. 
 
In the MIBC subgroup, the TURBT is not only potentially redundant but it may also be 
damaging. For example, TURBT often incorrectly under-stages MIBC patients as NMIBC 
(91) leading to delayed MIBC treatment. It is also possible that the invasive procedure 
within the bladder, with the cystoscope, could lead to dissemination of the tumour (92). 
Furthermore, imaging post-TURBT can be challenging due to surgical artefacts (for 
example, damaged tissue) (73) leading to incorrect treatment choices. Service 
evaluation data show that delays to MIBC treatment are common (93, 94).  
 
The current NHS guidelines for the time from receiving a GP referral to starting 
treatment for cancer is 62 days, with a second target of 31 days from confirmed 
diagnosis to starting treatment (95). For both MIBC and NMIBC, TURBT is considered the 
first treatment, despite the lack of efficacy of TURBT for MIBC. Therefore, although 31 





starting the appropriate treatment (figure 4). Varying delays have been identified, 
including, a study with a further median time from TURBT to cystectomy of 7 weeks (50 
days) (96) and another study showing that 90% of patients did not receive definitive 





     
 
   
 
Figure 4: The current standard pathway and NHS guideline targets for the management of NMIBC 
and MIBC.  
Continuous black line = time from hospital referral or diagnosis (where treatment plans are 
created) to treatment for NMIBC. Dashed line = the additional time to appropriate treatment for 
MIBC patients. X, Y = the true value for time 1 and 2 respectively. 
 
Thus, BladderPath is testing the hypothesis that NMIBC and MIBC patients could be 
separated at diagnosis, using Magnetic Resonance Imaging and biopsy at flexible 
cystoscopy (in particular patient subgroups) to replace the TURBT. Different pathways 
could then be followed sooner, with the aim to observe better outcomes in the MIBC 
subset. These patients previously identified as having poorer prognosis, potentially due 
to delays (96, 97), would be fast-tracked directly to the correct treatment (73). An 
example of a BladderPath trial patient pathway can be seen in section 1.5.2.1. 
1.5.2.1 Prostate and bladder cancer patient pathways 
An example patient pathway for a patient with prostate cancer entering the STAMPEDE 
trial and a patient with bladder cancer entering BladderPath can be seen in figure 5. 
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Diagnosed prostate cancer* 
Enter STAMPEDE trial with HSPC** 
Potential STAMPEDE treatments (as per figure 3): 
• SOC (arm A): Hormone therapy (ADT) +/- RT +/- docetaxel +/- 
abiraterone 
• Other treatments (arm B-L) e.g. docetaxel, abiraterone  
No recurrence 
 
Recurrence (development of CRPC 
disease) 
Further suitable treatment (where 
possible) (further progression possible) 
 
Continued follow-up until 
potential transfer into the 
recurrent state 
Continual follow-up or death 
 
Diagnosed bladder cancer 
Enter BladderPath trial 
Flexible cystoscopy 
Rigid cystoscopy (TURBT) or MRI 
NMIBC MIBC 
Correct treatment: 
























Figure 5: Example simplified clinical trial patient pathways. A) prostate cancer pathway in the 
STAMPEDE trial; B) potential disease state transitions from treatment failure with HSPC to CRPC. 
The red dashed line in A corresponds to the further details in B (I have created this figure based 
upon the figure previously published by the STAMPEDE trial team (88); C) bladder cancer pathway 
in the BladderPath trial. 
* Diagnosed with high-risk locally advanced disease localised to the prostate gland, the lymph 
nodes or metastatic (M1) sites, or relapsing disease after initial treatment to the prostate; HSPC = 
hormone sensitive prostate cancer; CRPC = castrate resistant prostate cancer; ** = one eligibility 
criterion includes the necessity to treat with long-term hormone therapy, hence, are required to 
have HSPC at randomisation; ADT = androgen deprivation therapy (hormone therapy); RT = 
radiotherapy; ^ = Patients can be randomised into the STAMPEDE trial with M0 or M1 HSPC. Upon 
hormone therapy treatment failure in these groups, CRPC is developed; NMIBC = non-muscle 
invasive bladder cancer; MIBC = muscle invasive bladder cancer. 
1.5.3 Clinical trial outcomes 
After patients enter oncology trials, outcomes are often collected in paper or electronic 
case report forms upon trial visits. Outcomes of interest include OS (time from 
randomisation into the clinical trial, until death of any cause) and other non-survival 
surrogates/proxies which aim to predict the OS but happen sooner than death. 
Alternative non-survival endpoints are useful for MAMS trials, as they enable more 
expedient assessment of trial treatments (see section 1.5.4). 
 
Prostate cancer outcomes include, disease progression, treatment failure, metastases 
(72) and skeletal-related events (SRE). Despite the use of such endpoints, in prostate 
cancer trials, no clinical endpoints have been accepted for advanced disease. 
Metastases-free survival (MFS) was the first (2017) accepted robust surrogate for OS but 
only in localised prostate cancer (98) (see section 1.5.4). These events are detected 
objectively (imaging), biochemically (a blood laboratory result change) or 
symptomatically (a change in symptoms) within the STAMPEDE trial (72).  
 
Other commonly collected outcomes in CRFs include, toxicity (adverse events (AE), 
serious adverse events (SAE)) and quality of life (72). During event reporting in 
STAMPEDE, it is only mandatory to collect data for the first event. 
1.5.4 Outcome definitions used in this thesis 
Failure-free survival (FFS): Within STAMPEDE, FFS is defined as the time to failure, 
where failure is the first of: death from prostate cancer, biochemical failure, local 





detected objectively, biochemically or symptomatically as discussed in section 1.5.3. To 
assess biochemical failure, a unique threshold prostate specific antigen (PSA) blood test 
marker is calculated for each patient, depending on the lowest value between 
randomisation and week 24. When the PSA is confirmed to have reached the threshold, 
biochemical failure (treatment failure) is confirmed as the date of the first increased PSA 
value. The FFS is then calculated as the time from randomisation to the first event. If no 
event is present, these data are censored at the last known visit (72) (table 2). 
 
Progression-free survival (PFS): This is determined to be the time to when the disease 
has worsened. Within STAMPEDE, progression is defined as, death from prostate cancer, 
local failure, lymph node failure or distant metastases and time to this first event from 
randomisation is defined as the PFS. If no event is present these data are censored at 
the last known visit (72, 99) (table 2). 
 
Metastases-free survival (MFS): This is defined as the time to when the disease has 
spread. Within STAMPEDE, events of interest include, any death (mortality by any 
cause), distant metastases or progression of metastases. The time to the first event is 
defined as the MFS. If no event is present these data are censored at the last known visit 
(72, 99) (table 2).  
 
Overall survival (OS): This is defined as the time to mortality by any cause. Time to this 
event from randomisation is the OS, this is the primary outcome for most oncology 
trials. If no event is present these data are censored at the last known visit (72, 99) 
(table 2). Cause-specific survival includes the cancer-related deaths only.  
 
Skeletal related events (SRE): The bone is usually the first site of metastases in prostate 
cancer. Two in three patients with cancer will develop bone metastatic disease, hence, 
skeletal activity can act as a surrogate for disease progression (100, 101). Within 
STAMPEDE, these events of interest include; pathological fracture, spinal cord 
compression, requirement for radiotherapy to the bone or requirement for surgery to 
the bone. If one of these events are identified, progression should be confirmed, and a 
progression form completed for this. If no event is present these data are censored at 


















FFS ü û ü ü ü ü 
MFS ü ü û û û ü 
PFS ü û û ü ü ü 
OS ü ü û û û û 
 
Table 2: STAMPEDE trial endpoints.  
In addition, SREs are used as an endpoint but are not included in the table. 
 
Time to correct treatment (TTCT): This is the primary outcome for the intermediate 
stage of the BladderPath trial. The correct treatment depends on the nature of the 
disease and the TTCT is the time from randomisation to the correct treatment (73). 
 
Adverse events (AE) and serious adverse events (SAE): AEs occur where a treatment 
has an adverse effect, for example exacerbation of an illness, an increase in an event, a 
condition detected after trial treatment initiation, or a symptom that worsens following 
the trial drug (72). Further to this, SAEs are defined as any adverse event that is serious, 
for example, with death, life-threatening consequences, hospitalisation and persistent 
disability (72). 
1.6 Rationale for this thesis  
Routine data have frequently been used within clinical trial frameworks (102). However, 
in 2015 Professor Nicholas James identified that there was a lack of work into validating 
and where possible, making clinically useable methods to utilise these data within the 
oncology trial setting. This thesis was conceived to develop and validate novel methods 
to use routine data, using Professor James’ clinical trials as exemplar data. The long-
term ambition was to supplement or replace follow-up in an existing oncology RCT and 
to develop a novel clinical trial framework for a new RCT using routine data solely for 
follow-up.  
 
The following three studies interlink and hence were completed largely in parallel to 
validate different data sets and data items within routinely collected sources. This aimed 






This rationale is based upon the idea that, when enrolling into a trial (such as STAMPEDE 
and BladderPath), patients can consent for long-term information to be accessed from 
routine sources (72). Therefore, these rich routine data can be accessed, by linkage to 
the trial ID (figure 6). However, in order to extract meaningful outcomes data (as 
discussed above) for trials, models have to be created. 
 
 
Figure 6: The accumulation of longitudinal healthcare data in parallel to the movement through 
the trial, from randomisation until death or last known follow up.  
N = number of events as multiple events can occur; x = an unknown time, unique to each patient 
and event. FFS, MFS, PFS, SREs, TTCT and AEs are defined in section 1.5.4. 
 
1.7 Potential positive implications of using routine data for trials 
If routine data can be used to identify trial outcomes, either to supplement standard 
data collection techniques or to replace standard methods, alongside the concerns 
proposed in table 1, there are many potential positive implications (table 3). The main 
overall implication linked to all of the aspects shown in table 3 is patient benefit. 
 
Aspect Implications 
New hypotheses Can hypotheses be explored that previously were not possible using standard trial data? 
Validation Can standard CRF events be validated using routine data? 
More events  Can additional events be identified using routine data, that were lost to follow-up using standard trial data? Or extra events that could flag at risk patients? 
Reduced burden Can routine data reduce burden on site staff reporting events and patients visiting for follow-up? 
Reduce costs Can routine data reduce the costs compared to running a trial with standard data collection techniques? 
Increase timeliness Could timeliness of event collection be increased using routine data? 
 







• Endpoint (FFS, MFS, PFS, SRE, TTCT)N  (time = x) 











Hypothesised positive implications include: 
 
• Events could be investigated that were not previously known to be significant. 
Previously these events would not have been collected in the pre-defined follow-up 
CRFs and it would not be possible to retrospectively acquire these data for large 
cohorts (to be investigated in chapter 3) (table 3). 
 
• Traditionally collected trial CRF events could be validated (to be investigated in 
chapter 3 and chapter 4) (table 3). 
 
• Acquiring trial outcomes from routine resources may reduce burden on site staff 
reporting events and on patients visiting for frequent follow-up assessments (103, 
104). A reduced number of follow-up visits over a trial with long follow-up may be 
desirable to patients and enhance recruitment (table 3). 
 
• The use of routinely collected data may reduce the cost (103, 105) of conducting the 
trial due to a proposed reduction in resources that are required (table 3). This is 
dependent on what additional resource is required to utilise the routine data (103). 
 
• Loss to follow-up may be reduced. Events usually lost to follow-up may be 
identifiable in the routine data, for example, events previously missed due to recall 
bias or those occurring at another hospital (to be investigated in chapter 3, chapter 
4 and chapter 5) (table 3). 
 
• The timeliness of event collecting may increase. The feasibility of near real-time data 
collection may enhance event capture, compared to standard data collection at 
interim trial visits. Especially as these visits can occur at progressively more distant 
intervals (explored in chapter 5) (table 3). 
 
Ultimately the aim is to enhance clinical trials. Hence, more interventions would 
potentially become available to patients, with the overall aim to directly improve patient 





1.8 Aims and objectives  
1.8.1 Aims 
• To develop clinically useable instruments, that utilise routinely collected 
healthcare data, to detect outcomes for use in trials. The aim is to: 1) assess the 
use of routine data as the basis of follow-up for a new RCT and if this is 
identified as feasible, set up a framework to do this, 2) identify if existing follow-
up can be replaced or supplemented for an existing RCT and create models to 
identify events. 
 
• To answer the thesis question, ‘Can routinely collected data be used to inform 
randomised controlled trial outcomes in oncology’? 
1.8.2 Objectives 
Direct methodology (retrospective model) (chapter three) 
 
• Determine if it is possible to perform analyses for events that were not routinely 
collected in the trial CRFs. 
• Establish the quality of the routine data compared to the standard trial data and 
clinical noting data. 
• Illustrate the potential data use by investigating a clinical hypothesis using the 
model. 
 
Indirect methodology (retrospective model) (chapter four) 
 
• Identify in the literature if trial non-survival endpoints have previously been 
developed using routine data. 
• Determine if it is possible to identify trial outcomes not explicitly collected by 
routine data. 
• Establish data quality compared to traditional trial data and clinical noting data. 
• Develop and validate an algorithm to identify events of interest for a trial. 







Direct methodology (prospective model) (chapter five) 
 
• Identify how routine data have been used to conduct oncology trials previously. 
• Validate the quality of the routine data. 
• Develop an algorithm to identify events of interest. 
• Develop a framework for the BladderPath trial data collection. 
• Acquire routine data for the trial. 
1.9 Thesis outline 
Hence, in line with the aims (section 1.8.1) and objectives (section 1.8.2), this thesis 
presents three main chapters, 1) retrospectively assessing if analysis can be undertaken 
using routine data to answer questions not previously possible using standard data 
collection and if possible conduct such analyses; 2) retrospectively assessing if it is 
possible to indirectly identify outcomes not collected in the routine data and if feasible 
try to perform survival analyses to replicate previous trial analyses; 3) investigating if 
routinely collected data can be used to identify events that are directly identifiable in 
these data. The aim was to develop a framework to utilise routine data as the basis of 
data collection as this has not been done in a secondary care or oncology RCTs 
previously. 
 
These studies were completed to create an overarching knowledge set to determine 
feasibility and where possible, implement the use of routine data to, 1) 
replace/supplement STAMPEDE trial follow-up, 2) enable conduct of the BladderPath 
trial using routine data as the basis of follow-up.  
1.10 Thesis summary 
Reviews of the literature confirmed that no studies had been undertaken to identify 
oncology trial surrogate outcomes to perform trial time to event analyses, to identify 
treatment effectiveness. Including, no urology trials using routine data to identify trial 
non-survival endpoints. I also believe that no RCTs have been designed to perform 
follow-up using routine data as the basis of follow-up, in oncology or a secondary care 
setting. To accomplish this, there were shared approaches between the studies which 





2 CHAPTER TWO: Shared methodology, methods and further considerations 
As discussed in section 1.9 the three studies interlink but the shared approaches across 
the three studies are presented below. The methods are described as the tools used to 
undertake the research and the methodology as the broader strategy and rationale that 
impacts the methods. Hence, the methods are part of the overall methodology. In 
addition, shared data sources, approvals, terminology and bias considerations are 
shown. 
2.1 Shared methodology 
This thesis undertook both primary and secondary research. The primary research 
includes the studies where I collected and performed the research myself. The 
secondary research includes the literature reviews, where the primary analyses were 
previously conducted by another researcher (106). All three analyses chapters (3-5) 
include both primary and secondary research (table 4).  
 
Both qualitative and quantitative approaches were used and hence, a mixed methods 
study was adopted. Firstly, qualitative approaches were taken, which were then 
followed by the quantitative approaches. The qualitative approach refers to where I 
sought to, ‘come to terms with the meaning, not the frequency’ of data (107). For 
example, by analysing patient case histories, or published literature. In contrast, the 
quantitative approach refers to where data were analysed statistically.  
2.2 Shared methods 
All studies involved the validation of the routine data against a reference and algorithm 
development to identify events. Where note review was undertaken, data were 
extracted in Microsoft Excel designed data collection tools. Where systematic literature 
reviews were undertaken, databases were screened and Endnote Web (108) was utilised 
to manage the references. No second reviewers were utilised for these reviews due to a 
lack of resource. However, advice was given by H. Parsons and the University of Warwick 
librarian. Algorithms were developed to identify outcomes in the routine data, and these 
outcomes were compared to reference data sets to perform sensitivity analyses. In all 





The algorithmic design and analyses were checked by Dr Helen Parsons. Specific details 
of individual research methods are detailed in the appropriate chapter (chapter 3-5). 
2.3 Shared data sources 
Three data sources were analysed throughout the research. The reference (‘gold 
standard’) was considered to be the hospital clinical noting (where available) and the 
clinical trial data in the absence of clinical noting (table 4):  
 
1. Routinely collected healthcare data: Administrative data: Hospital Episode Statistics 
(HES) or local Hospital interactions Data (HID) and registry data: Systemic Anti-
Cancer Therapy dataset (SACT). 
 
2. Clinical trial data: The STAMPEDE trial case report form (CRF) reported data 
(reference). 
 
3. Hospital clinical noting: Patient clinical noting and radiotherapy machine generated 
data (reference). 
Although the three data sources were shared, not all datasets were used for each study. 
For example, the SACT data were only used within chapter 3.  
2.3.1.1 Temporal data considerations 
During the conduct of these analyses, there were temporal changes in the datasets. 
Temporal changes affected all three sources of data. Routinely collected data undergoes 
changes, for example in the way events are coded and accuracy. To ensure these 
changes were reflected in the work, these data were validated against the reference 
sources and analysed by year.  
 
The clinical trial data were also affected by temporal changes. The case report form 
(CRF) designs can change over time and different variables can be collected. Hence, the 
relevant CRF data needed to be extracted for each analysis. The clinical noting data also 
were also affected by temporal changes in data collection; the transition from paper to 
electronic clinical noting. The single site University Hospitals Birmingham, Queen 





the first outpatient departments in the United Kingdom to record clinical data 
electronically. Hence, this enabled access to the majority of patients clinical noting via 
the computer system. However, I undertook training to enable me to request paper 
noting for the early patients analysed.  
 
To ensure that the three data sets were comparable, where appropriate, I used data 
freezes to enable comparison. This is because these three data sets are documented at 
different times through the patient’s disease trajectory. That is, after the patient event 
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2.4  Shared ethics and other approvals 
Due to these studies using patient level, personally identifiable data, approvals to access 
and analyse these data were required for all three data sources (routine data, trial data 
and clinical noting). The approvals required can be seen below. 
2.4.1 Routine data: Hospital Episode Statistics (HES) and the local Hospital Interactions 
Data (HID) 
The HES data were analysed from two different sources via two different applications. 
Initial feasibility studies were undertaken using HES data previously acquired for the 
STAMPEDE trial from the Health and Social Care Information Centre (HSCIC) (becoming 
NHS Digital, NHSD in 2016 (111)). After feasibility was determined, analyses were 
undertaken using multi-site data acquired from Public Health England (PHE). I completed 
the application for these data (appendix section 8.1.3 and 8.1.4), which took sixteen 
months from the initial contact with PHE (27/06/17) to receiving these data (08/11/18). 
This specific sub-study also obtained Research Ethics Committee (REC) approvals (NHS 
Health Research Authority West Midlands Edgbaston Research Ethics Committee, REC 
reference: 04/MRE07/35) and is consequently an ancillary study within the STAMPEDE 
protocol (section 17.4 of the STAMPEDE protocol) (72).  
 
When entering the STAMPEDE trial, the patients consent to follow-up using routine 
data, enabling us to access their routine data. These routine data were sent from PHE to 
the data controller, the Medical Research Council, Clinical Trials Unit at University 
College London (MRC CTU at UCL). Hence, I acquired an honorary contract with UCL to 
enable me to access these data within the Data Safe Haven (DSH). I have also signed the 
STAMPEDE delegation log to enable me to perform analyses for the trial. Conditions of 
the contracts include, updated Good Clinical Practice (GCP), information governance 
training, the completion of the standard operating procedures (SOP) including tests after 
each module, and General Data Protection Regulation (GDPR) training, which was 
required during the completion of these studies; hence, all of the above were completed 








The local Hospital Interactions Data (HID) for the BladderPath feasibility work were 
acquired from the University Hospitals Birmingham, Queen Elizabeth Hospital (UHB 
QEH) informatics department. The work was registered as an audit on the UHB systems 
and these data were transferred internally within the hospital from the informatics 
department. I also completed a Data Protection Impact Assessment (DPIA) which was 
sent to the information governance team at UHB QEH. The BladderPath protocol (73) 
also documents the data feasibility study (section 10 and 17 of the protocol). Both the 
STAMPEDE trial and the BladderPath trial also have the relevant information regarding 
data access available in the trial patient information sheets. 
 
Initially, the HSCIC (now NHSD) sent monthly HES extracts to the UHB QEH informatics 
department for linkage to the STAMPEDE trial ID. The STAMPEDE-HES linked datasets 
were analysed at UHB QEH after this linkage process. In contrast, these data from PHE 
were sent to the MRC CTU at UCL in one retrospective drop, already linked to the 
STAMPEDE trial ID, so no further linkage was required. The MRC CTU at UCL securely 
provided the required linkers (STAMPEDE ID, NHS number, date of birth (DOB) and the 
date the patient entered the trial), to enable data to be sent for events six-months prior 
to randomisation to the last available routine data interaction. In order to be linked by 
PHE, a PHE linkage requirement included that the patient was registered with cancer in 
the registry records and had a cancer record in the HES data. Manual checks on valid 
NHS numbers were undertaken by PHE prior to extraction of the individual eligible 
patient records from the cancer registration data. NHS number rules were used to 
extract patients with valid NHS numbers. The patients with eligible events and a correct 
NHS number were linked to the STAMPEDE trial ID, the direct identifiers were stripped, 
and these data returned securely to the MRC CTU at UCL for analyses. 
2.4.2 Routine data – other  
The PHE data application which I completed enabled the access to HES, National 
Radiotherapy Dataset (RTDS), Systemic Anti-Cancer Therapy dataset (SACT) and cancer 
registration data. These SACT data were used in addition to the HES during chapter 3. 







2.4.3 Clinical trial data 
STAMPEDE is run according to GCP and the Declaration of Helsinki, with relevant 
regulatory and ethical approvals (9, 81, 83, 84) (STAMPEDE registration numbers: MRC 
PR08, ISRCTN78818544, NCT00268476). As mentioned in section 2.4.1, this specific sub-
study also obtained Research Ethics Committee approvals and is consequently an 
ancillary study within the STAMPEDE protocol. 
 
As with the requirements to access the linked HES data, I signed the delegation log for 
the trial to access STAMPEDE data. Paper trial case report forms (CRF) were utilised 
initially and these were extracted and re-filed by site data managers to ensure safety (of 
both archived and unarchived CRFs). For larger analyses, I completed two trial data 
release requests to the MRC CTU at UCL, to apply for the electronic STAMPEDE CRF data 
to be sent to the UHB QEH. This was necessary due to the volume of patient data 
required from multiple sites. This was sent to UHB QEH via a secure transfer, to ensure 
integrity and confidentiality of these data. All data transfers to the UHB QEH were 
signed off by the head of research and development governance. Further to this, the 
GCP exams, and mandatory yearly UHB training enabled me to access these data; I 
passed all of the modules. 
2.4.4 Hospital clinical noting data 
I obtained a UHB QEH honorary contract to access data at the hospital. Again, an 
updated GCP certificate, frequent information governance training and other mandatory 
training sessions were required. In addition, a disclosure and barring service (DBS) check 
was undertaken. Audits were also registered on the clinical audit system, to access the 
hospital clinical noting data for the STAMPEDE patients and the non-trial bladder cohort. 
The Wellcome Trust Clinical Research Facility (WTCRF) at UHB QEH initially oversaw the 
use of these data and booked particular computers to use. The honorary contract also 
enabled visits to outpatient clinics and inpatient procedures, all providing an 









2.5 Shared terminology 
Terminology was shared across the chapters and further details can be seen below in 
section 2.5.1 and 2.5.2. 
2.5.1 Outcomes and endpoints 
Various clinical trial outcomes/events were being investigated throughout this project, 
for example, adverse events (AE) and non-survival time to event endpoints. The 
terminology therefore is defined within this thesis as: all endpoints are outcomes but 
not all outcomes are endpoints. Hence, within this thesis an endpoint is defined as an 
outcome/event.  
2.5.2 Inferred 
The terminology inferred was used within this thesis where non-statistical assumptions 
were made to account for missing routine data. Instead, clinical justifications were used. 
For example, in one analysis, for patients who had severe neutropenic events but no 
chemotherapy details in the routine data, it was assumed that these events were 
chemotherapy induced. This is because clinical experience leads us to believe, in this 
population, the majority of severe neutropenic events are triggered by chemotherapy. 
2.6 Shared bias considerations 
Different types of bias are present within these three studies. This includes selection, 
sampling, ascertainment, temporal, design and detection bias (112).  
 
Sampling bias may arise due to the small single-site studies undertaken within chapter 3, 
4 and 5. Clinicians at different trusts will recruit different patients and in addition, the 
coding may be different across sites. Hence, single-site analyses may not be 
representative of the population. There are also issues due to the reporting limitations 
of the routine data used (HES, SACT); The HES and the SACT are only reported in England 
and NHS patients. Hence, patients receiving private care and those outside of England 








Due to data not being collected for patients receiving private care, this may influence 
the cohorts, such as by socioeconomic status. Within chapter 3 (neutropenic event 
study), if a patient is admitted for a severe neutropenic event, this should be to an NHS 
emergency department. Hence, the exclusion of private cases should have minimal 
impact. These patients may be receiving different patterns of care and excluding these 
patients may bias the results. 
 
Selection bias is also present within these studies. For example, patients within clinical 
trials may be receiving a better quality of care and hence, this may impact the coding 
which may not be representative of the whole population. If the patients were in the 
STAMPEDE trial, these have been selected as are eligible for the trial. Hence, patients 
not meeting the STAMPEDE inclusion criteria would have been excluded from the trial 
analyses. For example, patients with a second tumour would not be randomised into the 
trial and would therefore be excluded from the analyses. In addition, the patients 
recruited into STAMPEDE have high-risk or advanced prostate cancer and hence, 
selecting for patients with worse outcomes. This may again not provide a representative 
prostate cancer population and may select for patients with worse outcomes.  
 
The routine data also directly leads to selection bias. For example, more expensive 
procedures may be coded for, in comparison to less expensive ones which may be 
excluded. This will have an impact on event detection and therefore model 
development. Socioeconomic status should make no difference to the quality of coding 
but as described above, patients receiving private care would not have HES data coding 
and therefore this may restrict the socioeconomic groups in the analyses. 
 
Ascertainment bias may also be present, for example, in the failure to represent all 
classes of cases. Where patients on particular trial arms were chosen or patients with 
particular events (for example, skeletal related events, SREs in chapter 4), this may have 
introduced bias, by excluding other cohorts. Ascertainment bias may also have been 
present when performing the time to correct treatment analyses in chapter 5. Codes 
were used to extract the patient cohort and those without the codes were excluded 
from the analyses. This would have biased the results, for example, by excluding 








There are also temporal biases; over time the coding schemes have changed and also 
the motivations for coding. This means that outcomes could have been missed within all 
the studies but also patients could have been excluded from the analyses. Over time 
clinical pathways change and also clinician preference, which may have also impacted on 
the ability for the algorithms to function, for example in the chapter 5 (BladderPath) 
time to correct treatment study. 
 
Design bias was also present. For example, in chapter 3 (neutropenic event study), there 
was a potential for partially paired data to be present. Hence, it is possible that the 
effect of two processes could not be separated. Severe neutropenic events may have 
been due to repeated exposure to chemotherapy, rather than an individual regimen 
(discussed further in chapter 3). 
 
Detection bias was also present; events could only be detected if they were present in 
these data. Hence, in all studies the outcomes may not have been completely impacted 
by an event of interest (for example, chemotherapy or progression) but actually due to 
the impact of missing data. In addition, there was often no access to a reference for 
patients that did not experience an event, due to no known ‘truth’. Therefore, it is not 
possible to verify that the patient did not have an event. Bias is discussed throughout 
this thesis with regards to the individual studies. 
 
This chapter summarised the shared approaches utilised throughout these studies. 
However, methods unique to each individual study are further presented within chapter 












3 CHAPTER THREE: Direct RCT data collection (retrospective model) 
3.1 Abstract 
3.1.1 Introduction:  
Lack of clinical and pathological data in routine data sources, means that only particular 
outcomes can be identified directly in the routine data, whilst others need to be 
indirectly identified. The aim of this chapter was to assess the feasibility of using routine 
data to directly identify events. The example was neutropenic toxicity, a serious adverse 
event (SAE), in the STAMPEDE trial, to investigate the relationship with the timing of 
docetaxel administration. This example was chosen because docetaxel was initially 
licenced for castrate-resistant prostate cancer (CRPC), but more recent evidence showed 
docetaxel at hormone-sensitive prostate cancer (HSPC) diagnosis improved survival. 
Higher neutropenic toxicity rates were reported in the HSPC trials, but it is unclear if this 
was due to the timing of docetaxel or differences in the patient case-mix. This presented 
an ideal setting to identify if toxicity follow-up information could be feasibly identified in 
the routine data.  
3.1.2 Methods:  
The STAMPEDE trial patient data and the routine clinical National Health Service (NHS) 
data were linked (Hospital Episode Statistics (HES), Systemic Anti-Cancer Therapy 
Dataset (SACT)). Note review was undertaken, which was linked to the routine data to 
assess neutropenic admission rates and the feasibility of routine data event detection by 
hormone-sensitivity (HSPC & CRPC docetaxel) at a single site (Number (N)=44). This was 
used to develop and validate algorithms to detect neutropenic events across the entire 
data set. The algorithms were also restricted to detect sepsis-only and sepsis plus 
neutropenia events (N=3642). Missing HES CRPC chemotherapy regimens were also 
‘inferred’ with HES data alone or enhanced with SACT data (N=1573). The rates of events 
were calculated across settings. Data quality was assessed throughout the analyses. 
3.1.3 Results:  
Neutropenic admission events were accurately detected from within the HES data (92%; 







regimens were not accurately coded in HES (0% regimens; 0/15; cohort one) or SACT 
(42% regimens; 83/200; cohort three). Therefore, the model was designed to utilise 
STAMPEDE data for detection of HSPC regimens. However, the accuracy of detecting 
CRPC regimens in the routine data was higher than at HSPC. The HES data quality 
improved over the last five data years (neutropenic events detected in the routine data 
compared to STAMPEDE trial reported events: 2009, 30% to 2013, 100%). The incidence 
of neutropenic events by HSPC and CRPC chemotherapy varied by method; for most 
methods, algorithm-detected neutropenic event rates at CRPC were higher than in the 
published CRPC trial (TAX-327) but similar to or higher than the algorithm-detected 
HSPC neutropenic event rates.  
3.1.4 Conclusion:  
This analysis enabled validated investigation into an outcome not possible with the 
standard trial data. Clinically, these data suggest that docetaxel administered in a CRPC 
setting has a similar or higher rate of neutropenic admission events than if administered 
in a HSPC setting and supports docetaxel use in this HSPC setting. However, due to the 
lack of clinical disease variables (for example, hormone-sensitivity) and poor coding 
quality in the routine data, the results of these analyses are hypothesis-generating and 
not conclusive, thus requiring further investigation. 
3.2 Declaration 
An abstract describing work contained in this chapter was submitted and accepted to be 
presented at the European Society for Medical Oncology (ESMO) annual meeting 









3.3.1 Clinical trial routine data use 
In this thesis, I set out to determine the feasibility of using routine data for clinical trial 
data collection and analysis. There are trial outcomes that can be directly identified in 
these data and outcomes that cannot be. This is because routine data contains limited 
clinical variables and therefore methods to directly collect outcomes may not be 
possible, so techniques need to be developed to indirectly detect such events (explored 
in chapter 4). These limited variables include clinical and pathological data, and this 
limitation is largely due to the fact that many of the data sources are focused on 
resource use rather than patient outcomes. Hence, analysis of some trial endpoints, 
such as progression, are often not directly possible. However, if the outcome of interest 
can be explicitly identified in these data, direct data analysis is theoretically possible, 
and is being explored here. These include events such as attendance at clinic, clinical 
interventions (surgery, chemotherapy) and diagnoses, which are commonly interrogated 
directly in the literature in non-trial non-oncology settings (43) (42). Therefore, this 
chapter aims to assess the feasibility of such methods in oncology randomised 
controlled trials (RCT) to answer a clinically relevant question that was previously not 
possible using traditional trial data collection techniques.  
 
I set out to identify if events constituting serious adverse events (SAE) (113) could be 
identified using routine data; SAEs are key events for trial conduct. The overall objective 
was to investigate the data scope for collecting these uro-oncology outcomes. If this was 
possible, it could be anticipated that other SAEs may be identifiable within the routine 
data, however, it is imperative that the quality and completeness of the routine data are 
validated with respect to each individual outcome. The STAMPEDE trial is aiming to 
reduce long term clinic-based follow-up for certain historical treatment arms and is 
scoping the possibility of routine data only follow-up on prospective trial arms. Hence, 
the aim for this thesis was to investigate the feasibility of such methods.  
 
Anecdotally, new rationale and hypotheses can arise during trial conduct; for example, 
the recent requirement to assess the rates of sepsis occurring on docetaxel 







(CRF) were not designed to collect these data required to test the new hypothesis, then 
this analysis is not traditionally possible. Furthermore, it is often not possible to 
retrospectively request this information directly due to recall bias; loss to follow-up 
and/or the resources needed to interrogate large sample sizes. These limitations can 
apply both to patients and to clinical sites. Hence, when new hypotheses arise, often 
single-site audits are conducted, or comparisons are made across trials, using partial 
data. Where outcomes cannot be identified through randomisation in a single trial, it is 
appreciated that ‘there are inherent dangers associated with any attempt to directly 
compare the outcomes observed in independently conducted clinical trials’ (115). This is 
largely due to differing patient study inclusion criteria and therefore heterogenous 
populations, but also differing definitions for outcomes, across studies, make 
comparisons difficult. Thus, I set out to assess direct data analysis techniques using 
neutropenic toxicity as an example, within a single randomised population. 
3.3.2 Neutropenic sepsis 
Neutropenic sepsis is a common complication from the anticancer agent chemotherapy 
(116). Incidences as high as 70-100% have been reported after intensive therapy (117). 
During chemotherapy treatment, infection fighting neutrophils in the blood can be 
destroyed (called neutropenia (agranulocytosis)), leading to increased susceptibility to 
infection, contributing to both sepsis and mortality events. Neutropenic sepsis is a 
medical emergency and treatment involves intravenous infusion of antibiotics during a 
hospital admission (118). One study published an overall in-hospital mortality rate of 
9.5% after diagnosis of sepsis, increasing to greater than or equal to 21.4% if the patient 
had more than one comorbidity (additional conditions) (119). The median length of stay 
was 11.5 days with a median cost per episode of $8,376 (119). In a United Kingdom (UK) 
based lung cancer study, the burden of neutropenic sepsis was also investigated (120). 
The mean length of stay for confirmed neutropenic sepsis was 9.2 days and the mean 
cost was £3,163 per episode (120). 
 
Therefore, sepsis events account for not only a high mortality rate but also an extensive 








Neutropenia occurs when the number of neutrophils in the blood reduce to defined 
levels, and either a temperature higher than 38 degrees (febrile neutropenia) or ‘signs 
and symptoms of clinically significant sepsis’ are experienced (121). The body is then 
susceptible to bacteraemia (infection) and if this leads to a severe inflammatory 
response, this is defined as neutropenic sepsis (122). The neutrophil nadir usually occurs 
10-14 days following chemotherapy treatment and neutrophil levels usually increase 
again in two to four weeks following the chemotherapy (123). These different patient 
presentations can often lead to ambiguity in reporting these events. 
3.3.2.2 Neutropenic sepsis coding 
A coding consultation was launched by NHS Digital (NHSD) regarding the national 
standard of how to code sepsis events in administrative data sources. The aim was to 
refine a coding standard for use from the 1st April 2018. This included coding for sepsis, 
septic shock, severe sepsis and neutropenic sepsis events. It was highlighted that there 
was large variation in how sepsis events were coded between different hospital trusts, 
which was reported to potentially be due to variation in the source medical records 
(124, 125). NHSD proposed that the coding teams worked closely with the clinicians to 
reduce this variation so that monitoring of sepsis could then be investigated nationally 
(124, 125). The optimum coding for sepsis events was outlined (125), which contained 
the codes seen in table 5. However, for events prior to the 1st April 2018, no 










• Other sepsis (or the specific sepsis type recorded 
in the medical record) (124, 125) 
R65.1 
• Systemic inflammatory response syndrome of 
infectious origin with organ failure (only use if the 
sepsis is documented as severe) (124, 125) 
U82.X; U83.X; U84.X 
• U82.X - Resistance to beta-lactam antibiotics; 
U83.X - Resistance to other antibiotics; U84.X - 
Resistance to other antimicrobial drugs (only use 
if the sepsis is resistant to antibiotics or 
antimicrobial drugs) (124, 125) 
D70.X 
• Agranulocytosis (to use in addition to the above 
codes, to distinguish neutropenic sepsis from 
severe sepsis) (124, 125) 
Further ICD codes (from drugs, medicaments 
and biological substances causing adverse 
effects in therapeutic use (Y40-Y59)) 
• If documented in the clinical noting that the 
neutropenia was due to a drug, then an adverse 
effect code should be used in addition (124, 125) 
 
Table 5: ICD coding that should be utilised post 01/04/18 to document neutropenic sepsis events. 
Code descriptions taken directly from the coding consultation report (124, 125). 
3.3.2.3 Neutropenic events in advanced prostate cancer 
Historically, hormone therapy has been the standard-of-care (SOC) for patients with 
advanced metastatic or high-risk hormone-sensitive prostate cancer (HSPC). However, 
recently (2015) two large randomised controlled trials (STAMPEDE and CHAARTED) 
evaluated the use of docetaxel (brand name Taxotere (Sanofi-Aventis)) chemotherapy at 
diagnosis for HSPC, paradigm shifting treatment in this patient subset. Both STAMPEDE 
(83) and the CHAARTED trial (126) (ChemoHormonal Therapy Versus Androgen Ablation 
Randomised Trial for Extensive Disease in Prostate Cancer) reported an increase in 
survival when docetaxel was administered upfront at diagnosis as first-line therapy for 
HSPC, rather than as a second-line therapy at disease relapse with castrate-resistant 
prostate cancer (CRPC). At disease relapse, the prostate cancer that was previously 
responding to hormone therapy (hormone-sensitive disease, HSPC) can become 
resistant to the therapy, leading to castration-resistant (CRPC) disease (87). Due to these 
studies, docetaxel plus hormone therapy is now regarded as the SOC in HSPC (127). 
 
As explained above, chemotherapy is known to lead to neutropenia (128) and 
potentially severe neutropenic events, defined here as those requiring hospitalisation; 
for example, severe neutropenia, febrile neutropenia, neutropenic sepsis, infection with 







The increase in adverse severe neutropenic events was observed in both STAMPEDE and 
CHARRTED, alongside other studies including local audits (table 6). There was also a 
raised neutropenic toxicity incidence in the GETUG-AFU15 RCT. GETUG-AFU15 was 
evaluating ADT alone, or with docetaxel, in HSPC metastatic patients. GETUG-AFU15, 
however, found a non-significant OS hazard ratio for docetaxel use in the HSPC setting 
(hazard ratio (HR) Docetaxel + ADT vs. ADT alone: 1.01, 95% confidence interval (CI) 
0.75–1.36) (129). In all of these studies the rates of febrile neutropenia were higher than 
those previously reported for use in the CRPC setting of the TAX-327 (published 2004) 
trial, at disease relapse (CRPC) (130). The TAX-327 trial was a Sanofi-Aventis 
pharmaceutical registration study that began recruiting in 2000, providing evidence to 
license docetaxel in the metastatic CRPC setting (130).  
 
Whilst utilising Docetaxel in a HSPC disease setting (upfront at diagnosis rather than at 
CRPC for relapsed disease), studies report an increase in serious neutropenic events, 
when compared to administration at development of CRPC. It has therefore, been 
proposed that the risk of serious neutropenia-related events may outweigh the benefits 
of the systemic therapy, if this hypothesis is true. 
3.3.2.4 Neutropenic events in the STAMPEDE trial 
The STAMPEDE trial was a prime setting to test this hypothesis of increased sepsis at 
HSPC because of the large-scale patient recruitment. This would ensure a large sample 
of randomised patients were administered docetaxel in both the HSPC (trial arms C and 
E) (introduction, figure 3) and the CRPC (patients on all trial arms A-G, at relapse) 
settings. Hence, a randomised cohort of 3,642 men were available for this analysis. 
 
Neutropenic events are collected in the STAMPEDE trial if they are related to the upfront 
HSPC docetaxel trial treatment. It is not mandatory to collect additional events due to 
later non-trial treatments, for example, at relapse with CRPC disease/treatment failure. 
Therefore, using the standard trial data it was not possible to compare the neutropenic 








Severe neutropenic events are documented in two distinct STAMPEDE CRFs: 1) Follow-
up forms (from trial initiation 2005); these are not reported in real time as require that 
the patient attends a study follow up visit and 2) Serious Adverse Event (SAE) forms.  
 
Adverse events (AE) and serious adverse events (SAE) are both collected by the trial. AEs 
are defined as: ‘Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have to 
have a causal relationship with this treatment’ (131). In comparison, SAEs are major 
safety events which are required to be reported to the Medicines and Healthcare 
Products Regulatory Agency (MHRA) (introduction 1.5.4). SAEs are adverse events that 
are defined as serious (SAEs are therefore a subset of AEs). As per the STAMPEDE 
protocol, SAEs include AEs that: resulted in death; were life-threatening; required 
hospitalisation or prolongation of a hospitalisation; resulted in significant disability or 
incapacity; consists of a congenital anomaly or birth defect or another important 
medical condition (medical discretion). SAEs are required to be reported within 24 hours 
of completing the SAE CRF (72) and STAMPEDE also requires that all SAEs should be 
reported within 30 days after the last trial treatment.  
 
STAMPEDE utilises the Common Terminology Criteria for Adverse Events system (CTCAE) 
to define trial AE reporting. It enables the standardised allocation of a grade (1–5) to 
each adverse event experienced (132). The grades are allocated depending on the 
severity of the event. For example, grade one (mild), grade two (moderate), grade three 
(severe), grade four (life-threatening or urgent intervention required) and grade five 
(death) (132). Then a subset of these AEs are reported as SAEs if they are defined as 
serious (as per the definition above). 
 
Hence, an event is only deemed to be an SAE if it meets the seriousness criteria. This is 
not the same as the severity criteria as used to report AEs. The terms serious and severe 
are not synonymous (131). Severity is used to describe the intensity of an event (for 
example, mild, moderate, severe) but this may be to describe an event of minor medical 
significance; for example, a severe headache (131). In comparison, seriousness, is 








Due to this distinction, it is possible that a grade one or two AE could also be an SAE. For 
example, a mild/moderate event that led to the patient being hospitalised. In addition, 
not all grade three or four AEs are reported as an SAE. This is because although the 
definition of severe may be met, the event may not be serious. Hence, despite the 
severity of grade three and four AEs, it is not possible to classify all grade three and four 
AEs as serious (SAEs). In addition, not all grade five AEs are also reported as SAEs; this is 
dependent on the timing of the event. If a patient died whilst receiving trial treatment, 
then this would always be reported as an SAE. Hence, these events would be reported 
as a grade five AE and an SAE. However, if a patient died greater than 30 days after 
finishing the trial treatment, then this would not be reported as an SAE. Hence, not all 
grade five AEs are also reported as SAEs. I am currently aware of a project being 
undertaken trying to merge these data sources (AEs, SAEs) without duplicating or 
omitting events; this is not straightforward. However, due to the severity of grade three 
plus AEs, it is more likely that these events constitute SAEs. 
 
If a low white blood cell count was reported without any sign of infection, this would 
have been reported as neutropenia and documented in the ‘neutrophils’ category on 
the CRF. If there were signs of infection, this should have been reported in the ‘febrile 
neutropenia’ category (for example, documenting neutropenic sepsis). Febrile 
neutropenia should be classified as grade three or higher due to the severity. In addition, 
any neutropenia event (even without infection) that involved hospitalisation should be 
recorded as a grade three, or higher AE. If the trial treatment led to hospitalisation (for 
example, severe neutropenic events), this AE should also be reported as an SAE. Due to 
the potential non-synonymous nature of AEs and SAEs, both sources of data were 
utilised to try to identify the maximum number of admissions. 
 
Hence, the definitions used to identify STAMPEDE severe neutropenic events for these 
analyses were either: 1) any febrile neutropenia reports (grade one or higher AEs or 
SAEs), or 2) neutropenia reports of grade three or higher AEs or SAEs. This should 
correspond with hospital admissions and therefore it was used as a reference to validate 
the Hospital Episode Statistic (HES) routine data neutropenic event admissions. The 
corresponding definitions to identify events from both HES and the clinical noting can be 







3.3.2.5 The incidence of neutropenic events from upfront (HSPC) vs. relapse (CRPC) 
docetaxel 
As mentioned above (section 3.3.2.3), an increase in severe neutropenic events were 
observed across the trials. The rates of febrile neutropenia were reported as follows: 
STAMPEDE (15%) (83), CHAARTED (6%) (126), and GETUG-AFU15 (8%) (129) (table 6). In 
all of these studies the rates of febrile neutropenia were higher than those previously 
reported for use in the metastatic CRPC setting in the TAX-327 trial (3%) (130). The total 
severe neutropenia rates can be observed in table 6. Table 6 also highlights the 
interchangeable neutropenic event definitions collected across studies. For example, 
neutropenia, febrile neutropenia, neutropenic sepsis and infection with neutropenia.  
 















(83) STAMPEDE 12 15 NR NR 
Sweeney 




AFU15 32 8 NR 2 
Mahil 
(133) Audit NR 30* NR NR 
Tanguay 
(134) Audit 36** NR 20** NR 
CRPC Tannock (130) TAX-327 32** 3* NR NR 
 
Table 6: The incidence of neutropenic AEs across trials and audits.  
The table was restricted to AEs as SAEs were often not reported by the studies. The types of event, 
as specified in the studies (neutropenia, febrile neutropenia neutropenic sepsis or infection with 
neutropenia) have been documented in the table. NR = not reported, * = not specified as grade 3-
5, ** = Grade 3 and 4 only.  
3.4 Objective 
If a patient develops severe neutropenia (neutropenia grade three plus, febrile 
neutropenia, neutropenic sepsis, infection with neutropenia) post-cycle 
(chemotherapy), the patient would be admitted to hospital for urgent treatment. I 
therefore hypothesised that admissions for neutropenic events whilst on chemotherapy 
could provide us with a proxy marker for severe neutropenic events, due to the lack of 







provides a unique view of the disease history, which has the potential to be utilised to 
extract major trial outcomes. The objective of this chapter is to establish the feasibility 









3.5 Systematic literature review: Introduction 
3.5.1 Rationale 
As described above, it is a known concern that the largest HSPC docetaxel RCTs 
presented a higher toxicity rate, than at CRPC. However, since these conclusions were 
drawn from cross-study comparisons (see table 6), I postulated that a single population 
study was necessary to compare these outcomes. I first undertook a systematic search 
to identify publications that examined this controversial sepsis rate, after these pivotal 
RCTs (table 6) were published to assess the quality of the evidence. 
3.5.2 Aims and objectives 
The objective of the systematic review was to identify publications and compare the 
literature surrounding the increased incidence in neutropenic toxicity between HSPC 
and CRPC docetaxel chemotherapy. The aim was to assess the origin of the current 
evidence informing clinical practice, since the practice changing RCTs (STAMPEDE, 









3.6 Systematic literature review: Materials and methods 
3.6.1 Eligibility criteria 
3.6.1.1 Criteria for selecting studies for this review 
Types of studies: Any level of clinical evidence, including non-trial studies and response 
letters to studies. 
Types of participants: CRPC patients or advanced metastatic or high-risk HSPC patients. 
Types of interventions: Docetaxel chemotherapy, for HSPC or CRPC. 
Types of outcomes: Incidence of severe neutropenic events. 
 
The search was not restricted by date or country and can be seen in table 7 (see section 
3.6.3 for further details). 
3.6.2 Information sources and search strategy 
The search was undertaken using two databases: Ovid Medline (since the database 
began in 1946 to Week 48 (November) 2018) and EMBASE (1980 to Week 48 2018). 
Articles were identified from the two databases using the search strategy in table 7; 





















Table 7: The Medline search strategy that was used to identify articles for the narrative literature 
review.  
3.6.3 Study selection  
After the search, the abstracts and titles were initially screened using the inclusion and 
exclusion criteria below. The remaining article full texts were then further screened 
manually for eligibility. The preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines (2009 (135)) (figure 7) were adhered to, where possible 
and appropriate, to document the results from the systematic search (appendix 8.1.1). 
 
Inclusion criteria: Publications regarding the HSPC neutropenic event rate, with or 
without a CRPC comparison, with or without data analyses, all types of evidence, 
publications in any language, all types of literature (including grey literature, for 
example, conference proceedings), literature with an online publication date after the 
first date of publication (August 2015) of the HSPC docetaxel trials (STAMPEDE; 
21/12/15, CHARRTED; 05/08/15) were also included.   
 
Exclusion criteria: Literature where the focus was not on docetaxel-related neutropenic 
events (search terms were required in the title, but articles were further screened for 
exclusion), events due to other chemotherapy drugs (for example, cabazitaxel) were 
excluded. In addition, studies where the risk of neutropenia was predicted or where 
neutropenia was assessed as a survival marker for chemotherapy, were excluded; 
Number Searches Results 
1 neoplasm*.m_titl. 62584 
2 cancer.m_titl. 1872019 
3 tumour.m_titl. 88561 
4 “malignan*”.m_titl. 76782 
5 prostate.m_titl. 235970 
6 docetaxel.m_titl. 16458 
7 taxotere.m_titl. 775 
8 sepsis.m_titl. 62244 
9 neutropeni*.m_titl. 19940 
10 neutropenic sepsis.m_titl. 120 
11 febrile neutropenia.m_titl. 3203 
12 septic shock.m_titl. 15709 
13 1 or 2 or 3 or 4 2082122 
14 6 or 7 16796 
15 8 or 9 or 10 or 11 or 12 94306 
16 5 and 13 and 14 and 15 26 







studies investigating the effect of a dose alteration on neutropenic events and 
conference abstracts for the already included full text were also excluded. 
3.6.4 Data collection process 
I undertook all of the review; no other investigators were utilised due to lack of 
resource. All references identified by the search (16 studies) were imported into 
Endnote Web. Data for the review was collated in Microsoft Excel and a qualitative 
narrative review was undertaken.  
3.6.5 Data items 
The following variables were sought; participant setting (advanced metastatic or high-
risk, HSPC or CRPC, patients), type of study (any level of clinical evidence, including non-
trials and response letters to studies), year of publication (in addition, the e-publication 
date was identified), intervention (if docetaxel was administered for HSPC or CRPC 
disease) and outcomes (the incidence of severe neutropenic events). Database, author, 
title and journal were also extracted but were not discussed during the review. 
3.6.6 Risk of bias 
A general risk of bias analysis was performed, with the potential sources of bias 
considered by following the Cochrane handbook guidance (136); selection, performance, 
detection, attrition and reporting bias. Due to the heterogeneous types of study and the 
nature of the type of article (for example, abstract only), a risk of bias assessment could 
not formally be undertaken. However, the selection and reporting biases were 
investigated, where possible, for the three audits identified. The reasons for not 








Risk Rationale for the risk of bias assessment 
Selection How patients were allocated to treatments – assessed (important when making cross-study conclusions) 
Performance 
NR: Blinding of participants is not relevant in this analysis, an RCT was not being 
conducted – all patients were aware they were being administered chemotherapy 
and the impacts on the outcomes were therefore assumed to be equal and thus was 
not investigated 
Detection 
NR: Blinding of outcome assessors is not relevant in this analysis, an RCT was not 
being conducted – the rationale is that outcomes are affected by the knowledge of 
the intervention. All of the assessors were aware of the administration of 
chemotherapy  
Attrition NR: Missing data – an RCT was not being conducted 
Reporting The reporting of all outcomes – an RCT was not being conducted. However, the comparability of reported outcomes was assessed 
 
Table 8: Rationale for the risk of bias investigation. 
NR = not reported 
3.6.7 Summary measures 
Incidence values of neutropenic events were identified in the literature. The studies did 
not report 95% confidence intervals (CI) for the incidence values, so these were 
calculated in R (109), RStudio (110) given the reported data. An asymptotic binomial 
distribution was assumed. The number of events experienced were also estimated when 
a percentage number of events experienced in a cohort was provided, but no event 
number. 
3.6.8 Synthesis of results/additional analyses 









3.7 Systematic literature review: Results 
3.7.1 Study selection 
The number of publications identified using each search term can be seen in table 7. 
2,082,122 articles were identified in oncology, 235,970 related to prostatic disease, 
16,796 related to docetaxel and 94,306 related to neutropenic events. 26 articles were 
identified that were deemed (by the electronic search) related to neutropenic events 
occurring due to docetaxel for prostate cancer. One further publication was identified 
from another source upon a manual search, Google Scholar (137), totalling 27. Once 
duplicates were removed, 17 papers remained (figure 7). 
 
 
Figure 7: A PRISMA flow diagram showing the stages undertaken to identify the seven papers 
analysed in the qualitative narrative review. 
 
Ten papers were then manually excluded during abstract screening; those that assessed 
neutropenia risk factors (N=5); those where chemotherapy was not docetaxel 
(cabazitaxel) (N=1); those that were presenting a conference abstract for an already 
excluded full-text (N=1); those that assessed neutropenia as a survival marker (N=2) and 
those that assessed the effect of a lower dose of docetaxel on febrile neutropenia (N=1). 







3.7.2 Summary of the literature identified 
The seven publications (five letters, one full-text publication and one conference 
proceeding) identified in the search are summarised in table 9. Two studies enabled 
comparison of both HSPC and CRPC patients: Schweizer (138) and Maria (139). 
Schweizer compared rates within the same population (audit (138)) and Maria, within 
different populations (meta-analysis (139)). The meta-analysis my Maria examined the 
toxicity rates of multiple published phase II and III clinical trials and enabled analysis 
across both settings. Two papers analysed rates in the single hormone setting (HSPC) 
through single site audits (Tanguay (134), Mahil (133)). As both Tanguay and Mahil 
analysed data within a single hormone setting, assumptions made of higher HSPC 
toxicity, than at CRPC, relied upon cross-audit or cross-trial comparisons, as did Maria 
despite the multiple site nature of a meta-analysis (139). There were also three letters 
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Table 9: Summary of the search results. 
3.7.3 HSPC vs. CRPC neutropenic toxicity 
Varying toxicities were documented for HSPC patients across the different studies (table 
10). The audits by Mahil (133) and Tanguay (134) suggested that the incidence of 
neutropenic events was higher in the HSPC setting (table 10) than the CRPC setting 
(compared to TAX-327) and that the incidence of events may also be higher than 
previously reported by STAMPEDE (83), GETUG-AFU15 (129) and CHAARTED (126). This 
was also summarised by Tsao in an opinion piece (140). This was in contrast to the 
conclusions by Maria (139) (aggregate meta-analysis) and Schweizer (audit) (138), both 
reporting no significant differences by hormone sensitivity.  
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 Table 10: HSPC and CRPC neutropenic event (neutropenia, febrile neutropenia, neutropenic sepsis or infection w
ith neutropenia) incidence values identified in 
the review
 studies (term
inology as reported w
ithin each individual study).  
 ^ = The incidence of the four RCTs (STAM
PEDE, CHARRTED, GETUG-AFU15 and TAX-327), w
hich are used in the com
parisons; NR = Not reported; * = not 
specified as grade 3-5; ** = grade 3 and 4 only; *** = Defined as neutropenic fever. As TAX-327 did not publish the absolute num





 the percentage rate published. The w
indow
 of recording toxicity events varied across trials. For exam
ple, the result reported above in 
STAM
PEDE included events up to 30 days after discontinuation of protocol treatm
ent. The STAM
PEDE protocol states, ‘All Serious Adverse Events (SAE) and 
Adverse Events (AE) are reportable from
 the tim
e of random
isation until 30 days after discontinuation of protocol treatm
ent (refer to Section 11.1.2)’ (72). 
CHAARTED did not specify the reporting w
indow
, other than that results w
ere reported for w
here follow
-up w
as available, therefore the entire trial period w
as 
potentially used. GETUG-AFU15 reported events in the first 6 m
onths of treatm
ent and TAX-327 collected events that occurred or w
orsened during treatm
ent, 
but no further inform
ation w
as provided; X = The num
ber of patients in each group w
ere not published, 5,088 patients w
ere included in the m
eta-analysis 
across seven studies but the num
ber of HSPC or CRPC patients w








Tanguay (134) undertook an audit of HSPC docetaxel neutropenia and neutropenic 
sepsis events (N=39) at a single site. In this audit, grade 3 and 4 neutropenia was 
experienced in 14/39 (36%) of patients and grade 3 and 4 neutropenic sepsis in 8/39 
(21%) of patients (although this value was incorrectly rounded in the published article to 
20%) (table 10). In the Mahil (133) single site audit of HSPC febrile neutropenia events 
(N=53), 16/53 (30%) developed an event. The two following issues were described in the 
single setting non-trial audits (Mahil, Tanguay), 1) a higher event incidence at HSPC was 
identified than in the STAMPEDE HSPC trial population and 2) the HSPC incidence was 
higher than in the CRPC group, when compared to TAX-327 (figure 8).  
 
In contrast, Schweizer (138) conducted an audit of non-trial (N=61) patients at a single-
site. 2/22 (9%) developed neutropenic fever in the HSPC setting compared to 2/39 (5%) 
in the CRPC setting but still concluded this ‘did not demonstrate that docetaxel is more 
toxic in the mHSPC (m = metastatic) setting compared to the mCRPC setting’ due to a 
non-significant p-value (p=0.95). The aggregate meta-analysis by Maria (139) included 
seven RCT studies (total number of patients across groups: N=5,088); 6.6% of patients 
that received docetaxel in the CRPC setting developed febrile neutropenia, compared to 
12.4% in the HSPC setting (the number of patients in each hormone state were not 
documented). Despite this, there was also no statistically significant difference (p=0.7) in 
the febrile neutropenia rate by hormone-sensitivity (HSPC 12.4%; CRPC 6.6%). The exact 
model used to generate the incidence and P-values were not reported. However, the 
risk ratio calculations were conducted using the Mantel-Haenszel method with a fixed-
effects model.  
 
When comparing the incidence values for febrile neutropenia or neutropenic sepsis, 
from the single hormone-state studies (Mahil, and Tanguay) to the CRPC TAX-327 trial, 
an increased toxicity in the HSPC setting was seen (30% Mahil, 21% Tanguay, 3% TAX-
327). The meta-analysis by Maria and the audit by Schweizer, also identified an increase 
in febrile neutropenia events compared to TAX-327 (12% and 9% respectively). 
However, when comparing both HSPC and CRPC groups in the Schweizer and Maria 









Figure 8: Across study reported rates of febrile neutropenia.  
One study (Schweizer) used a different terminology for febrile neutropenia (neutropenic fever). 
 
Confidence intervals were estimated for the event incidence rates, as these were not 
reported (table 11).  
 
Setting Author Type 





Mahil (133) Audit 16/53 (30) 0.18-0.43 (febrile neutropenia) 
Tanguay (134) Audit 8/39 (21) 0.08-0.33 (neutropenic sepsis) 
Schweizer (138) Audit 2/22 (9) 0.00-0.21 (neutropenic fever) 
STAMPEDE* RCT 84/550 (15) 0.12-0.18 (febrile neutropenia) 
CHARRTED* RCT 24/390 (6) 0.04-0.09 (febrile neutropenia) 
GETUG-AFU15* RCT 15/189 (8) 0.04-0.12 (febrile neutropenia) 
CRPC Schweizer (138) Audit 2/39 (5) 0.00-0.12 (neutropenic fever) TAX-327* RCT 9-11/332 (3) 0.01-0.04/0.05 (febrile neutropenia) 
 
Table 11: Estimated confidence intervals calculated from the audit AE rates, compared to 
published RCT incidence values (*). 
 
In the TAX-327 RCT, 3% of 332 developed febrile neutropenia, it was therefore 
estimated than 9-11 events were experienced (95% CI: 0.01 – 0.04/0.05) (table 11). In 


































































0.18) (table 11). In the CHAARTED RCT, 6% experienced febrile neutropenia (grade 3 or 
4) (24/390, 95% CI: 0.04 – 0.09) and in GETUG-AFU15, 7% (14/189) experienced a grade 
3-4 febrile neutropenia event and <1% (1/189) experienced a grade 5 event, therefore 
8% (15/189) experienced a grade 3-5 event (95% CI: 0.04 - 0.12) (table 11). The 
confidence intervals for the audits can also be seen in table 11, ranging from 0.00 – 0.43 
in the HSPC setting (three studies) and 0.00 to 0.12 in the CRPC setting (single study). 
 
The seven individual studies (figure 8) were analysed to investigate explanations for 
these increased HSPC toxicity concerns, including: heterogeneous populations (cross-
trial/audit comparisons), translation of results to a real-world setting, sample size and 








3.8 Systematic literature review: Discussion 
No randomised, or large-scale non-randomised analyses (the only non-randomised 
comparison study was by Schweizer, N=61) or comparisons were identified that 
compared HSPC and CRPC neutropenic events within the same population. In the 
absence of this, conclusions were drawn from making simple comparisons, which may 
have led to reporting bias and invalid conclusions being drawn. An increased toxicity in 
the HSPC setting was concluded by Mahil and Tanguay, whilst making cross-study 
comparisons (due to conducting single hormone-setting analysis) to the CRPC TAX-327 
trial. It is difficult to generalise these conclusions drawn from cross-study comparisons, 
due to heterogeneity in the patients recruited, for example, with a difference in baseline 
inclusion criteria. This may mean that some cohorts have a fitness advantage, biasing 
the outcome. 
 
In contrast, when comparing HSPC and CRPC febrile neutropenia rates within the same 
population (Schweizer (138)), there was no statistically significant difference between 
the groups, despite a higher rate in the HSPC group. All of these audits had small cohort 
numbers and were run at single-sites; Mahil (N=53), Tanguay (N=39) and Schweizer 
(N=61). In Maria’s meta-analysis, there was an increase observed in the HSPC group, and 
again, there was no statistical difference between the groups. Although the meta-
analysis was based upon cross-trial comparisons, this is a better level of evidence than 
comparing the results of single audit studies, due to higher power, with an overall larger 
cohort size. When the population was homogenised, by either increasing sample size by 
including more trials (Maria), or investigating patients from within the same site 
(Schweizer), no significant difference was identified between the groups. Hence, single 
cross-study comparisons may have been leading to incorrect conclusions. 
 
Furthermore, the studies did not report confidence intervals (CI) for the incidence 
values. However, where possible, I estimated the 95% CIs, which are shown in table 11. 
In the HSPC setting, wider confidence intervals can be seen (Mahil (133), Tanguay (134) 
and Schweizer (138)) due to the smaller sample sizes (table 11). The lower limits in the 
HSPC group of 0.08 (Tanguay (134)) and 0.00 (Schweizer (138)), suggest that the HSPC 
incidence of severe neutropenic events could have been very low; this would have 







TAX-327 (in the Schweizer study). The TAX-327 intervals also overlapped with the HSPC 
trials CHAARTED and GETUG-AFU15; giving further potential evidence towards less 
distinct rates by hormone-sensitivity. The above HSPC toxicity rates should therefore be 
interpreted with caution due to these overlapping confidence intervals, across studies.  
 
Where there is ambiguity in the documentation and classification of events (124, 125) 
(such as neutropenic events), it is difficult to make cross-study comparisons. For 
example, the terms neutropenic sepsis and febrile neutropenia are often used 
interchangeably (122). This lack of standardised criteria can be seen across the studies 
above (table 10), resulting in difficult cross-study comparisons. The three single-site 
audits (Mahil (133), Tanguay (134) and Schweizer (138)) reported different types of 
neutropenic events (table 10); Mahil (133) reported febrile neutropenia but the grade 
was not specified, Tanguay (134) reported neutropenia and neutropenic sepsis but 
grade 3 and 4 only and Schweizer (138) reported neutropenic fever but did not specify 
the grade. Therefore, comparison of febrile neutropenia rates across audits was not 
possible. Tanguay reported HSPC neutropenia and neutropenic sepsis rates and 
compared these to the STAMPEDE rates. However, although STAMPEDE reported a 
neutropenia rate, STAMPEDE did not publish a neutropenic sepsis rate and instead 
reported febrile neutropenia. Tanguay also wrongly reported the published STAMPEDE 
rate of febrile neutropenia and as previously stated, incorrectly rounded the 
neutropenic sepsis audit rate. Maria (139) quoted a febrile neutropenia rate but did not 
specify the grade, nor was it possible to determine how the included studies graded 
events.  
 
In the HSPC RCTs, STAMPEDE, CHAARTED and GETUG-AFU15 all published grade 3-5 
neutropenia rates, but only grade 3-4 were reported in TAX-327 (CRPC). Grade 3-5 
febrile neutropenia was also reported in STAMPEDE, CHAARTED and GETUG-AFU15 but 
the grade was not specified in TAX-327. Neutropenic sepsis rates were not reported by 
the RCTs, although neutropenic sepsis is the term often used. GETUG-AFU15 was also 
the only study to report both AE and the subset of SAEs, therefore it was not possible to 
compare SAEs across the trials. It cannot always be assumed that all grade 3+ events 
resulted in hospitalisation. Therefore, not all grade 3+ AEs equal SAEs; this can be seen 







as grade 3+ (see section 3.3.2.4 for further details). As reported by Sydes (114), these 
varying toxicity criteria and classification of events make audit-trial comparisons and 
cross-trial comparisons challenging and ‘greater standardisation in reporting is required’ 
(114). 
 
There were also further considerations making conclusions drawn from the published 
literature challenging; it was often not reported whether drugs had been administered 
in combination with a drug called granulocyte colony-stimulating factor (G-CSF) (to help 
reduce the damage to the white blood cells), this may have had incidence implications. 
Furthermore, the rates of febrile neutropenia reported in the audits will have been 
identified from clinical noting, this may not have documented the neutrophil count or 
fever and may have led to an overestimation in cases. Some events may have also been 
missing if they occurred at other hospitals (142). Some events may also have been 
checked (screened) for more frequently; therefore, more events would potentially have 
been reported. For example, the TAX-327 licencing trial regularly checked for 
neutropenia using laboratory abnormalities. In contrast to STAMPEDE, when docetaxel 
was an established treatment, laboratory screening was not routinely undertaken, 
hence a higher reporting rate of neutropenia was expected in TAX-327. 
 
Patient selection can also lead to a risk of bias. In small single-site audits, the results may 
reflect local clinical practice, for example, patient selection for treatment, rather than 
true drug effects. Patients may have been selected based upon fitness and fitter patients 
may be less at risk of events. No patient characteristic tables including age, Charlson 









3.9 Systematic literature review: Conclusion 
Much of the evidence of higher toxicity burden when utilising docetaxel for HSPC arose 
from making cross-trial comparisons which are inherently challenging (144). 
Furthermore, these comparisons were made in the absence of randomisation; 
randomisation is the ‘gold standard’ technique to control differences in patient 
characteristics and other factors, that may otherwise bias conclusions when making 
cross-study comparisons. I explored possible explanations for these different 
neutropenia event rates, including, small audit sample sizes effecting significance (133, 
134), overlapping confidence intervals and interchangeable definitions (134, 140, 141).  
 
Due to an absence of any randomised studies comparing rates, there is an unmet clinical 
need to resolve this toxicity uncertainty. Hence, this is an ideal setting to investigate if 
routine data could be used to perform analysis not previously possible with standard 
trial designs. This chapter outlines a method to utilise routine data to enable direct 
comparison in the same patient population. Due to the broad eligibility criteria of the 
STAMPEDE trial (72) and the vast numbers of patients recruited, I believed that valid 
within-trial comparisons of neutropenic event rates could be undertaken, whilst 








3.10 Use of routine data to evaluate severe neutropenic events in patients 
administered docetaxel for HSPC and CRPC: Rationale 
Routine healthcare data can contain limited variables (clinical/pathological details), 
necessitating the development of indirect models to enable outcome analysis (explored 
in chapter 4). However, if the routine data contains the variables required to answer a 
research question, then these data can be interrogated directly (introduction 3.3.1). In 
order to assess the feasibility of using these data directly for oncology clinical trial 
outcome reporting, neutropenic AEs were investigated within the STAMPEDE trial, as an 
example. The use of routine data was evaluated whilst comparing severe neutropenic 








3.11 Materials and methods 
3.11.1 Approvals 
Details of the approvals required for this study can be found in chapter 2, section 2.4. 
For example, STAMPEDE trial consent for routine data access; STAMPEDE ethics 
approval (hence, this study is consequently an ancillary study within the STAMPEDE trial, 
as detailed in section 17.4 of the protocol) (72); registration for the University Hospitals 
Birmingham, Queen Elizabeth Hospital (UHB QEH) audit and applications to the Medical 
Research Council, Clinical Trials Unit at University College London (MRC CTU at UCL) for 
STAMPEDE database access. As detailed in section 2.4.1, routine HES data for the single 
site UHB QEH were previously provided upon application to the Health and Social Care 
Information Centre (HSCIC, now NHSD) (27). For multiple-site data analyses I applied to 
Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS) 
for multiple dataset access. The HES (admission data set) and Systemic Anti-Cancer 
Therapy Dataset (SACT) (cycle and regimen datasets used) were utilised during these 
analyses (see table 12 and figure 9) (52). 
 
Dataset Data start Data end 
HES admission data 14/11/2005 31/01/2018 
SACT cycle data 09/04/2010 31/12/2017 
SACT regimen data 23/06/2009 31/12/2017 
 
Table 12: The earliest and latest interaction events identified in the HES and SACT datasets, 








Figure 9: The earliest and latest interaction events identified in the HES and SACT datasets.  
The figure graphically displays the information shown in table 12. 
 















Four distinct cohorts were analysed, and participants may have fit in multiple cohorts 
(table 13, table 14, figure 10). The overall rationale for inclusion was as follows: all 
participants were enrolled in the STAMPEDE study in England. The cohorts chosen were 
dictated by the trial arms, the date of randomisation with regards to the availability of 
the routine data and further routine data specifics (data available and linkage successful) 
(figure 11).  
 
 As STAMPEDE uses a Multi-Arm-Multi-Stage (MAMS) trial design (section 1.1 and 1.5.1), 
patients were analysed across multiple treatment arms (A-G). See the introduction 1.5.1 
for a description of the treatment arms and the trial protocol for further treatment arm 
details (72).  
 
Patients were required to have consented for routine data access. Participants included 
in the analyses were randomised between 15/11/2005 and 17/01/2014 (table 13). 
However, for the cohort three analyses, only patients randomised after 01/04/12 could 
be included due to the availability of the SACT data, which in turn reduced the number 
of trial arms which could be analysed (i.e. D or F patients were excluded) (figure 11) 
(figure 12). 
 
Cohort One Two Three Four 
Number of 
patients 44 
113 (69 unique 
vs. cohort 1) 
1,573 (1,548 unique 
vs. cohort two) 
3,642 (2,069 unique 
vs. cohort three) 
Arm A-F A-G A, B, C, E, G A-G 
Randomised 23/05/06- 22/02/13 
28/02/06-
20/12/13 01/04/12-17/01/14 15/11/05-17/01/14 
Site Single-site (UHB QEH) 
Single-site 
(UHB QEH) Multi-site (England) Multi-site (England) 
 
Table 13: The four cohorts used in the analyses. 
 
Cohort one and two were single site studies, however, cohort three and four were large 
multi-site analyses (table 13). The number in each cohort can be seen in table 13 and the 










Cohort Cohort Total 1 2 3 4 
1 44 44 3 41 44 
2 44 113 25 106 113 
3 3 25 1573 1573 1573 
4 41 106 1573 3642 3642 
Total 44 113 1573 3642 - 
 
Table 14: Cross-tabulation of STAMPEDE participants and membership in each cohort.  











Figure 10: Venn diagrams illustrating the overlap between study cohorts. 
A) The patient overlap between the largest cohorts (four) and the other cohorts (one – three). B) 




Cohort 3 Cohort 4 
2,069 1,573 0 
Cohort 1, 2 or 3 Cohort 4 






























Figure 11: Patients included in the large-scale analyses, cohorts three and four.  
 
* = Docetaxel HSPC regimens were identified using the STAMPEDE database for all algorithms in 
the cohort 3 and 4 analyses. However, additional data available in the SACT dataset identified 
extra chemotherapy regimens shortly before randomisation, these patients were excluded (N=2), 
due to the potential for confounded classification of HSPC treatment. ** = Where it was not 
possible to infer a chemotherapy end date, the patients were excluded (N=1). It was not possible 
to classify the hormone-setting of these events by date using the rules, due to the missing data. 
 
For the multi-site studies, the 3,971 patient cohort comprised of all eligible STAMPEDE 
England arm A-G patients that had been identified as consenting to data linkage at the 
time of the final analyses (figure 11). After linkage to the routine data by the provider 
and after exclusions due to date and event timeliness (for example, after 
randomisation), 1,573 and 3,642 patients were available for cohort three (SACT and 
HES) (figure 12) and four (HES-only) analyses, respectively (figure 11) (figure 12).  
329 excluded (not received from PHE: 
failed linkage or no HES data) 
2,066 excluded (arms D, F and 
contemporaneous A patients and those 
randomised before 01/04/12) 
3 excluded (regimens shortly before 
randomisation, N=2* or no chemotherapy 
end date, N=1**) 
3,971 STAMPEDE patients in total in the AG, ABCE, ADF comparisons 
from England sites that consented for follow-up using flagging data 
COHORT 4: 3,642 patients in the HES A-G comparisons 
1,576 patients in the comparisons with HES data (randomised 
01/04/12 – 17/01/14, no arm DF patients due to dates) 
COHORT 3: 1,573 patients with regimens after 










Figure 12: Cohorts analysed from the STAMPEDE trial.  
Red arrow: For cohort three analyses, only A, B, C, E and G were recruiting whilst the SACT data 
were available (patients randomised between 01/04/12 – 17/01/14). Black arrow: The other 
cohort analyses (one, two and four) included patients from all arms, as the HES data were not 
restricted by date; therefore all patients could be captured and hence analysis included patients 








3.11.3 Data sources and events of interest 
Data were extracted for the cohorts from three separate sources (post-STAMPEDE 
randomisation): 1) STAMPEDE trial database, 2) routine data records (HES and SACT 
datasets) and 3) reference clinical noting (single site UHB QEH) (see section 2.3). Events 












Figure 13: Figure to show the three separate sources of data and their intersections. 
RD = routine data (HES, SACT); TD = trial data (STAMPEDE trial); CND = clinical noting data (single 
site). 
 
The elements extracted from the three datasets can be seen in table 15. The STAMPEDE 
database records that were extracted included: treatment allocation, neutropenic 
events plus when the event occurred (weeks post-randomisation) and randomisation 
date. Routine data and clinical noting records of interest were extracted including: 
neutropenic admission events (see table 16 for routine data codes) and chemotherapy 


































1 HSPC docetaxel given? ü û 
2 Later chemotherapy given upon relapse?^ (proxy for CRPC chemotherapy) ü ü 
3 Chemotherapy drug ü ü* 
4 Estimated week commenced ü ü* 
5 Neutropenic events (severe – not including blood only changes) ü ü 
6 The number of weeks post randomisation of the event ü ü 
7 Severe neutropenic events due to HSPC or CRPC chemotherapy ü ü 
8 Further notes on the event ü û 
 
Table 15: The data elements extracted from the clinical noting, STAMPEDE data and the routine 
data.  
* = identifiable in the SACT data only, not HES. ^ = confirmed via note review. However, when the 
events were extracted from the routine date, in the absence of a reference, these events were 
inferred using a validated proxy. 
 
The clinical records were considered the reference standard and were analysed via a 
case series note review to identify the event of interest: admission for suspected 
neutropenic event. This was defined as: admission to hospital for suspected neutropenic 
sepsis/febrile neutropenia/severe neutropenic event, plus a requirement to be on a 
chemotherapy regimen at the time of the event. Biochemical neutrophil count was not 










X903 Neutropenia drugs band 1 
ICD coding 
D70X* Agranulocytosis 
A400 Sepsis due to streptococcus, group A 
A401 Sepsis due to streptococcus, group B 
A402 Sepsis due to streptococcus, group D 
A403 Sepsis due to Streptococcus pneumoniae 
A408 Other streptococcal sepsis 
A409 Streptococcal sepsis, unspecified 
A410* Sepsis due to Staphylococcus aureus 
A411* Sepsis due to other specified staphylococcus 
A412* Sepsis due to unspecified staphylococcus 
A413* Sepsis due to Haemophilus influenzae 
A414* Sepsis due to anaerobes 
A415* Sepsis due to other Gram-negative organisms 
A418* Other specified sepsis 
A419* Sepsis, unspecified 
R572 Septic shock 
R579 Shock, unspecified 
R651* Systemic inflammatory response syndrome of infectious origin with organ failure 
 
Table 16: Codes identified in the routine data by the algorithms to identify neutropenic 
admissions.  
* = codes referenced in the NHS coding consultation detailed in the introduction for this chapter 









X701 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 1 
X702 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 2 
X703 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 3 
X704 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 4 
X705 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 5 
X708 Other specified procurement of drugs for chemotherapy for neoplasm in Bands 1-5 
X709 Unspecified procurement of drugs for chemotherapy for neoplasm in Bands 1-5  
X711 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 6 
X712 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 7 
X713 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 8 
X714 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 9 
X715 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 10 
X718 Other specified procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
X719 Unspecified procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
Chemotherapy delivery 
X352 Intravenous chemotherapy 
X373* Intramuscular chemotherapy 
X384* Subcutaneous chemotherapy 
X721 Delivery of complex chemotherapy for neoplasm including prolonged infusional 
treatment at first attendance 
X722 Delivery of complex parenteral chemotherapy for neoplasm at first attendance 
X723 Delivery of simple parenteral chemotherapy for neoplasm at first attendance 
X724 Delivery of subsequent element of cycle of chemotherapy for neoplasm 
X728 Other specified delivery of chemotherapy for neoplasm 
X729 Unspecified delivery of chemotherapy for neoplasm 
X731* Delivery of exclusively oral chemotherapy for neoplasm 
X738* Other specified delivery of oral chemotherapy for neoplasm 
X739* Unspecified delivery of oral chemotherapy for neoplasm 
X748 Other specified other chemotherapy drugs 
X749 Unspecified other chemotherapy drugs 
Y123* Electrochemotherapy to lesion of organ NOC (not otherwise classifiable) 
 
Table 17: OPCS codes identified by the HES routine data algorithms to identify chemotherapy 
regimens.  
Nota bene: The SACT + HES algorithm used detailed drug data to identify chemotherapy regimens 
(SACT acquired) and not the above routine data codes. * = Broader codes included to detect 
miscoded chemotherapy events. 
 
Chemotherapy was identified in the clinical noting. It was either determined to have 
been given upfront in STAMPEDE (classified as administered for HSPC), or not, which 
was therefore classified as being given at relapse despite hormone therapy (72, 145) 
(classified as administered for CRPC).  
 
Chemotherapy regimens were also identified in the routine data and classified as being 
administered for the two groups: 1) HSPC or 2) CRPC. Due to the extent of the missing 
routine data HSPC regimens, these regimens were identified using the STAMPEDE 
database; if the patient was randomised to trial arm C or E (see figure 12), these patients 







in the routine data documenting hormone settings, the timing of administration was 
used as a proxy for identifying CRPC docetaxel regimens in the routine data. Hence, 
when the algorithm was using routine data to define hormone settings, these were not 
defined by a trial documented response to treatment but by a series of assumptions. 
 
 It is possible that a patient could have had chemotherapy in both HSPC and CRPC 
settings. Neutropenic admission events were also identified, and further rules were 
created to classify whether the routine data-derived neutropenic event occurred due to 
HSPC or CRPC chemotherapy, or if unrelated. It is possible that a patient had 
chemotherapy in both HSPC and CRPC settings, hence, it is possible that a patient could 
have had a neutropenic event in both settings. Therefore, partially paired data are 
possible (146). However, all patients were included to reflect the reality of clinical 
practice (see discussion 3.13). Data were treated as independent events and no further 
statistical tests were undertaken to account for this. 
 
Once a neutropenic event was identified, it was presumed to be associated with 
chemotherapy if it occurred within four weeks of the last cycle administration. This is 
due to the neutrophil nadir which was discussed in section 3.3.2.1 (123). Neutropenic 
events outside of the four-week time frame were assumed to be either due to CRPC 
chemotherapy or unrelated to chemotherapy. These events were assessed to identify if 
they were CRPC-related using a series of rules (as described in section 3.11.7.1). If the 
event was determined to be unrelated to chemotherapy, they were excluded from the 
analyses. 
3.11.4 Data censor 
Dates of available follow-up data for each cohort differed by data source and are shown 
in table 18. 
 
• Cohort one, two and four: Data for each participant were analysed from the date of 
STAMPEDE randomisation (table 18) and censored at the last available HES episode 








• Cohort three: Data were analysed from the first patient randomised (table 18) after 
SACT data began being collected (01/04/12) and censored at the SACT data freeze 
(31/12/17) (table 18). Although SACT collection began prospectively in April 2012, 
collection at sites became mandatory from July 2015. Retrospectively input data 
prior to prospective data collection in April 2012 were excluded from the analysis, 
hence, data analysis began on the 01/04/12. Due to performing analyses on 
restricted published STAMPEDE cohorts (A-G), no patients randomised past 
17/01/14 were available for this study. Therefore, all events were prior to 
mandatory data collection, with clear accuracy implications.  
 
Cohort Start/censor STAMPEDE randomisation date 
HES 
admission 
SACT cycle & 
regimen 
Cohort 1 Start analysis 23/05/06 23/05/06 NA Censor 22/02/13 30/07/16 NA 
Cohort 2 Start analysis 28/02/06 28/02/06 NA Censor 20/12/13 31/03/17 NA 
Cohort 3 Start analysis 01/04/12 01/04/12 01/04/12 Censor 17/01/14 31/12/17 31/12/17 
Cohort 4 Start analysis 15/11/05 *14/11/05 NA Censor 17/01/14 31/01/18 NA 
 
Table 18: Censor dates used for the analyses.  
* = Data were provided six months prior to randomisation; therefore, it was possible to find 
events prior to randomisation, hence, an admission was reported one day prior to randomisation. 
 
3.11.5 Routine data linkage 
The routine HES and SACT data were linked to the STAMPEDE trial data by PHE NCRAS 
(as described in 2.4.1). The trial to routine data linkage rates were calculated as the 
number of patients that were linked to the routine data sources (HES and SACT), as a 
percentage of the total.  
3.11.6 Data preparation 
Data preparation was required to extract meaningful data from the routine data 
resources. The HES data required for the analyses were present within one data table, 











DIAG (all fields) (ICD codes) 
OPERTN (all fields) (OPCS codes) 
 
Table 19: Fields utilised from the HES data table for analysis. 
 
The SACT data required were between two tables, the SACT REGIMEN and CYCLE table. 
Therefore, the SACT data had to be processed in order to make a single analysable 
dataset. The SACT REGIMEN and CYCLE table were merged (by the unique variable 
MERGED_REGIMEN_ID_PS) to create a data table of required fields (table 20) containing 
a start and an end date of treatment. 
  




START_DATE_OF_REGIMEN   
DATE_OF_FINAL_TREATMENT   
 
Table 20: Fields utilised from the SACT data tables for analysis. 
 
When not available in the REGIMEN table, the dates of final treatment were identified 
as the last cycle date (variable: START_DATE_OF_CYCLE) from the CYCLE table. The dates 
of final treatment (variable: DATE_OF_FINAL_TREATMENT) were often missing and 
sometimes the values were prior to the last cycle dates in the CYCLE table. Therefore, a 
rule was created: if the date of final treatment (variable: DATE_OF_FINAL_TREATMENT) 
was prior to the last (final) cycle date (variable: START_DATE_OF_CYCLE), then 
substitute the date of the final treatment (variable: DATE_OF_FINAL_TREATMENT) with 








3.11.7 Analytical methods 
3.11.7.1 The algorithms  
Algorithms were developed in the software R v3.3.2 (109) using RStudio v1.0.136 (110) 
to identify the events of interest from the routine data (chemotherapy (table 17) and 
neutropenic admissions (table 16)) (code available on request). Incidence values could 
then be calculated as the proportion of patients experiencing a neutropenic admission 
whilst on HSPC or CRPC chemotherapy. 
Rules/assumptions 
The algorithms were based upon a series of rules/assumptions (table 21) to extract the 
relevant Office of Population Censuses and Surveys Classification of Interventions and 
Procedures (OPCS) procedure codes (33) and International Statistical Classification of 
Diseases (ICD) diagnosis (32) codes to identify the neutropenic and chemotherapy 
events. The neutropenic events then had to be classified as occurring in the HSPC or 
CRPC setting or if were unrelated to chemotherapy (figure 14). An algorithm was 
developed to use HES data alone, but in addition missing CRPC regimens were inferred 
with HES or supplemented using SACT data. 
 
The main classifications were to: 
 
• Identify and classify chemotherapy regimens as being administered for HSPC or 
CRPC. STAMPEDE data (treatment arm) were linked to the HES data to ensure 
maximum HSPC chemotherapy regimen detection. The CRPC regimens were to be 
identified in the routine data alone (both HES and SACT) as they are not required to 
be documented in the trial data. 
 
• Identify neutropenic events and classify them as being HSPC or CRPC chemotherapy-










Figure 14: The potential classification of events from the administration of chemotherapy. 
NE = neutropenic event; Y = yes and event occurred; N = no event occurred. 
 
In order to classify these events, nine main rules were developed (table 21) and applied 
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  Rule 
Algorithm 1 2 3 4 5 6 7 8 9 
HES + + + - + + + + - 
HES (Inferral) + + + + - + + - + 
HES + SACT + + + - + + + + - 
 
Table 22: Table showing which algorithms utilised which rules. 
 
Many of the rules (table 21) were based upon the below rationale for the timing of 
chemotherapy regimens and neutropenic events. All algorithm rules were developed to 
identify events in the absence of clinical variables in both the HES and SACT routine data 
(for example, hormone-setting and outcomes, including the cause of the neutropenic 
events). 
 
Chemotherapy timing rules 
 
In the published STAMPEDE docetaxel comparison (12), the median time to starting 
chemotherapy was 2.4 weeks after randomisation (arm C) and the maximum was not 
reported, so I estimated this to be 5 weeks post randomisation. The docetaxel regimen 
should involve six cycles (without dose modification), every three weeks (week = 0-1 #1 
docetaxel, week = 3-4 #2 docetaxel, week = 6-7 #3 docetaxel, week = 9-10 #4 docetaxel, 
week = 12-13 #5 docetaxel, week = 15-16 #6 docetaxel). Therefore, the algorithm 
utilised the estimate of the maximum time to beginning the STAMPEDE docetaxel 
regimen (5 weeks) plus the time taken to complete six full cycles (16 weeks), 21 weeks. 
Therefore, if chemotherapy was identified in the routine data occurring in week 0 – 21 
(≤21) this was a proxy for HSPC-related chemotherapy and week 22+ (>21), this was a 
proxy for CRPC chemotherapy. 
 
When SACT was used in addition to the HES data, SACT was an alternative source of 
chemotherapy data. Fields were present in SACT to enable identification of start and 
end dates of treatment (absent in HES). Where the dates of treatment were available, if 
chemotherapy occurred at randomisation (less than or equal 5 weeks after 
randomisation), then it was inferred that this was HSPC and not CRPC treatment. This 







the chemotherapy began before, or on, week 5 (maximum estimate), the chemotherapy 
event was classified as being for HSPC. 
 
Neutropenic event timing rules 
 
The distinction of whether the neutropenic event occurred due to HSPC, CRPC 
chemotherapy or unrelated to chemotherapy was based upon the timing of the 
neutropenic event compared to the timing of the chemotherapy administration (table 
21).  
 
As described in the introduction (section 3.3.2.4), a neutropenic event is most likely to 
occur within 4 weeks after chemotherapy administration (123). Therefore, with the 
rationale that most HSPC chemotherapy regimens were completed in 21 weeks, 
neutropenic events identified less than or equal 25 weeks from randomisation were 
classified as HSPC-related and not CRPC related. However, if the patient had HSPC 
chemotherapy, but the event occurred greater than 25 weeks after randomisation, then 
the neutropenic event was classified as related to CRPC therapy and not HSPC. Varying 
time intervals for classification of associated neutropenic events were explored 
(associated event four and twelve-weeks post-chemotherapy).  
 
The last chemotherapy date in the routine data was used to identify if the neutropenic 
event was unrelated to chemotherapy. The last row in the HES data was used as a proxy 
for the end of the regimen. However, the length of the regimen was predicted as there 
was no regimen start or end date available in the HES. If the event occurred greater than 
4 weeks after the last chemotherapy, or before it was initiated, then the event was 
classified as being unrelated to chemotherapy. If the event occurred less than 25 weeks 
before the last HES-identifiable chemotherapy, or less than or equal 4 weeks after the 
last HES-identifiable chemotherapy, the event was classified as being related to 
chemotherapy (≥-25 or ≤4 from the last chemotherapy event). 
 
A SACT alternative was developed because the start and end date of regimens were 
available. If the event occurred less than 0 weeks from the start of the regimen, this was 
classified as an unrelated HSPC event, as occurred prior to randomisation into 







less than or equal to 4 weeks after the last cycle, the event was classified as being 
related to chemotherapy. If no HSPC or CRPC chemotherapy regimens were identified 
using the HES or SACT algorithms, then any admission events identified were classified 
as being unrelated to chemotherapy.  
 
Inferral algorithm rules 
 
To identify further regimens, different rules were utilised in addition for the HES 
algorithm, called the inferral rules. Previously, if no HSPC or CRPC chemotherapy 
regimens were identified using the HES algorithm, but neutropenic admission events 
were identified, these events were classified as unrelated to chemotherapy. However, 
during inferral, even when no chemotherapy regimens were identified, if a neutropenic 
admission was identified, then this event was classified as a true positive and assigned a 
HSPC or CRPC setting. This was to account for the missing chemotherapy regimens in 
HES, leading to misclassification of events. 
 
SACT algorithm rules 
 
Although the SACT algorithm utilised the same rationale for the identification of events 
as the HES algorithm, rule variations were required in the coding and sequence. 
Additional data manipulation was also required such as that outlined in the text above 















HES (four-week) ü ü ü ü 
HES (inferral) (four-week) ü ü ü ü 
HES (12-week) ü ü û û 
HES + SACT û û ü û 
 
Table 23: The algorithms developed for the different analyses. 
3.11.7.2 Statistical analyses 
I created an algorithm to extract patient characteristics from the STAMPEDE data, 
including, treatment arm, broad disease grouping, Prostate specific antigen (PSA) at 







randomisation and age at randomisation (median and range). C. Brawley at the MRC 
CTU at UCL calculated the age statistics for cohort two, three and four, as I did not have 
access to date of birth in the STAMPEDE data. This is because it was not necessary 
compared to the highly identifiable nature of the variable. I calculated the age for cohort 
one using the UHB QEH clinical noting. 
 
Incidence values were calculated with 95% confidence intervals. Although patients can 
experience multiple neutropenic events per regimen, only detection of one instance was 
required per hormone-setting, to enable calculation of incidence at a hormone-
sensitivity level (the count of incidence per patient, per regimen, was not examined). 
This also accounted for duplicate HES reporting.  
 
Odds ratios (OR) with their 95% confidence intervals were calculated to compare the 
odds of HSPC neutropenic events with those at CRPC. The directionality of affect was as 
follows; an OR less than one favoured the HSPC chemotherapy group. A forest plot was 
constructed to compare ORs. The absolute percentage difference for the incidence 
values were also calculated (HSPC % - CRPC %). Descriptive statistics including sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) were 
calculated where possible, to assess the accuracy of the routine data. However, all were 
estimates of an unknown truth, with no 100% accurate gold standard (147). Within this 
chapter, the definitions of the sensitivity, specificity, PPV and NPV are as follows: 
 
• Sensitivity (se): The proportion of patients with events who were correctly 
identified by the algorithm out of the total number of true positives with events (as 
determined from the clinical noting or the STAMPEDE trial data).  
 
• Specificity (sp): The proportion of patients who did not have events who were 
correctly identified by the algorithm out of the total number of true negatives 
without events (as determined from the clinical noting or the STAMPEDE trial data).   
 
• PPV: The probability of the patients that were identified with the algorithm as 
having an event (chemotherapy or neutropenic events), truly having an event (as 








• NPV: The probability of the patients that were identified with the algorithm as not 
having an event (chemotherapy or neutropenic events), truly not having an event 
(as determined from the clinical noting or the STAMPEDE trial data).  
 
Various different processes were undertaken during the cohort one to four analyses 
(table 24) (figure 15). 
 
Analysis Cohort 1 Cohort 2 Cohort 3 Cohort 4 
Note review comparison ü ü* û û 
STAMPEDE trial events comparison ü û ü ü 
SACT use ü ü* ü û 
Algorithms run & incidence calculated ü ü ü ü 
Odds ratios, p-values, CIs calculated ü ü ü ü 
12-week event detection ü ü û û 
Explicit ‘sepsis-only’ coding analysis û û ü ü 
 
Table 24: A summary of the analysis completed in each cohort.  
* = Targeted note review or SACT comparison to confirm events detected by different algorithms.  
 
To summarise, during all cohort analyses, the algorithms (table 24) were run down the 
HES data (plus SACT where required) to calculate the incidence values and odds ratios 
(OR). 
 
In addition, during cohort 1 analyses, routine data coding quality was assessed, an Excel 
spreadsheet was designed to compare the datasets (what was extracted can be seen in 
table 15). Note review was undertaken of the clinical noting to identify chemotherapy-
related events as occurring whilst, or shortly after, chemotherapy. Cohort 2 analyses 
included investigation into extra chemotherapy events identified during inferral. These 
were queried in the clinical noting via targeted note review and were compared to the 
SACT data.  
 
During cohort 3 analyses the HES neutropenic event coding was analysed for a sample of 
70 events (identified using the ‘SACT-HES’ algorithm) and classified as sepsis-only or 
neutropenia-only (agranulocytosis) coding (table 16). All STAMPEDE HSPC arm C/E 
patients (docetaxel) (N=200) were compared to the SACT data and the SACT accuracy 







analysis to explicit ‘sepsis/septic shock’ coding was assessed (table 16). In addition, all of 
the algorithm detected HSPC neutropenic events were compared to the STAMPEDE 
documented events (febrile neutropenia events, plus grade 3+ neutropenia events). 
Including those with and without an explicit admission documented in the STAMPEDE 
data; accuracy was assessed by year. The ability of the SACT to detect HSPC STAMPEDE 





Figure 15: The various processes undertaken in the stage one to four cohort analyses. 
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3.12.1 Routine data linkage statistics 
8,673 English unique patient IDs were sent to PHE for linkage, 227/8673 (2.6%) failed 
linkage due to an invalid NHS number. Of the remaining 8,446 patients, 7863/8446 
(93.1%) had linked HES data and 4156/8446 (49.2%) had linked SACT data. When 
restricted to patients randomised after April 2012 (when SACT began collecting), 
976/1956 (49.9%) patients had linked SACT data. Those not linked were due to further 
missing or inaccurate routine data records.  
 
Note: During a consent audit by the MRC CTU at UCL in June 2019, additional patients 
were identified in the linked dataset who had not given consent for their routine data to 
be used. As soon as I was made aware of this issue, up to the final analyses cut-off, I 
excluded these patients from further analyses and removed them from the study 
cohorts. However, as discussed in section 6.1.1.3 (overall Discussion), currently further 
investigation is being undertaken which may confirm that these patients remain eligible. 
3.12.2 Patient characteristics 









 Characteristic  
  
Number of patients (% of cohort) 




Cohort 3  
(N=1,573) 





A* 9 (20%) 31 (27%) 636 (40%) 1265 (35%) 
B* 8 (18%) 14 (12%) 95 (6%) 413 (11%) 
C*^ 6 (14%) 16 (14%) 97 (6%) 408 (11%) 
D* 6 (14%) 11 (10%) 0 (0%) 206 (6%) 
E*^ 9 (20%) 16 (14%) 103 (7%) 424 (12%) 
F* 6 (14%) 13 (12%) 0 (0%) 206 (6%) 
G* 0 (0%) 12 (11%) 642 (41%) 720 (20%) 
Broad disease 
grouping 
Newly diagnosed N0M0 10 (23%) 26 (23%) 415 (26%) 843 (23%) 
Newly diagnosed N+M0 3 (7%) 10 (9%) 306 (19%) 585 (16%) 
Newly diagnosed M1 30 (68%) 73 (65%) 780 (50%) 2025 (56%) 
Previously treated M0 0 (0%) 1 (1%) 33 (2%) 88 (2%) 
Previously treated M1 1 (2%) 3 (3%) 39 (2%) 101 (3%) 
Age at 
randomisation 
Median (IQR) 63 (57-69) 64 (71-58) 67 (63-72) 66 (62-71) 
Range 48-80 41-81 39-85 39-94 
PSA at 
randomisation 
Median (IQR) 109 (57-348) 92 (37-334) 52 (20-154) 59 (21-175) 
Range 10-5000 3-8028 0.2-21460 0.2-21460 
T category at 
randomisation 
T0 0 (0%) 0 (0%) 4 (0%) 10 (0%) 
T1 0 (0%) 2 (2%) 12 (1%) 34 (1%) 
T2 2 (5%) 5 (4%) 141 (9%) 330 (9%) 
T3 27 (61%) 67 (59%) 1085 (69%) 2410 (66%) 
T4 7 (16%) 17 (15%) 255 (16%) 612 (17%) 
TX 8 (18%) 22 (19%) 76 (5%) 246 (7%) 
N category at 
randomisation 
N0 13 (30%) 42 (37%) 711 (45%) 1613 (44%) 
N+ 22 (50%) 57 (50%) 798 (51%) 1838 (50%) 
NX 9 (20%) 14 (12%) 64 (4%) 191 (5%) 
Metastases at 
randomisation 
M0 31 (70%) 37 (33%) 819 (52%) 2126 (58%) 
M1 13 (30%) 76 (67%) 754 (48%) 1516 (42%) 
 
Table 25: Patient characteristics by cohort.  
T: Tumour status; TX: Tumour cannot be measured; N: Nodal status; NX: Nodal status cannot be 
measured; N+: Node positive; N0: Node negative; M: Metastatic status; M1: Metastatic; M0: 
Non-metastatic; *: Potential CRPC chemotherapy candidate; ^: HSPC chemotherapy administered. 
See figure 14 for the STAMPEDE schema and the introduction 1.5.1 for further details.  
3.12.3 Cohort one 
The spread of randomisation across arms A to F enabled analysis of a sample of patients 
that had been administered chemotherapy upfront (arms C and E, 34% of the whole 
cohort) and those that had not (66% across arms A, B, D and F). The majority of patients 
were newly diagnosed with M1 disease and the majority of patients were randomised as 
T3, N+ and M0. All subgroups for metastatic and nodal status were included. 
3.12.3.1 Note review analysis 
Note review identified a higher neutropenic event incidence if docetaxel or cabazitaxel 







administered docetaxel upfront for HSPC in STAMPEDE, of which 2/15 (13.3%) 
experienced a neutropenic event, both of which were also documented within the 
STAMPEDE trial data. 24 patients were administered chemotherapy at CRPC using 27 
different chemotherapy regimens (three patients had two CRPC chemotherapy 
regimens): N=1/27 carboplatin and etoposide; 22/27 docetaxel, 4/27 cabazitaxel. 8/24 
(33.3%) patients experienced at least one neutropenic event (table 26) (table 27) (OR: 
0.40, 95% CI: 0.07 – 2.14, p=0.28) (table 28). For all eight events, the patients had most 
recently been administered docetaxel or cabazitaxel, not carboplatin and etoposide. 
There were also multiple neutropenic events per patient (14 in total), 9/14 (64.3%) 
events appeared to be related to docetaxel administration and 5/14 (35.7%) appeared 
to be related to Cabazitaxel administration. 
 
Of the 22 patients that were administered docetaxel (other drugs were excluded from 
analysis) at relapse (CRPC), 6/22 (27.3%, 95% CI: 8.7 – 45.9) appeared to develop a 
neutropenic event related to the administration (table 26) (OR: 0.49, 95% CI: 0.09 – 









Total patients 44 
HSPC events 
Number of patients administered a chemotherapy regimen (docetaxel) 15 
Number of patients that experienced a related neutropenic admission  2 
Incidence - patients on docetaxel developing a neutropenic event (%) 13.3 
CRPC events (all chemotherapy) 
Number of patients administered a chemotherapy regimen (not restricted to docetaxel) 24 
Number of patients that experienced a related neutropenic admission 8 
Incidence - patients on chemotherapy developing a neutropenic event (%) 33.3 
Neutropenic events due to docetaxel 9/14 (64%) 
Neutropenic events due to cabazitaxel 5/14 (36%) 
CRPC events (docetaxel only) 
Number of patients administered docetaxel at relapse 22 
Number of patients that experienced a related neutropenic admission 6 
Incidence - patients on docetaxel developing a neutropenic event (%) 27.3 
 
Table 26: The number of patients on HSPC and CRPC chemotherapy regimens and the incidence of 
neutropenic events. 
3.12.3.2 Routine data analysis 
3.12.3.2.1 Chemotherapy data quality 
The HES data identified 0/15 (sensitivity: 0.00) HSPC chemotherapy regimens. Therefore, 
the HES-only algorithm was developed by merging the HES with the STAMPEDE trial 
HSPC regimens. Hence, by definition, the algorithm would identify 100% of HSPC 
regimens correctly, as such, 15/15 (sensitivity: 1.00) were then identified. In the CRPC 
setting, 21/24 patients who were administered at least one regimen (all chemotherapy 
drugs) were identified in the HES (identification required at least one cycle to be present 
in these data) (figure 16) (the accuracy of chemotherapy coding was further assessed in 
chapter 5). All patients identified by the algorithm as having been administered CRPC 
chemotherapy, were true positive events, compared to the reference (PPV: 1.00). The 
three missing HES regimens were identified during the inferral analysis because a 
neutropenic admission event was present (see the inferral algorithm rules, section 


















(Algorithm) CRPC chemotherapy (patients) 21 0 PPV 1.00 
(Algorithm) No CRPC chemotherapy (patients) 3 20 NPV 0.87 
 Se 0.88 Sp 1.00  
 
Figure 16: Number of CRPC chemotherapy regimens identified by the HES-only algorithm, prior to 
inferring missing regimens. 
 
Of the 27 CRPC regimens, only 5/27 were prescribed after April 2012 (when SACT 
chemotherapy data began collection). SACT was able to identify 4/5 (80%) which were 
all prescribed after 2014. 
3.12.3.2.2 Neutropenic event data quality 
At a patient level, 7/10 (sensitivity: 0.70) patients were correctly identified as 
experiencing a neutropenic event by the algorithm (for both HSPC and CRPC regimens) 
and 33/34 patients were correctly identified as not experiencing a neutropenic event 






sepsis (patients)  
(Algorithm) Neutropenic events 
(patients) 
7 1 PPV 0.88 
(Algorithm) No neutropenic 
events (patients) 
3 33 NPV 0.92 
 Se 0.70 Sp 0.97 
 
 
Figure 17: The number of neutropenic events identified by the algorithms, prior to inferring 
missing events. 
 
After inferring missing chemotherapy, 9/10 (sensitivity: 0.90) patients with a 
neutropenic event were identified, and 32/34 patients were correctly identified by the 
algorithm as not having a neutropenic event (specificity: 0.94) (PPV: 0.82, NPV: 0.97). All 
events detected were correctly allocated to HSPC or CRPC chemotherapy (table 27).  
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Overall, utilising the ‘HES algorithm’, a 13.3% (95% CI: 0.00 – 30.5) neutropenic event 
incidence was identified, appearing to be related to HSPC docetaxel and a 28.6% (95% 
CI: 9.2 – 47.9) neutropenic event incidence upon CRPC chemotherapy (OR: 0.47, 95% CI: 
0.08 – 2.64, p=0.39). If missing chemotherapy events were inferred, the CRPC incidence 
increased to 37.5% (95%, CI: 18.1 – 56.9) (table 27) (OR: 0.36, 95% CI: 0.07 – 1.87, 
p=0.21) (table 28). The HSPC neutropenic event incidence remained unchanged due to 
identifying all HSPC regimens through linkage to the STAMPEDE database. The ORs for 
experiencing a neutropenic event due to HSPC compared to CRPC chemotherapy can be 
seen in table 28. Despite the OR favouring an increased neutropenic event incidence for 
CRPC, the ORs were not significant (p>0.05), suggesting no differences were present 






incidence (%) (95% CI) 
CRPC chemotherapy 
neutropenic event 
incidence (%) (95% CI) 
OR (95% CI) OR p-value 
Note review (all 
chemotherapy) 13.3 (0.00 - 30.5) 33.3 (14.5 – 52.2) 0.40 (0.07–2.14) 0.28 
Note review 
(docetaxel only) 13.3 (0.00 - 30.5) 27.3 (8.7 – 45.9) 0.49 (0.09 – 2.76) 0.42 
HES algorithm 13.3 (0.00 - 30.5) 28.6 (9.2 – 47.9) 0.47 (0.08 – 2.64) 0.39 
HES algorithm 
(inferral) 13.3 (0.00 - 30.5) 37.5 (18.1 – 56.9) 0.36 (0.07 – 1.87) 0.21 
 
Table 28: Cohort one analysis HSPC and CRPC rates and the corresponding ORs. 
 
When widening the classification window for developing a chemotherapy-related 
neutropenic event from within or equal to, four weeks after chemotherapy, to twelve, 
one additional event was classified. However, this patient had already been classified as 
























Number of patients administered HSPC docetaxel 15 15 15 
Number of patients experiencing a neutropenic event 2/15 2/15 2/15 
Neutropenic event incidence (HSPC) (%) 13.3 13.3 13.3 
Number of patients administered CRPC chemotherapy 21 21 24 
Number of patients experiencing a neutropenic event 6/21 6/21 9/24 
Neutropenic event incidence (CRPC) (%) 28.6 28.6 37.5 
 
Table 29: The incidence of neutropenic admissions from HSPC or CRPC chemotherapy, identified 
using the HES algorithms (± inferral) with the neutropenic event inclusion of ≤4 or ≤12 weeks after 
the last chemotherapy event. 
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 Table 30: Detection of neutropenic events.  
‘-‘ = the sensitivity, specificity, PPV and NPV w
ere not docum
ented for the reference, as w
ould be 1.00 for all, due to being the reference; NA = at an individual event 
level there w
as an infinite num
ber of tim
es w







3.12.4 Cohort two 
The greatest number of patients were randomised to arm A (27.4%), with a relatively 
equal distribution across the other arms B – G (lowest D, 9.7%; highest C/E, 14.2%) 
(table 25). 
 
Using the routine data algorithms, a higher incidence of neutropenic events was 
identified for chemotherapy at CRPC than HSPC, although, non-significant ORs were 
calculated. 4/32 (12.5%, 95% CI: 1.0 – 24.0) of the patients that had HSPC chemotherapy 
developed a neutropenic event and 9/47 (19.1%, 95% CI: 7.9 – 30.4) with CRPC 
chemotherapy (OR; 0.65, 95% CI: 0.19 – 2.30, p=0.51). When widening the detection 
window from four to twelve weeks, one more event was identified, increasing the CRPC 
















Number of patients 
(HSPC Docetaxel) 
32 32 32 32 32 
Number of HSPC 
docetaxel neutropenic 
events (patient level)  
4 4 4 4 4 
Number of patients 
(CRPC chemotherapy) 
47 47 52 53 50 




9 10 18 15 12 
HSPC docetaxel 
neutropenic event 
incidence (%) (95% CI) 
12.5 (1.0 – 
24.0) 
12.5 (1.0 – 
24.0) 
12.5 (1.0 – 
24.0) 
12.5 (1.0 – 24.0) 




incidence (%) (95% CI) 
19.1 (7.9 – 
30.4) 
21.3 (9.6 – 
33.0) 
34.6 (21.7 – 
47.5) 





Table 31: The incidence of neutropenic events by the timing of chemotherapy (HSPC, CRPC) 
identified using the routine data algorithms (varying time intervals for event association, clinical 












Algorithm OR (95% CI) 
OR p-
value Interpretation 




The odds of a neutropenic event with HSPC chemotherapy was 
0.65 of the odds at CRPC (non-significant) 
 
The CIs were wide. Crossed the null hypothesis that the odds 





The odds of a neutropenic event with HSPC chemotherapy was 
0.36 of the odds at CRPC (non-significant) 
 
The CIs were wide. Crossed the null hypothesis that the odds 







The odds of a neutropenic event with HSPC chemotherapy was 
0.44 of the odds at CRPC (non-significant) 
 
The CIs were wide. Crossed the null hypothesis that the odds 
ratio was equal to 1, with no difference between groups 
 
Table 32: Odds ratios comparing the incidence of experiencing a neutropenic event by 
chemotherapy setting.  
ORs <1 favour the HSPC group.  
 
A further 9 events were identified during inferral of missing routine data chemotherapy 
events, increasing the CRPC chemotherapy neutropenic event rate to 18/52 (34.6%, 95% 
CI: 21.7 – 47.5) (table 31) (OR; 0.36, 95% CI: 0.11 – 1.16, p=0.08) (table 32). 
 
Note review determined that 3/9 of the extra neutropenic events identified by inferral, 
were missed previously due to the fact that they occurred after the detection window of 
four or twelve weeks from the last identifiable chemotherapy event. The remaining 6/9 
were missed due to missing chemotherapy HES data (appendix, table 78). Note review 
analysis confirmed that chemotherapy was administered in all six of the cases but was 
not coded in the HES (table 33). Therefore, the true rate of neutropenic events at CRPC 
was actually closer to the inferred value, increasing the incidence to 15/53 (28.3%, 95% 























1 188 Docetaxel ü 
TRAPEZE trial - not in HES. Event occurred 
during the chemotherapy regimen. 
9 358 Docetaxel ü 
Two events identified. Whilst on 
docetaxel; event occurred during the 
chemotherapy regimen. 
9 358 Cabazitaxel - 
Two events identified. Not whilst on 
cabazitaxel; event did not occur during 
the following cabazitaxel regimen, hence, 
potential duplicate 
10 82 Docetaxel ü 
TRAPEZE trial - not in HES. Event occurred 
during the chemotherapy regimen. 
12 40 Docetaxel ü 
TRAPEZE trial - not in HES. Event occurred 
during the chemotherapy regimen. 
17 101 Cabazitaxel ü 
Cabazitaxel event. Event occurred during 
the chemotherapy regimen. 
18 191 Docetaxel ü 
Docetaxel event. Event occurred during 
the chemotherapy regimen. 
 
Table 33: Assessment of the six extra events that were identified during the inferral analysis.  
Further details are in the appendix table 78 with corresponding IDs; - = potential duplicate. 
 
Of these, 3/6 (50%) were identifiable in the SACT data but the other 3/6 (50%) occurred 
prior to SACT data collection, so could not be assessed. These three extra events 
identified using SACT, occurred in 2015, 2016 and 2017. Hence, the addition of SACT 
enabled detection of 12/50 (24.0%, 95% CI: 12.2 – 35.8) neutropenic events at CRPC 








3.12.5 Cohort three 
The majority of patients were randomised into arms A (40%) and G (41%), with fewer on 
B (6%), C (6%) and E (7%). No patients were analysed in D or F, due to the SACT data 
collection (see methods, figure 12). The broad disease grouping showed that the 
majority of patients were newly diagnosed metastatic (M1) patients, with a low 
percentage of those previously treated. Most patients were diagnosed with T3, N+, and 
M0 disease at randomisation (table 25). 
 
Using the ‘SACT-HES’ algorithm enabled analysis restricted to docetaxel. A similar 
incidence of events at HSPC and CRPC were identified. 41/200 (20.5%, 95% CI: 14.9 – 
26.1) developed a neutropenic event with HSPC chemotherapy and 60/297 (20.2%, 95% 
CI: 15.6 – 24.8) with CRPC chemotherapy (OR: 1.01, 95% CI: 0.66 – 1.57, p=0.95) (table 
34). Although the OR showed a difference between the groups, the p-value was non-
significant. The HES algorithm identified 41/200 (20.5%, 95% CI: 14.9 – 26.1) patients 
with a HSPC chemotherapy neutropenic event and 51/378 (13.5%, 95% CI: 10.9 – 16.9) 
with a CRPC neutropenic event. However, the ORs were again non-significant (OR: 1.52, 
95% CI: 0.97 – 2.37, p=0.06) (table 34). With inferral, a statistically significant OR was 
identified, 163/448 events occurred in the CRPC group (36.4%, 95% CI: 31.9 – 40.8) (OR: 
0.56, 95% CI: 0.38 – 0.82, p=0.03), compared to 20.5% in the HSPC group (table 34).  
 
81 extra chemotherapy regimens were coded for in HES than in SACT (HES is not 
restricted to docetaxel only). In addition, using the HES inferral algorithm, 70 further 
chemotherapy regimens were identified, than using the non-inferral algorithm. 151 













The odds at HSPC were similar to CRPC (non-significant) 
 
The CIs were wide. Crossed the null hypothesis that the odds 





The odds in the HSPC group were 1.52 of the odds at CRPC 
(non-significant) 
 
The CIs were wide. Crossed the null hypothesis that the odds 





The odds in the HSPC group were 0.56 of the odds at CRPC 
(significant result) 
 
The CIs were narrower and did not cross 1, suggesting 95% 
confidence that the odds were lower in the HSPC setting 
 
Table 34: ORs comparing the incidence of experiencing a neutropenic event by chemotherapy 
setting. 
 
In a sample of 70 patients that experienced a neutropenic admission, only 7/18 of the 
eligible codes (table 16) were identified in the routine data. Of these, only 8/70 (11.4%) 
events were coded as agranulocytosis alone, with no explicit ‘sepsis’ coding. The 
majority of events 62/70 (88.6%) were explicitly coded as ‘sepsis/septic-shock’ related.  
 
SACT data quality was also assessed; SACT detected 83/200 (41.5%) STAMPEDE upfront 
regimens. The quality did not improve between 2012 and 2013 (table 35). 
 
Year Events Detected % 
2012 152 63 41.5 
2013 48 20 41.7 
Total 200 83 41.5 
 








3.12.6 Cohort four 
Patients were randomised into all arms A-G, with the majority in arm A (35%), followed 
by arm G (20%). The majority were newly diagnosed with most patients randomised as 
T3, N+, and M0 (table 25). 
 
The HES algorithm identified 134/832 (16.1%, 95% CI: 13.6 – 18.6) patients with a HSPC 
docetaxel neutropenic event and 148/1182 (12.5%, 95% CI: 10.6 – 14.4) with a CRPC 
chemotherapy neutropenic event (OR: 1.29, 95% CI: 1.00 – 1.65, p=0.05) (table 36); 
however, again the OR was non-significant. Upon inferral, 489/1350 CRPC 
chemotherapy neutropenic events were identified (36.2%, 95% CI: 33.7 – 38.8) (OR: 
0.44, 95% CI: 0.36 – 0.55, p=1.4e-14) (table 36). Hence, this inferral suggested there were 
lower odds of developing a HSPC neutropenic event.  
 
When removing non-explicit sepsis coding from the analysis, 182 unique patients 
experienced sepsis due to HSPC or CRPC chemotherapy (183 events in total, one patient 
experienced an event in both settings). The incidence of sepsis-only events using the 
HES-only algorithm was 69/832 (8.3%, 95% CI: 6.4 – 10.2) at HSPC and 114/1182 (9.6%, 
95% CI: 8.0 – 11.3) at CRPC (OR: 0.86, 95% CI: 0.63 – 1.17, p=0.34) (table 36). Despite the 








Algorithm OR (95% CI) p-value Interpretation 
HES only 1.29 (1.00 - 1.65) 0.05 
The odds of a neutropenic event in the HSPC group 
were 1.29 of the odds in the CRPC group (significant) 
 
The confidence interval touched 1, meaning the odds 
could have been equal in both groups 
HES only 
(inferral) 
0.44 (0.36 – 0.55) 1.4e-14 
The odds of a neutropenic event in the HSPC group 
were 0.44 of the odds in the CRPC group (significant) 
 
The confidence intervals were narrower and did not 
cross 1, suggesting 95% confidence that the odds were 




0.86 (0.63 – 1.17) 0.34 
The odds of a neutropenic event in the HSPC group 
were 0.86 of the odds in the CRPC group (non-
significant) 
 
The confidence intervals were wide. Crossed the null 
hypothesis that the odds ratio was equal to 1, with no 
difference between groups  
 
Table 36: ORs comparing the incidence of experiencing a neutropenic event depending on 
chemotherapy setting. 
 
In this cohort, 83 neutropenic events were documented in the STAMPEDE database as 
occurring due to HSPC docetaxel, showing an incidence of 83/832 (10.0%, 95% CI; 7.9 – 
12.0). These events were documented as: neutropenia, neutropenic sepsis, febrile 
neutropenia, neutropenia (infection), pyrexia, neutropenic infection, pneumonia and 
infection. 59/83 (sensitivity: 0.71) STAMPEDE events were identified in the HES with 75 
false positives (PPV: 0.44). 749/832 with HSPC chemotherapy did not experience a 
neutropenic event, HES identified 674/749 without an event (specificity: 0.90) (figure 18, 
A). When STAMPEDE admission-only events were analysed (52/83 were related to 
admissions) (figure 18, B), 48/52 (sensitivity 0.92) events were identified. However, the 
PPV reduced to 0.36, as 86 false positives were identified. HES also identified 11 










 STAMPEDE event No STAMPEDE event    
HES algorithm +ve 59 75 134 PPV 44.0 
HES algorithm -ve 24 674 698 NPV 96.6 
 83 749 832   
 Se Sp    
 71.1 90.0    
 
 STAMPEDE event No STAMPEDE event    
HES algorithm +ve 48 86 134 PPV 35.8 
HES algorithm -ve 4 694 698 NPV 99.4 
 52 780 832   
 Se Sp    
 92.3 89.0    
 
Figure 18: The sensitivity, specificity, PPV and NPV for detecting neutropenic events in the routine 
data compared to the STAMPEDE trial. 
A) All STAMPEDE documented neutropenic events grade 3+ or any febrile neutropenia grade 1+; 
B) Events identified in A that led to an admission identifiable in the STAMPEDE database. 
 
The accuracy of HES neutropenic event detection compared to the STAMPEDE 
documented events varied over time. The accuracy decreased to 30% in 2009 from 









Year Events Detected % 
2006 1 1 100.00 
2007 6 4 66.67 
2008 5 4 80.00 
2009 10 3 30.00 
2010 14 10 71.43 
2011 20 14 70.00 
2012 22 18 81.82 
2013 5 5 100.00 
Total 83 59 71.08 
 
Table 37: The number of events identified in the routine data that were documented by the 













Figure 19: The accuracy of detecting STAMPEDE documented events in the HES data (2006 – 
2013). 
3.12.7 Overall results 
Overall, these analyses do not support that HSPC docetaxel has a higher severe 
neutropenic event risk than CRPC use. Rates varied by the algorithm used, but these 
data suggest CRPC docetaxel leads to a similar neutropenic event rate than use in HSPC. 
However, caveats to this study can be seen below. The incidence values for the largest 
cohorts can be seen in table 38 and are illustrated in a forest plot in figure 20. Table 39 




















































Figure 20: Forest plot showing the number of events (n) by the number of patients (N) in each 
analysis. ORs are displayed, an OR < 1 favours the HSPC group. 
 
 
Although a different measure of neutropenic events was developed compared to 
standard trial definitions and measures, this analysis enabled a direct comparison of 
major neutropenic events occurring in the different settings. The routine data had 
limitations such as missingness and lack of clinical details impacting event detection (for 
example, in the CRPC group in the HES only analyses). However, in the absence of 
standard randomised follow-up data, routine data were able to test the hypothesis. 
However, due to these limitations, this study was not able to generate conclusive 
evidence and further investigation is required. 















































                                                            HSPC                 CRPC                                                             OR            p-value 
                     (n/N)                (n/N) 
<- Reduced HSPC odds- -Reduced CRPC odds ->  
Algorithm  
0.35   0.50.  0.71.  1.0.  1.41 
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 Table 39: The num
ber of events identified by the algorithm




Black = the largest algorithm
 cohorts, being: SACT = cohort three; HES (w
ith and w
ithout inferral) = cohort four; note review






3.13.1.1 Main results summary 
During cohort one analyses (section 3.12.3), the note review and the routine data 
algorithms found a higher incidence of chemotherapy neutropenic admission events at 
CRPC. However, overlapping confidence intervals and non-significant odds ratios 
suggested no differences may have been present between the two groups (table 28). 
Note review confirmed that missing HES events (chemotherapy and neutropenic 
admissions) were impacting the incidence as the reference value lay between the HES 
algorithm with and without inferring missing chemotherapy regimens (table 28). This 
showed that inferring events enabled detection of more true positive events, but did 
also lead to more false positives, which after investigation, were identified as 
neutropenic events unrelated to chemotherapy.  
 
Due to missing HSPC HES chemotherapy data, the algorithm required linkage to the 
STAMPEDE trial arm data, to ensure correct identification of the HSPC incidence. 
However, due to the lack of CRPC data in the trial database, hence the requirement to 
use routine data for the analyses, it was not possible to identify the CRPC chemotherapy 
drug administered. Because the drug name could not be identified in the HES data, the 
CRPC incidence values included the reporting of all chemotherapy drugs. However, SACT 
data, although limited by timeliness (restricting the analyses), was able to enhance 
chemotherapy event detection and could identify drug name. Despite this, it was 
thought reasonable to infer that unspecified CRPC chemotherapy regimens were 
docetaxel as there was usually only one chemotherapy drug available during this time. 
Chemotherapy could have been administered for another cancer, but this is estimated 
to have had little impact on the CRPC estimates. Often patients with other previous or 
current cancers are excluded from the STAMPEDE trial (72), hence the greatest concern 
is confounding chemotherapy for a second primary after the diagnosis of prostate 
cancer (chemotherapy for metastatic prostate cancer is certainly an event of interest). 
 
In the larger single-site analyses (cohort two, section 3.12.4), again the HES algorithms 





The HSPC and CRPC incidence values were converging inversely to sample size, 
compared to the estimates in cohort one. The confidence intervals still overlapped and 
the ORs were non-significant (table 32). Chemotherapy data were again missing from 
HES and due to this, the value in the CRPC setting was confirmed (by note review) to be 
closer to the inferred value (table 31). SACT was able to enhance the detection of 
chemotherapy events including specifying drug name, although this was only possible 
for events after April-2012 but was not mandatory to collect until July-2014, leading to 
sporadic reporting. 
 
During the cohort three analyses (section 3.12.5), the HES plus SACT algorithm identified 
similar odds at HSPC and CRPC, although a non-significant odds ratio was present. 
Although SACT data were seen to enhance detection of CRPC events, early SACT was not 
able to identify HSPC events with high accuracy. When using the HES-only algorithm, a 
marginally lower incidence of neutropenic events was seen in the CRPC setting, 
compared to HSPC, but the inferred incidence of events was higher at CRPC.  
 
Most HES events were classified as ‘sepsis/septic shock related’, but some were coded 
as neutropenia-only events at admission. Thus, less severe events may have led to an 
admission, impacting rates. 
 
When utilising the HES algorithm in the cohort four analyses (section 3.12.6), the HSPC 
and CRPC incidence rates further converged and the incidence of neutropenic events 
across groups were similar but marginally increased at HSPC. However, when restricting 
the analysis to ‘sepsis-only’ coding, the incidence became lower in the HSPC setting, 
hence the odds ratio favouring the HSPC group (table 36). As identified during the 
previous cohort analyses, the HES data were missing chemotherapy events, and when 
inferred, the incidence at CRPC was higher than at HSPC.  It is suspected that the true 
value lies between both indicators.  
 
In addition, the sensitivity of HES to detect STAMPEDE neutropenic event admissions 
was high, but the PPV was low, due to potential false positive events (figure 18). 
Although there were many routine data false positive HSPC admission events, 





identifying missed trial events (being reclassified as true positives). I have proposed that 
the MRC CTU at UCL send queries to individual sites to confirm these events. 
 
Due to the limitations of the routine data proposed here, the results presented are 
hypothesis generating and thus not conclusive; hence, further investigation is required.   
3.13.2 Hypothesis generation 
Note review was undertaken to create a reference for routine data feasibility 
assessment and enabled the calculation of the incidence of neutropenic admissions in 
the HSPC and CRPC settings. This note review took a long time to ensure accuracy and 
completeness of events and hence, was highly resource intensive. Due to the HES data 
lacking clinical details (e.g. drug name), during the note review the incidence was 
calculated for both docetaxel-alone and for all chemotherapy drugs, to enable 
comparison to the HES-derived outcomes. When undertaking the note review, it was 
identified that if chemotherapy was administered in the CRPC setting, the incidence of 
neutropenic admissions were higher than if administered at HSPC diagnosis (table 26). 
When restricting to docetaxel only, the CRPC incidence was marginally lower than that 
for all chemotherapy drugs; however, still remained much higher than in the HSPC group 
(table 26). This suggested that other chemotherapy drugs, for example, cabazitaxel, may 
lead to a higher rate of neutropenic events than docetaxel, however, other 
chemotherapy drugs were not frequently available, as discussed above. The p-values for 
the odds ratios were not significant, and the 95% CIs between groups were extremely 
wide and overlapping due to the small cohort number and the small number of events in 
each hormone-setting (HSPC, CRPC) (table 28). However, there was initial evidence that 
there may be no difference between the groups.  
 
Both of the HSPC neutropenic events identified in the clinical noting and the trial data 
were identifiable in the routine data, showing some initial evidence/proof-of-concept 
that routine data could be used to identify events collected in the trial. Therefore, it was 
hypothesised that such a resource may be able to collect events not collected by the 
trial CRFs. The STAMPEDE trial is required to collect data on events that occurred due to 
the trial drug (docetaxel in this instance), however, does not mandate collection of 





diagnoses of CRPC. The HES algorithms identified events with odds radios comparable to 
those derived from the note review but again due to small cohort numbers, no statistical 
significance was found, and thus larger cohort analyses were required. Again, the false 
positives that were identified in the HES data that could not be confirmed at site by note 
review, may have been true positives occurring at other hospitals. 
 
This small cohort analysis enabled hypothesis generation only but suggested that 
routine data may be a feasible technique for collection of events not collected in a trial. 
It was also initial evidence that the previous hypotheses drawn from the cross-study 
comparisons may have been leading to biased conclusions. This was to be further 
investigated using different cohorts. 
3.13.3 Routine data - chemotherapy 
From analysing the routine HES data, in addition to the lack of clinical detail (for 
example, drug name), it was also identified that events were being missed (section 
3.12.3.2.1). This is suspected to be due to the setting of administration; chemotherapy is 
normally administered in an outpatient setting and it is commonly known that historic 
HES outpatient coding quality was poorer, prior to accreditation (2008) (46). HSPC trial 
chemotherapy regimens could not be identified in the HES data (0/15 were identified). 
This was because of the ‘Payment by Results’ function of these data (section 1.2.1.1) and 
the funding structure for trial drugs. If the healthcare provider (for example, the 
hospital) has not paid for the clinical trial treatment, it would not be coded, as the 
hospital would not need to be reimbursed. Due to this, it was assessed that the 
algorithm should be developed which linked the HES data to the STAMPEDE database to 
accurately enable the identification of HSPC chemotherapy regimens. When this 
algorithm was developed, by definition, all HSPC chemotherapy regimens were 
identified. The majority of CRPC regimens were identified in HES, but as this is not 
routinely collected in the STAMPEDE trial, the HES data could not be supplemented by 
the trial database. Some CRPC regimens were missed due to starting another trial upon 
development of CRPC disease, with the same ‘Payment by Results’ implications and 
therefore lack of a routine data fingerprint. HES event quality was investigated further 
for neutropenic events and chemotherapy quality was also further analysed in depth in 






The impact of these missing data on the results, needed to be assessed, so the effect of 
inferring missing chemotherapy regimens was undertaken. An algorithm inferring events 
was developed to assess the impact of this missing coding on the incidence rates. The 
aim was to identify if missing regimens could be inferred. A patient may experience a 
neutropenic event, but it may or may not be related to chemotherapy. The initial 
algorithm rules specified that if the neutropenic event occurred whilst not on 
chemotherapy, then the event was unrelated to chemotherapy and was excluded from 
the analysis. However, due to missing chemotherapy regimens, neutropenic events were 
being falsely classified as being unrelated to chemotherapy. The inferral rationale aimed 
to classify every neutropenic event as occurring due to chemotherapy. This was 
hypothesised to identify false positive chemotherapy-related neutropenic events, as it is 
known that neutropenic events can occur in the absence of chemotherapy. However, 
the aim was to identify if missing chemotherapy regimens could be identified and to 
assess the impact of missing chemotherapy regimens on the CRPC neutropenic event 
incidence. 
 
Upon inferral, events previously classified as unrelated were reclassified as true 
positives, increasing the CRPC incidence (table 28). This suggested that many more 
neutropenic events were occurring, which could have been due to CRPC chemotherapy. 
A sample of these extra events that were identified by inferral were investigated by note 
review (six events). The note review confirmed that chemotherapy was administered in 
all six of these cases (table 33), the majority were clinical trial treatments, and therefore 
not coded for in the HES data. This suggested that the true CRPC incidence value may be 
greater than that without inferral and the data quality was having implications on the 
incidence values.  
 
Due to the implications of these missing data, I determined that a different routine data 
source should be tested, that, 1) collects regimen drug details, 2) is not affected by 
funding structures and 3) has a potentially higher data quality. The additional routine 
data source I analysed was the SACT and the ability of SACT to detect chemotherapy 
regimens were assessed to try and enhance chemotherapy event detection and alleviate 






The SACT data documented chemotherapy drug details, including name and dates of 
administration, and therefore enabled direct analysis of docetaxel-only events. 
However, SACT data only began collecting in April-2012, in contrast to the HES which 
was available since STAMPEDE began. This led to analysis restrictions and meant that 
the largest cohort available for SACT analysis was 1,573 and not 3,642 participants as for 
the HES analyses. All patients were randomised prior to mandatory collection (July 2014) 
with hypothesised implications on data quality and reporting completeness. A primary 
function of SACT is not payment, as with the HES data. Hence, trial chemotherapy 
regimens should not be excluded. This SACT coding was assessed by comparing the SACT 
data to the HSPC STAMPEDE chemotherapy regimens (table 35). However, the quality 
was low due to the non-mandatory requirement to collect data in the restricted cohort 
(randomised 2012-2013). However, more HSPC regimens were identified than within the 
HES data (HES, 0%; SACT, 41.5%). SACT HSPC accuracy requires further investigation for 
the trial, when a more contemporary STAMPEDE cohort is available for analysis 
(randomised post-July 2014). As recruitment to docetaxel containing arms ceased in 
2012, a much smaller sample of patients would be available, those that received 
docetaxel as standard-of-care. Currently too few events are estimated (discussed with 
the MRC CTU at UCL) to have occurred for these patients after 2014 to perform this 
updated analysis. 
 
The ability of SACT to detect CRPC chemotherapy regimens was assessed by note review 
as these data are not routinely required to be collected in STAMPEDE. In cohort one, 
only five regimens occurred after SACT began collecting, but four of these were 
identified (all after 2014). In cohort two further investigation was undertaken; in the six 
patients that had missing chemotherapy events, identified upon inferral, three of these 
regimens were identifiable in the SACT data, after 2014. The other three occurred prior 
to SACT collection. In this small sample, as additional events could be identified, it is 
suggested that the accuracy of event detection after 2014 (when documentation was 
mandatory) had improved. The SACT data were therefore able to enhance the collection 
of CRPC events. There were also coding errors in the SACT. For example, single regimens 
were sometimes coded as multiple regimens and although it was possible to request 





appropriate in their completeness for analyses. SACT data were provided until 
December-2017 as there is currently a data lag from the provider making more recent 
data analysis difficult. Timeliness is a further limitation of using routine data for clinical 
trial analysis. I have some evidence that SACT is a feasible resource to supplement trial 
collected CRPC therapies, but no evidence for accurate HSPC detection, due to analysing 
regimens prior to mandatory collection. Assessment is required in a more contemporary 
cohort (post July-2014). 
3.13.4 Routine data - neutropenic events 
Neutropenic event quality was assessed as the routine data were required to detect 
these events. I found that HES neutropenic event quality was improving post-2009 
(figure 19). Due to these being inpatient admission events, anecdotally the early coding 
quality of the admitted patient care is known to be higher that of the outpatient coding, 
hence the distinct accuracy values seen for inpatient events (neutropenic admissions) 
and outpatient events (chemotherapy administration). This is further investigated in 
chapter 5 by comparing surgery, an inpatient procedure with radiotherapy, an 
outpatient procedure. Individual neutropenic events were missing from the HES data 
but due to these events only being identifiable in the HES admission data, missing data 
could not be supplemented using additional resources. However, missing data are also 
present within traditional trial collected data (148, 149). 
 
One potential cause for these missing neutropenic data were the ambiguity in the 
documentation and classification of neutropenic events clinically. Unified criteria are 
required for the correct documentation of neutropenic events. It was discussed in the 
NHSD coding consultation (125) that there was no simple way to classify all instances of 
sepsis within a single national standard, ‘a single standard cannot compensate for 
deficiencies in the documentation, recording or coding process’. It was also proposed 
that if a simplified standard was implemented, this may increase the risk of 
underreporting sepsis events. It was also noted that clinicians may have been reporting 
events as ‘sepsis’, where sepsis was not experienced but where infection was actually 






Neutropenic sepsis and febrile neutropenia are often used interchangeably. This 
therefore, has direct implications to the routine data, as accurate administrative data 
relies upon distinct and accurate clinical noting. Non-standardised note completion also 
leads to erroneous routine data completion and subsequently missed outcomes. In the 
coding consultation, it was stated that ‘inconsistencies and inaccuracies in the recording 
of sepsis within the medical record will have a negative effect on the reliability of the 
coded data which in turn will have a statistical and financial impact’. There are no 
specific guidelines on documenting sepsis in the medical records. Thus, it was suggested 
that an improvement in reporting guidelines would be superior to restricting coding. The 
consultation made it the responsibility of the organisation to ensure that sepsis is 
correctly recorded for future evaluation (125). All of these analyses were undertaken 
using data prior to the coding consultation in 2018 (table 5), hence, no unified criteria to 
detect neutropenic events were available. 
 
Due to the inconsistencies in coding and lack of standardised definitions, I set out to 
identify a unified definition of neutropenic events that could be identified within the 
restricted routine data details. Due to these restricted data, a proxy marker was created 
for events such as febrile neutropenia, neutropenic sepsis and infection from 
neutropenia - severe neutropenic admission events. Although not comparable to a single 
neutropenic definition, due to the HES coding inflexibility, this definition created a 
marker that could be directly comparable across the patient groups, defined as; 
admission for suspected severe neutropenic event, and concurrent chemotherapy 
administration. The routine data algorithms were therefore identifying a different 
neutropenic event measure, not directly comparable to previous trial definitions but it 
enabled direct comparison between hormone-states. The definition used to extract the 
relevant severe neutropenic events from the STAMPEDE data was neutropenic events 
grade 3 or higher, or febrile neutropenia grade 1 or higher. These should result in 
hospitalisation by definition and therefore is a directly comparable data source for the 
HES derived event definition. 
 
There was the potential to misclassify less serious neutropenic events with more serious 
events or to identify miss-diagnosed neutropenic events in the routine data. Despite the 





admitted for another reason and neutropenia may have been noted as a co-morbidity. A 
sample of all the neutropenic event HES coding was analysed to assess this, a small 
proportion of events were being classified as agranulocytosis only, suggesting that 
patients were potentially being admitted for other diagnoses (whilst on chemotherapy) 
and upon which were determined to have a low neutrophil count, but not a severe 
neutropenic event due to chemotherapy. Therefore, to assess the distribution of severe 
events, the algorithm was restricted to just definitive sepsis coding (excluding 
agranulocytosis and neutropenia drugs band 1 only events). Upon restriction, the odds 
ratio showed no significant difference between groups (table 36). The HSPC neutropenic 
event incidence reduced 8% upon restriction and the CRPC neutropenic event incidence 
reduced 3%, suggesting that if HSPC chemotherapy does lead to an increased number of 
neutropenic events, they are potentially less severe than in the CRPC setting. Further 
patients could have also been admitted for a suspected event but upon admission may 
not have been neutropenic and this event may have still been documented due to 
inaccurate note completion. Anecdotally, upon admission to emergency care, patients 
suspected of sepsis are immediately coded as such, to enable fast treatment. The impact 
of this is hypothesised to have contributed to the low PPV values (75 false positives) 
when comparing HES detected events to the STAMPEDE trial (figure 18, A). 
 
71% of the STAMPEDE documented neutropenic events were identified in the HES data 
(figure 18, A). HES identified events that were not documented as admissions in the 
STAMPEDE data but were documented as neutropenic events without admission in 
STAMPEDE. The routine data were able to detect many events; however, events were 
missed. Therefore, whilst not being accurate enough to act as a follow-up source alone, 
additional events were identified which could be used to supplement the trial data using 
querying techniques. When restricted to STAMPEDE admission events only, HES had an 
extremely high sensitivity of detection (92%) (figure 18, B). This suggested that many of 
the STAMPEDE events may not have led to admissions despite being documented as 
grade 3+ neutropenic events or febrile neutropenia and therefore would not be able to 
be detected in the HES admission data. When looking at accuracy of detection by year 
(table 37), post-2009 there was an increase in accuracy. Although a low routine data PPV 





events, due to loss to follow-up, for example admission at another site (future 
investigation at sites is required to assess this).  
 
Routine data may enhance trial data collection, especially if targeted data queries could 
be undertaken. This technique of using targeted data queries was to be investigated 
during this thesis (chapter 5).  
3.13.5 Routine data linkage 
Routine data linkage is required to enable these data to be used for clinical trial 
analyses, so each patient can be identified by the unique trial ID. To undertake this 
matching, both the trial data and the routine data are required to not contain errors in 
the ‘linkers’, for example, NHS number and DOB. As shown in the results (section 
3.12.1), 227 STAMPEDE patients had errors in the NHS numbers and therefore could not 
be matched. Queries need to be sent to STAMPEDE sites for these 227 patients to check 
the invalid NHS numbers to ensure that this can be rectified for future linkage purposes. 
If routine data are being used for trial follow-up, during trial set up (as described in 
chapter 5) care should be maintained when documenting these values, or the patient 
will be instantly lost to follow-up via any routine data sources. The MRC CTU at UCL 
were informed to rectify these issues retrospectively but also to accurately document 
such linkers prospectively for future follow-up. This was investigated and anecdotally 
this occurred due to misinterpretation during telephone randomisation between the 
MRC CTU at UCL and the sites. I believe the MRC CTU at UCL team plan to 
retrospectively correct these issues and be more cautious with newly randomised 
patients. 
 
The majority of the patients with valid NHS numbers were linked to the HES data 
(93.1%). It is to be expected that patients would interact with the NHS during the 
disease history (from six months prior to randomisation, to death or last follow-up) but 
reasons for failed linkage for the 6.9% of patients I proposed to be, 1) private healthcare, 
and 2) inaccurate routine data (no cancer diagnosis). HES and SACT data are not 
collected for non-NHS interactions and so these patients would be lost to follow-up. This 





query missing data. In addition, if no cancer diagnosis was present in the HES data, these 
data would not be provided by PHE, due to data release regulations.  
 
The low matching rate of SACT was to be expected (49.2%), as this dataset only began 
collection in 2012, so any data present prior to this (2005-2012) was for retrospectively 
added data. Despite also restricting the linkage statistic calculation to patients 
randomised post 01/04/12, the rate of linkage was still exceptionally low (49.9%) 
(section 3.12.1). This sustained low SACT linkage rate I suspected to be due to drug type; 
STAMPEDE ensures all patients are at least being treated by the standard-of-care 
(hormone therapy) and therefore every single patient will have been administered at 
least one anti-cancer regimen, hormone therapy. As all anti-cancer agents are required 
to be documented in SACT, it would therefore be expected that all patients had at least 
one documented regimen in the SACT. However, it is possible that those on hormone 
therapy alone (arm A) may not have coded data due to the non-mandatory nature of 
when these data were collected. I consulted PHE regarding this who confirmed all 
hormone therapy prescribed within a hospital is required to be documented. However, 
even after the mandatory requirement for data collection in 2014, it still took time until 
full site conformance. Further to this, missing data may also be due to patients receiving 
private prescriptions, not collected in the database. 
3.13.6 Algorithm rules 
Although, it was identified that neutropenic events were directly identifiable in the 
routine data, the lack of clinical disease variables (hormone-sensitivity (HSPC, CRPC)) 
made the analysis challenging and indirect identification of outcomes was still required. 
The algorithms were designed to identify the incidence of events but to do this required 
a complex set of rules based upon many assumptions, due to the restricted clinical data 
in HES. Chemotherapy events and neutropenic events had to first be identified, and both 
had to be classified into HSPC or CRPC settings using a proxy (see section 3.11.7.1). Each 
event had to be confirmed as related to chemotherapy using the timing of event to 
enable calculation of the incidence values.  
 
These rules could ultimately have led to misclassified events. The time of chemotherapy 





sensitivity. Efforts were made to reduce misclassification by undertaking the early 
smaller cohort analyses to confirm the ability of the model rules to identify the disease-
setting correctly, by validation against note review retrieved data. Another rule that was 
developed included the interval where neutropenic events were hypothesised to be 
related to chemotherapy. The impact of widening this window to twelve, from four 
weeks, did not impact the overall incidence. This is suspected to be due to most 
chemotherapy-related neutropenic events occurring earlier in the regimen; it has been 
proposed that the risk may be highest following the first cycle (150). Therefore, less 
events may be occurring after the last cycle, regardless of the detection window. 
3.13.7 HSPC vs. CRPC routine data outcomes 
Cohort three (N=1,573) was chosen as the largest cohort that could utilise SACT data in 
addition to the HES and therefore docetaxel specifically could be investigated. Near 
equal incidences were identified from HSPC and CRPC docetaxel (20.5% and 20.2% 
respectively) with an odds ratio of 1.01, but the confidence intervals were wide, and a 
non-significant p-value was present. When the HES only algorithms were utilised in the 
largest sample (N=3,645), when restricted to sepsis-only (docetaxel was not specified), 
again similar incidence values were identified across chemotherapy settings. However, 
when analysing all potential neutropenic admissions, the CRPC event rate was 
marginally lower than the HSPC rate by 3.6%. Missing HES chemotherapy regimens were 
hypothesised to have led to this reduced CRPC rate and were further investigated by 
inferral. This technique (inferral), increased the CRPC rate above the HSPC neutropenic 
event rate. Therefore, from previous analyses, the true CRPC rate was hypothesised to 
lie somewhere between the HSPC upfront and CRPC relapse neutropenic event values.  
 
The STAMPEDE data identified a HSPC neutropenic event incidence of 10%, this was 
lower than the HES derived neutropenic event rates (16.1% in the largest HES cohort) 
(table 39) but higher than the sepsis only HES-derived indicator (of 8.3%). Different 
events were documented in STAMPEDE and HES due to different definitions utilised by 
the two studies, due to the routine data coding restrictions. However, as previously 







As the cohort size increased, the confidence intervals narrowed but still remained 
overlapping in both groups. The rates varied by method used, from between 13.3% - 
20.5% of events for HSPC chemotherapy and 12.5% - 36.2% for CRPC chemotherapy. As 
the cohort size increased, not only the confidence intervals became narrower but the 
difference between the rates also converged. The impact of small single-site audits can 
be seen with the converging HSPC and CRPC neutropenic event incidence values. In the 
smallest cohort there was a large increase in CRPC neutropenic event incidence (3x), 
compared to HSPC. However, in the largest analyses using the same algorithm, actually a 
marginally lower incidence was identified for CRPC and the differences were less 
distinct. Hence, assumptions based upon small single-site analyses, such as seen in the 
literature review, should be undertaken with extreme caution. However, to reiterate, 
the results proposed here are also hypothesis generating and not conclusive. 
3.13.8 Further considerations 
There are further caveats to the patient cohorts utilised in this analysis; STAMPEDE trial 
patients were investigated. Trial patients inherently could be fitter than the general non-
trial population and therefore these neutropenic rates may differ in the population. 
However, as routine healthcare data are collected automatically, there is a vast 
population-level data source available. If these data could be anonymised, then analysis 
such as the above may be possible for non-trial patients. In addition, the use of immune 
system stimulating drugs alongside docetaxel was also not identifiable and therefore the 
effect on neutropenia could not be determined. 
 
In addition to this, patients were included that experienced chemotherapy in both the 
HSPC and CRPC settings. These were included in the analyses, as this reflects clinical 
practice. However, it was noted that a patient did experience a severe neutropenic 
event at both HSPC and CRPC (see section 3.12.6). Therefore, this will potentially bias 
the results because it is possible that the combination of HSPC and CRPC chemotherapy 
could influence the CRPC neutropenic events. The inclusion of this partially paired data 
may statistically bias the results (146). Further investigation is needed to unpick the 
relationship between multiple chemotherapy regimens and how this may influence the 






3.14 Conclusion  
I believe that routine data could be a feasible source for acquiring outcomes that could 
not have been investigated within the same patient cohort using standard trial data. Due 
to the inherent limitations of using routine data which were identified during the 
analysis, only exploratory hypothesis generation was possible. As such, no conclusive 
evidence could be drawn. However, routine data were used to identify an event of 
interest (toxicity on chemotherapy) that had not previously been investigated within a 
randomised cohort using standard trial data. Therefore, techniques such as this may 
have direct impact on patients, with the aim to enhance RCT design with the 
predominant purpose to increase quality and length of patient life. I identified that 
required events (both neutropenic and chemotherapy events) were missing and that the 
coding did not enable analysis of standard definitions of neutropenic events.  
 
Routine data missingness and restricted detail have major implications when using 
routine data for trial analyses. Prior to using routine data for trial purposes, the scope of 
what data are present needs to be considered, as these data may not be available. 
Datasets should be rigorously validated to ensure quality and completeness for data 
integrity for each investigated outcome. I propose utilising routine data in addition to 
standard trial data as a superior method of data collection which allows detection of 
events not documented in the trial. Due to the data quality issues identified, chapter 5 
explores an alternative method developing a framework to enhance routine data 
integrity, with the aim to use the routine data as the main clinical trial follow-up data 
source. 
 
Despite these limitations, I have shown in this exploratory analysis that the 
administration of docetaxel at diagnosis for metastatic or advancing disease, may result 
in a similar rate of neutropenic admissions, than if given as a relapse treatment. 
Although not definitive evidence, first-line docetaxel should remain the standard-of-care 
in suitable patients with HSPC disease; the differences may be less distinct than those 
seen whilst making cross-study comparisons. However, further investigation is required. 
 
This chapter aimed to assess the ability of routine data to identify a trial outcome which 





identified that due to the lack of data about hormone-sensitivity (HSPC, CRPC) proxies 
still had to be constructed. The next chapter details a study which aimed to identify 







4 CHAPTER FOUR: Indirect RCT data collection (retrospective model) 
4.1 Disclosure 
I presented work from this chapter at the Trials using Cohorts and Routine Health Data 
international symposium on the 15th May 2019 and the abstract is subsequently planned 
to be published in Trials journal (in press). I have also been accepted to present work 
from this chapter at the International Clinical Trials Methodology Conference (ICTMC) in 
October 2019. All ICTMC abstracts are proposed to be published within Trials journal. 
4.2 Abstract 
4.2.1 Background 
Robust, validated trial endpoints (surrogates) that occur earlier than overall survival (OS) 
are desirable to expedite oncology trials, as long follow-up is often required to reach the 
OS endpoint. Routine administrative healthcare data have the potential to supplement 
standard trial conduct; however, such databases often contain limited and erroneous 
data, meaning standard trial ‘time to event’ analysis is not directly possible. I proposed 
major outcomes could be indirectly identified in routine datasets and demonstrate a 
worked example of development and validation of a novel routine data trial surrogate. 
This work was embedded in the STAMPEDE trial using the Hospital Episode Statistics 
(HES). 
4.2.2 Methods 
A subset of STAMPEDE patients had details of their hospital service interactions 
extracted and triangulated from three datasets: STAMPEDE trial data, clinical records 
and routine data records. An algorithm was developed with the aim to process routine 
healthcare data, to identify events such as progression, capable of predicting OS 
differences. Hazard ratios (HR) were calculated using Cox-proportional hazards models 
to compare treatment effects and were compared to standard STAMPEDE non-survival 
endpoints. Correlation analyses were conducted to determine the strength of 






To identify outcomes of interest, the algorithm was based on prostate cancer activity 
(healthcare interactions) over defined time periods of 8-weeks. Although the algorithm 
was not identifying events directly analogous to any single standard trial endpoint, such 
as failure, metastases or progression-free survival (FFS, MFS, PFS), the model identified a 
composite, which had elements of all three. During initial validation (N=46), 36/46 
patients experienced a FFS, MFS or PFS event and of which, the Hospital Episode 
Statistics (HES) algorithm corresponded to 30/36 (14/33 FFS, 23/29 PFS and 22/28 MFS). 
HRs capable of identifying treatment benefits were found, comparable to trial data 
methods. For example, in the largest validation cohort (N = 1,695), the routine data HR 
was 0.88 (95% CI 0.77 – 1.01), compared with the STAMPEDE MFS HR of 0.82 (95% CI 
0.71 – 0.95). 
4.2.4 Conclusion 
Despite not being able to identify standard trial non-survival endpoints in routine 
healthcare data, I developed a novel oncology endpoint based upon HES-activity – 
‘activity-free survival’ (AFS). This enabled the estimation of OS treatment effects and 
identified events unreported by the trial. However, prior to use in other settings, 
validation is essential. Such a technique is proposed to reduce clinical burden, time, 
resources and costs. In addition, this technique could be used to identify and validate 
events missed in a trial and could enable comparison of trial data to real-world data. 
This activity-based indicator may also have the added benefit of directly correlating with 







When patients are randomised into randomised controlled trials (RCT), follow-up is 
required for documentation of events that have occurred, and these are subsequently 
incorporated into the trial database. Follow-up reports events, such as, when patients 
have had a change in their disease: progression, metastases, or failure. These disease 
outcomes are required to enable treatment efficacy comparisons to be made. Overall-
survival (death) is often the most ‘valued’ endpoint for researchers and patients in 
oncology trials, as it is unambiguous, however, this can often take a long time to reach. 
Therefore, these other surrogate events that are collected at follow-up, can be used to 
determine treatment efficacy, prior to follow-up for OS being met. New and validated 
oncology trial endpoints are highly sought after, to ‘provide a robust surrogate for OS 
that will expedite the design and conduct of future adjuvant therapy trials’ (151). The 
overall aim is to increase the quality and length of patient life. In addition to this, patient 
reported outcome measures (PROM) are also central within clinical trials (152) and 
these outcomes are dictated around the patient experience; for example, quality of life 
assessments. It has been proposed that the ‘greatest potential benefit for the majority of 
patients, whether survivors or not, will be through addressing quality of life issues’.  
 
Documenting trial outcomes through standard patient-clinician follow-up techniques 
can be burdensome for patients (153, 154) and clinical staff, has high costs associated 
with it, and uses a large amount of resources and time (154). Loss to follow-up is also a 
known trial limitation where events may go unreported (66, 155). The main aim of this 
thesis (section 1.8.1) was to investigate if routinely collected healthcare data could 
identify trial outcomes in oncology; hence, the ability to detect surrogate endpoints 
using routine data was to be investigated. Routine data may offer opportunities for 
endpoint development and long-term tracking of patient response, however, major 
challenges are acknowledged (2). 
 
As discussed in the introduction (1.2.1), healthcare systems collect extensive 
administrative patient records, for example the Hospital Episode Statistics (HES) data 
(27). This documents National Health Service (NHS) inpatient, outpatient and emergency 
visits, containing diagnoses and procedure records (populated by International 





Surveys Classification of Interventions and Procedures (OPCS) codes (33) respectively). 
As explored in chapter 3 and chapter 5, if the event is identifiable in the routine data 
coding, such as sepsis admissions and surgery, these events can be directly identified. 
However, the HES contain no data on disease or treatment outcomes (patient reported 
or non-patient reported outcomes) and therefore, major trial endpoints, for example, 
progression-free survival (PFS) cannot be directly found. Hence, I proposed that routine 
administrative data could indirectly be used to identify these outcomes. 
 
To my knowledge, worldwide, there is limited evidence for using routine healthcare 
records to indirectly identify oncology outcomes and extremely limited evidence of 
developing such models in a trial setting. I also believe that a novel routine data 
surrogate proxy with the ability to replicate results produced from standard oncology 
clinical trial outcomes has never been developed, nor validated; including, no studies 
have been published using HES data to identify oncology trial outcomes. Hence, a 
validated method to identify clinically useable trial surrogates in oncology from routine 
data is overdue. This study was embedded in the STAMPEDE trial (introduction, 1.5.1). 
The primary outcome of STAMPEDE is overall survival (OS) and secondary endpoints 
include PFS, metastases-free survival (MFS), failure free-survival (FFS) and skeletal 
related events (SRE) (see introduction, 1.5.3 for details); STAMPEDE also collects quality 
of life data (72).  
 
The aim of this chapter was to generate a validated endpoint using routinely collected 
data. Routine data are frequently used to identify survival-based endpoints (156) due to 
mortality records being collected directly in these data. However, non-survival based 
endpoints are infrequently derived from routine data (despite the known potential) due 
to the limitations of the data source; hence, this being the motivation for the study.   
 
Here I present a systematic literature review, followed by the outline of a novel method 
developed to extract trial outcomes from routine healthcare records. This is presented 






4.4 Systematic literature review: Abstract 
4.4.1 Background and objectives 
This systematic review aimed to identify if methods had been developed to utilise 
routine data to identify clinical trial non-survival endpoints or events (for example, 
recurrence and progression) in oncology.  
4.4.2 Search methods 
A systematic review of literature was undertaken across four electronic databases: Web 
of Science (WoS), PubMed, MEDLINE and EMBASE, plus manual reference checks. The 
studies were screened against inclusion and exclusion criteria. Content analysis was 
undertaken to assess weakness and bias and a thematic summary was also performed to 
identify method themes. 
4.4.3 Results 
A total of 661 articles were extracted from the literature systematic search, with nine 
further identified from searching the included full-text reference lists. 50 papers 
remained after duplicates, unrelated titles and conference abstracts were excluded and 
37 remained after the abstracts were assessed for eligibility. 27 studies, which were 
identifying subsequent oncology events using routine data, were included for the 
analyses after the full texts were screened. No papers were identified which developed, 
validated and utilised a clinically relevant indirect methodology for RCT purposes in the 
UK; Worldwide, two studies were identified. 
4.4.4 Authors conclusions and implications 
A method to extract oncology events from trial data would uncover hidden but routinely 
available, cheap, rich outcome data to allow further clinical questions to be answered, 






4.5 Systematic literature review: Aims and objectives 
This literature review aimed to assess the current methods used to extract outcome 
events from routine data sets. The objective of an initial search was to identify studies 
where routine data were linked to RCTs; however, only two studies were found to 
undertake this, so the search was broadened to trial and non-trial methodologies 






4.6 Systematic literature review: Materials and methods 
4.6.1 Criteria for selecting studies for this review 
4.6.1.1 Review question 
What models have been developed to utilise routine healthcare data to identify 
oncology clinical trial-related outcomes (not including those directly using metastases 
diagnoses codes only)?  
4.6.1.2 Types of studies 
Included research designs were: single case reports to RCTs documenting the use of a 
methodology, using routine data for the analyses. Systematic reviews of meta-analyses 
were excluded; however, the references were analysed for inclusion of the primary 
resources. 
4.6.1.3 Types of participants 
Any oncology patients whose routine healthcare data had been analysed.  
4.6.1.4 Types of interventions 
Creation of an algorithm to identify clinical trial-related disease events, including, 
recurrent, progressive and metastatic disease markers. 
4.6.1.5 Types of outcome measures 
Algorithm design/method to identify clinical trial-related disease events including, 
recurrent, progressive, and metastatic disease markers. 
4.6.2 Search methods for identification of studies 
4.6.2.1 Electronic searches 
The search was undertaken using four databases to 31/05/19; WoS (157), PubMed 
(158), Medline (159) and Embase (159). The final search for the whole review period was 







The search was not restricted by date or country as it was important to gain an 
international perspective. The search strategy used can be seen broadly in 4.6.2.2 and 
the details can be seen in table 40. I carried out all of the searches, however, Samantha 
Johnson from the University of Warwick library gave assistance, where required.  
4.6.2.2 Main constituents of literature search 
• Database: Hospital episode statistics, routine, administrative, registry, claims data 
• Disease: Neoplasm, cancer  
• Intervention: Algorithm 






Database Search criteria 
Web of Science 
(WoS) 
TS=((hospital episode statistic* OR routine NEAR/4 data OR administrative NEAR/4 
data OR registry OR registries OR claims NEAR/4 data) AND (recurrence OR 
progressive disease OR progression OR metastases OR metastatic) AND (algorithm) 
AND (neoplasm OR cancer)) 
PubMed ((hospital episode statistic* OR routine NEAR/4 data OR administrative NEAR/4 data 
OR registry OR registries OR claims NEAR/4 data) AND (recurrence OR progressive 
disease OR progression OR metastases OR metastatic) AND (algorithm) AND 
(neoplasm OR cancer)) 
MEDLINE & 
Embase 
1 hospital episode statistic*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, 
px, rx, ui 
2 (routine adj3 data).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
3 (administrative adj4 data).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, 
px, rx, ui 
4 registry.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
5 registries.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
6 (claims adj4 data).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
7 recurrence.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
8 progressive disease.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, 
ui 
9 progression.mp [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
10 metastases.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
11 metastatic.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
12 algorithm*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
13 1 or 2 or 3 or 4 or 5 or 6 
14 7 or 8 or 9 or 10 or 11 
15 12 and 13 and 14 
16 neoplasm*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
17 cancer.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui 
18 16 or 17 
19 15 and 18 
20 remove duplicates from 19 
 
Table 40: The systematic search terms used to conduct this literature review. 
4.6.2.3 Searching other resources 
To identify missed eligible publications, reference lists were analysed, and the relevant 
articles were screened. 
4.6.3 Exclusion and inclusion criteria  
Studies were excluded and included to identify the desired 1) type of literature and 2) 
methods utilised to identify the outcomes. The inclusion and exclusion criteria are 






Inclusion criteria Exclusion criteria Reason 
Types of literature 
- 
Abstract only or grey 
literature, including 
theses and posters 
Peer-reviewed full-texts were required to ensure 
validated details could be extracted for the review 
- Studies not translated into English To ensure details could be extracted 
- Summary/review papers 
To ensure details could be extracted. The primary 
studies in the summary/review papers were 




of outcomes (unless, 
RCT linkage was 
present) 
Administrative databases do not routinely collect 
data on outcomes (directly); events therefore must 
be inferred (indirectly) 
 
Directly: analysing diagnosis coding. The recording 
of such variables is not mandatory, so the coding is 
limited. Therefore, this technique was excluded, as 
is not a feasible method RCT data collection. 
Indirectly: analysing clinical coding indicators 
(focus of the review) 
 
The aim was to find papers identifying clinical trial 
outcomes, therefore, to ensure all papers were 
captured, if the research involved an RCT but only 
used direct coding, then the paper could be 
included. Otherwise, as stated, the use of direct 
coding only was an exclusion criterion 
Oncology outcomes 





The focus of this chapter was to identify oncology 
outcomes not routinely collected in administrative 
data. RCTs already collect events e.g. incident 
cases and diagnosis stage and hence these are not 
outcomes desired to be collected here 
Papers developing 
algorithms to identify 
the outcomes of 
interest 
- 
The methods designed to extract the outcomes 
were a pivotal part of the review and hence papers 
were required to document the development of 







Administrative data use was required; non-routine, 
manually collected databases with limited RCT 
feasibility, for example, registries and laboratory 
data, were excluded 
- 
Papers developing 
predictive models for 
outcomes 
Interventional RCTs are run to identify response to 
treatment, hence, predictive outcomes were not of 
such interest for this study 
 
Table 41: The inclusion and exclusion criteria for the review. 
4.6.4 Data collection process 
The search included methods as described in the Cochrane Handbook for Systematic 
Review of Interventions (136). After the search articles were generated using the 
strategy (table 40), references from the four databases were manually screened, and 
where possible automatically screened, for duplicates. Endnote (108), the reference 





firstly, titles were screened, secondly, abstracts were screened and finally the full texts 
were screened; articles were removed throughout this process. From abstract screening 
onwards, information was extracted for included publications and reasons for exclusion 
were coded. These data were extracted from the literature using predesigned Microsoft 
Excel data collection forms. Data items were also collected for the content weakness 
and bias analyses in a Microsoft Excel pre-defined data collection table. 17 criteria were 
developed which were influenced by the criteria within the Critical Appraisals Skills 
Programme (CASP) guidelines (160). The criteria were analysed to homogenise different 
aspects of the literature. The criteria included: participant, intervention/algorithm, 
outcome and overall quality assessments.  
 
Data were collected for the thematic analyses in a Microsoft Excel document; however, 
the content of the studies informed the design of the thematic groups and hence, the 
data collection tool was retrospectively designed. The studies were also analysed in 
depth to identify the main methodological constituents of the algorithms and the 
relevant details were extracted.  
4.6.5 Reporting 
A narrative synthesis qualitative systematic review was undertaken. The PRISMA 
guidelines (135) influenced (see appendix 8.2.1) the reporting of the systematic search 
and the PRISMA flow diagram was used to graphically present the results (135). Content 
analyses (to assess weakness and bias) and a thematic summary (to assess the methods 
designed to identify outcomes) were reported (161). In addition, the different 
algorithmic methods identified were reported in individual flow diagrams. 
4.6.6 Assessment of heterogeneity 
A multiple of outcomes and content were analysed with methodological heterogeneity, 
hence combining them would have led to clinically meaningless interpretation. Thus, 
due to the literature assessing non-comparable quantities, a meta-analysis was not 
undertaken (162). Alternative methods were adopted to assess heterogeneity and 





4.6.7 Risk of bias 
A custom risk of bias assessment was undertaken during content analyses. This 
consisted of assessment at a participant, intervention/algorithm, outcome and overall 
quality level. The tool that was developed to undertake these analyses can be seen in 
the appendix (section 8.2.3). 
4.7 Systematic literature review: Results and discussion 
4.7.1 Study selection - PRISMA  
The PRISMA flow diagram (figure 21) (135), shows the various stages undertaken during 

























Figure 21: A PRISMA flow diagram showing the stages of the review. 
 
4.7.2 Summary of the literature identified 
Summary of findings tables can be seen in table 42 and table 43, showing aggregated 
data from the included studies.
Studies included in 
qualitative synthesis 
(n = 27) 
Records identified through database 
searching 
























Additional records identified 
through other sources 
(n = 9) 
Records after duplicates and conference abstracts 
removed (n = 297) 
Titles screened 
(n = 297) 
Records excluded 
(n = 247) 
Full-text articles assessed 
for eligibility 
(n = 37) 
Records excluded, 
with reasons in text 
(n = 10) 
Abstracts screened 
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Figure 22: The number of papers published between 2002 and 2019 (until May). 
 
The majority of databases used were in the USA (15/27, 56%), however others were 
Denmark (4/27, 15%), United Kingdom (4/27, 15%), Canada (3/27, 11%) and Australia 
(1/27, 4%) (table 42). Research was undertaken in many different fields of oncology: 
leukaemia, breast, colorectal, head and neck, prostate, ovarian, lung, bladder and 
mixtures (including, cancers in adolescents). The most common field was breast (8/27, 
30%) with only one study (1/27, 4%) investigating bladder and prostate cancer 
individually, both in Denmark (table 42). Various subsequent cancer events were also 
identified; recurrence, second primary (breast cancer), metastases and progression 
(table 42). Often subsequent event terms were used interchangeably, but the overall 
aim for all studies was to identify subsequent cancer events. 
 
Only four papers (4/27, 15%) utilised the Hospital Episode Statistics (HES) data and 
identified outcomes across three specialities, head and neck, breast and lung cancer. 
Three of these studies were from the same research group (47, 172, 183) and one was 
from a different group which also used the general practice research database (GPRD) 
(now known as the CPRD) (170). In all four studies, HES data were used in addition to 























































Dataset (RTDS), Demographic Batch Service (DBS), Personal Demographics Service (PDS), 
the GPRD and the National Cancer Registry (NCR) (table 42).  
 
Other databases within the other studies, included: Medicare (a US claims database), 
the Veterans Administration (VA) data and various Danish registries (table 42). The total 
number of databases used for each study varied from one to six. Utilising more 
databases enables more variables to be analysed, however, the time and resources 
needed to acquire and link the data sets increases and thus reduces the generalisability. 
The same principle applies for the type of coding utilised in the databases. If ICD codes 
are utilised (used in the majority of papers), the algorithms are more feasible for use 
internationally. However, often national coding systems were utilised, for example, in 
Denmark, restricting the applicability of the algorithm internationally, further reducing 
generalisability.  
 
The studies varied in size; the total cohort ranged from N=20 (47) to N=15,043 patients 
(164) and the number of subsequent cancer events validated ranged from N=11 (47)  to 
N=1,043 events (169). Validation was undertaken using various resources, the most 
common being medical record review, but other data sources for validation included: 
registries, electronic medical record warehouses (EMRs), general practice (GP) 
questionnaires, RCT data, and one study did not validate (176). Where medical note 
review was undertaken for validation, the largest number of events validated were 542 
(182). Only two studies validated the algorithms using RCT data (165, 171). 
 
Fifteen studies identified the timing of the event, hence, the remaining twelve only 
identified if a patient had experienced an event over the whole follow-up period, 
regardless of the date. There were varying levels of accuracy of event detection; using 
the Warren and Yabroff (189) described cut-off of administrative data event accuracy 
(determined as a sensitivity, specificity and positive predictive value of greater than 
80%), only 9/27 (33%) had a positive outcome (including the further requirement for a 
negative predictive value of greater than 80%). 15/27 (56%) studies documented poorer 





4.7.3 Content analysis – weakness and bias 
The participant, intervention/algorithm, outcome, and quality criteria for these studies 
were assessed during the content analyses. This was an opportunity to critically appraise 
the literature for sources of weakness and bias (appendix, 8.2.2, table 79, table 80). 
4.7.3.1 Participant weakness and bias 
The criteria studied are discussed below: 
One: Accurate identification of the study cohort 
Correctly identifying the patient cohort that are known to have a disease is vital for 
validation of the algorithms to detect events. Where cohorts were identified from varied 
across the studies. The majority of papers (24/27, 89%) (figure 23) identified cohorts 
from a validated source; a clinical trial cohort, a cancer registry or acquired from note 
review.  
 
However, two papers identified patients using only routine data (166, 177). Anaya (166) 
identified cases using an administrative diagnosis of colorectal cancer and thus, as 
stated in the discussion, may have led to ‘a systematic misclassification bias of potential 
cases’. Livaudais (177) similarly identified those diagnosed with ovarian cancer from the 
administrative data warehouse coding, again potentially leading to misclassification of 
patients and bias. It was also not specified where the Xu (186) cohort was identified 
from.  
 
Due to not having a ‘true’ gold standard to compare to, I am not able to confirm if 
eligible patients were included or not. Hence, these three algorithms may have been 
built using ineligible patients, potentially impacting the ability to identify events in a 
cohort of ‘true’ eligible patients. This may have led to inaccurate measures of event 
detection sensitivity and as such a true measure of algorithm performance may not be 
possible.  
 
For example, if the algorithm was built to detect cancer events in patients without 





data for a patient with cancer, ‘true’ events may be missed. Therefore, false negatives 
and positives may be present using the ‘truly’ eligible cohort, biasing the results. 
Two: Event sample size for model development or validation suitable 
A priori, a cohort number greater than or equal to 50 was deemed an appropriate 
sample size by myself and Dr Helen Parsons. The value of 50 was chosen as this was 
hypothesised to allow a reasonable sample to be confirmed. This figure has been 
previously regarded as the minimum to estimate precise measures of the standard 
deviation. Sim et al propose that for a high level of statistical confidence ‘a pilot study of 
at least n=50 is advisable’ (190). 
 
Although overall cohort numbers were often seen to be large, the number of 
subsequent events to be validated was the most important value. For example, one 
paper analysed only 11 events across 20 patients (47), whilst another analysed a larger 
cohort of 212 where only 43 patients experienced an event (173). Likewise, in the 
largest study (164), although over 15,053 patients were in the cohort, only 2% (335) 
experienced a recurrence event. The majority of papers, 21/27 (78%) (figure 23) 
analysed greater than or equal, 50 events.  
 
The six papers that investigated less than 50 events included, Earle (22 events) (163), 
Lamont (12 events) (165), Liu (11 events) (47), Deshpande (32 events) (174), Livaudais 
(32 events) (177) and Wong (16 events) (183).  
 
The larger the sample size, the more likely it is to find a range of patient disease 
pathways or trajectories. Hence, the more generalisable an algorithm may be. 
Conversely, if the algorithm has been built in a small sample, it is possible that the 
algorithms developed are not able to detect events with the same level of sensitivity in a 
broader patient set. The results from these papers should therefore be interpreted with 
caution.  
Three: Suitable patient exclusion criteria 
The extent of cohort exclusion criteria can provide a measure of bias. The more 





may be easier to detect events with more exclusions (under more tightly controlled 
circumstances) but reduces how applicable a model can be in a real clinical setting. The 
majority of methodologies were based upon tightly restrictive eligibility criteria. Only 
five papers used non-restrictive exclusion criteria.  
 
I observed that exclusion criteria could be grouped into two categories, 1) Clinical-based 
exclusions and 2) Data-based exclusions. Clinical-based exclusions were when patients 
were excluded due to some clinical detail. For example, if the patient did not have 
radical treatment (47). I believe that these exclusions were often to remove patients 
who may be more challenging to identify in the routine data. I believe these exclusions 
to be the most limiting, as excluding these patients could bias the results by driving up 
the sensitivity of event detection.  
 
Data-based exclusions included removing those that had record linkage errors and those 
where gold standard data were not available to validate the routine data events. Other 
data-based exclusions included those who were not identifiable in the routine data (for 
example, not being enrolled in a healthcare plan) and others who had missing routine 
data (commonly found in administrative sources). These data-based exclusions also bias 
results because patients are being excluded from the analyses that are more difficult to 
identify in the routine data. This could increase detection sensitivity, by excluding the 
more challenging cases. Both types of exclusion reduce the feasibility of utilising such 
methods in a clinical trial setting – in a real clinical setting, patients cannot be excluded 
from follow-up if they do not fit desired criteria. 
 
From the review literature, examples of excluded patients included; those not receiving 
all care at one particular hospital (Earle (163) and patients who had a recurrence within 
a year of diagnosis (McClish (164)). Further exclusions included, those that had not been 
enrolled for one year before and after diagnosis (unless death noted), to avoid 
identification of pre-existing comorbidities and initial cancer treatment and in addition, 
patients also had to be free of recurrence for 120 days after surgery to be eligible 
(Chubak (167)).  
 
Patients were also excluded where claims data (administrative data, for example 





multiple tumour types or those where the cancer stage changed within 60 days after the 
index date (Nordstrom (169)). The patients excluded by Nordstrom may have more 
complex disease pathways and therefore may be more difficult to identify in the routine 
data. By not including these in the training set, the model is less likely to be able to 
identify more complex patients in practice. Patients were also excluded due to 
experiencing events within 180 days of diagnosis that could ‘complicate identification of 
a recurrence’ (Lash (171)). Hence, this paper excluded the complicated pathways. 
However, in practice, in a clinical trial setting, patients cannot just be excluded from 
follow-up due to complicated data. Further exclusions included if the patient had not 
had cancer-directed surgery (Warren (176)), or if patients did not have radical treatment 
(Liu (47)). Again, limiting the generalisability of these algorithms in a wider patient 
cohort. 
 
To summarise, the results of these studies therefore need to be interpreted with 
caution. When these algorithms are exposed to a non-restricted sample (for example, 
use in a clinical trial setting), the sensitivity of event detection may be impacted. These 
algorithms may not be fit for purpose in a clinical trial setting; any excluded patients 
would be permanently lost to follow-up. 
 
In contrast to this, Lamont (165), Anaya (166), Ehrenstein (173), Haque (175) and Gupta 
(181) did not bias their patient sample with exclusion criteria. Of interest, Ehrenstein 
(173) excluded patients whose registry records contained distant metastases codes, 
however this was not to aid event detection, but was to identify events in the absence 
of this direct coding.  
 
These five papers were designed to capture events for as many patients are possible. 
These algorithms are therefore more likely to be fit for purpose within a clinical trial 
setting. It is possible that the lack of exclusion criteria in these five studies led to low 
event detection accuracy (4/5 studies had an accuracy of less than 80%). If these 
algorithms were applied within a restricted cohort (as seen in the other papers), I 
hypothesise that the detection accuracy would increase, due to the detection of 
additional events. I believe these criteria to account for one of the greatest sources of 





Four: Tabular patient characteristics 
Patient characteristics are important to confirm that results are generalisable to the 
general population. At the very minimum ClinicalTrial.Gov require age and gender (191) 
to be defined when reporting study results. Therefore, age and sex/gender (unless 
specified in the text, for example, men with prostate cancer, women with ovarian 
cancer) were used as the indicators for the minimum that were required to be 
documented in a tabular form. The majority of papers displayed such a representation, 
however, some papers such as the study by Earle (163) did not. Lash (171) did not report 
sex and was therefore ‘classified as negative’ in the content analysis. Ritzwoller (182) 
also did not explicitly say the cohort was women with breast cancer. Perhaps the author 
felt that this was clear as they were reporting a breast cancer cohort. However, this is 
not necessarily the case as breast cancer in men is possible (yet rare). 
 
Results with minimal patient characteristics should be interpreted with caution. The 
description of the cohort is vital to understand what cohort the algorithm could be 
applied to and to understand limitations of the study. For example, prior to utilising one 
of these algorithms in a clinical trial, the trial inclusion criteria would need to be 
compared to the sample in which the algorithm was developed. This would then help 
establish if the algorithm was capable of being used in the desired population. 
Therefore, the generalisability of the algorithms that did not publish patient 
characteristics is questionable. 
Five: Patients in a randomised controlled trial (RCT) 
Two pieces of literature included patients in an RCT (2/27, 7%) (figure 23) (Lash (171), 
Lamont (165)). The initial search screened to identify these RCT papers alone, however, 
this search was found to be too restrictive as these two papers were found. Hence, 
studies involving an RCT were credited in the overall risk of bias assessment, but the 
others were not excluded for completeness.  
 
Lamont analysed patients in the CALGB 9344, doxorubicin dose escalation, with or 
without taxol, for node positive breast cancer trial. The trial data were linked to the 





compared with the CALGB values to measure the algorithm accuracy (165). In the other 
study, Lash validated their algorithm in patients in the COLOFOL RCT, which compared 
two different regimes of follow-up after colorectal cancer resection (171). Lash plotted 
the cumulative incidence of events over time, as compared to the COLOFOL cohort. 
Neither studies used the administrative data to perform trial analyses, for example, 
replicating trial intervention efficacy analyses. 
 
If the algorithms have not been tested in the clinical trial setting, the feasibility of using 
the algorithm has not been validated for clinical trial use. Hence, these algorithms would 
need to be re-validated using clinical trial data prior to implementation, as they may 
behave differently. For example, alternative treatment pathways may be being followed 
within the trial and the algorithm may not have been designed to capture these events. 
The practical and regulatory impact, such as linkage to trial number and patient consent, 
were also not possible to investigate during these studies. These details are important 
when evaluating the use of routine data within clinical trials. 
Six: Multiple centre studies 
Whether studies involved one or more centres was investigated. If data are analysed 
from a single centre, there is a risk of bias, due to coding and clinical patterns specific to 
institutions. In contrast, the use of multiple centres reduces the risk of bias. The impact 
of this is discussed throughout the thesis, for example in section 2.6.  
 
17/27 (63%) (figure 23) of publications used multiple site data. It is possible that single-
site studies (10/27) reveal higher detection sensitivities as differences in coding and 
clinician preferences may not be present in the small data sample. If these single centre 
studies were to be validated in another centre to the one in which the model was 
developed, there is a chance the sensitivity of detection could reduce. Clinical trials are 






4.7.3.2 Intervention weakness and bias 
Seven: Events compared to a reference 
In order to validate the accuracy of the algorithm to detect events, the algorithm 
outcomes must be compared to a reference. All but one paper (176) compared the 
results of the algorithm to a reference (26/27, 96%) (figure 23). Warren (176) utilised no 
reference, therefore it is not known if the algorithm was able to accurately identify 
events. 
 
If an algorithm has not been validated, it is not feasible for use; the algorithm by Warren 
needs to be validated prior to any further use. Without validation it is not possible to 
assess if the events being detected are true positives. Due to the importance of 
validation, the majority of studies performed this. In addition to this, the quality of the 
reference data also needs to be considered, this is discussed below (criterion fourteen). 
Eight and nine 
• Eight: The algorithm was trained using a sample 
• Nine: Validation was undertaken using an unseen dataset or statistically by cross-
validation 
Statistical training of the algorithms were considered. A priori knowledge alone can be 
used without statistical training, but both can be used in combination. Training is 
undertaken by introducing code to data with the overall aim to identify particular 
patterns, to try to enhance model performance. There are various ways to train data, 
including statistically, for example, using logistic regression to identify variables 
predicting outcome but a priori knowledge can also be used, for example, choosing 
variables assumed to be important in identifying clinical outcome, without statistical 
confirmation. 
 
18 of the 27 papers (67%) (figure 23) of the papers trained an algorithm statistically (plus 
or minus a priori knowledge). Training was used to identify variables of importance and 





example, refining time windows for detection, such as the optimum treatment-free 
period needed prior to identification of recurrence from primary treatment.  
 
To identify variables, methods in the literature included, logistic regression (McClish 
(164), Anaya (166), Hassett (180), Ritzwoller (182)), classification and regression tree 
analysis (CART) (Chubak (167), Nordstrom (169), Xu (186), Xu (187)) and random forests 
(Nordstrom (178)). To optimise the identification of events, studies investigated 
optimum backdating time windows to find the true date of event from the date of the 
proxy event (Ricketts (172)). Optimum time windows for detection were identified 
(Ricketts (172), Ehrenstein (173)) and peaks in code counts were investigated to 
enhance the timing of events (Hassett (180), Ritzwoller (182), Uno (185)). 
 
The use of statistical methods improves the confidence in the algorithm performance. A 
priori knowledge alone may lead to missing events due to the routine data obscurities. 
For example, coding schemes and missing data may have implications on event 
detection if particular events are not documented; using a priori knowledge alone may 
not identify these obscurities. Using both statistical and a priori knowledge is the 
superior technique; clinical knowledge is important to ensure that the algorithm is not 
just identifying events due to the details in the coding. This combination technique was 
used by the majority of the studies.    
 
Criterion nine assessed if validation was undertaken using an unseen dataset or 
statistically. The test set allows development of the algorithm, whilst the validation set 
enables a non-biased analysis and tests for overfitting of these data. These criteria were 
aiming to identify the studies that had undertaken validation on an unseen patient 
sample or using cross-validation techniques on one sample. If a priori knowledge was 
used alone to train the algorithm, then the initial sample was defined as suitable for 
validation, as these data had not been used to train the algorithm and therefore, 
overfitting was not a risk; one such example of this was the study by Lamont (165).  
 
15/27 (56%) (figure 23) papers were validated using a separate sample of data (Xu (186) 





patients for validation, suggesting that a sample of the training data was utilised to 
validate the algorithm, potentially being at risk of overfitting.  
 
It is vital to identify if the algorithm is capable of identifying events in an unseen 
population, prior to use within a clinical trial. An alternative cohort may contain 
different clinical or coding intricacies and therefore the algorithm may miss events if 
challenged with this new dataset. For example, the study by McClish (164) should be 
interpreted with caution, if the same data has been used for development and 
validation. 
Ten: Algorithm can detect outcomes without pathology/lab reports or direct coding alone 
The ability of an algorithm to detect events using routinely collected variables is of 
utmost importance to this project. Therefore, whether outcomes could be collected in 
the absence of detailed clinical data or directly coded diagnosis codes were assessed. 
20/27 (74%) (figure 23) of papers were able to detect outcomes without these clinical 
data. The majority of papers using direct coding-only were excluded during the 
systematic review process. However, one paper linked clinical trial data to routine data 
and used direct coding alone (Lamont (165)) and was therefore included due to the 
importance of the clinical trial linkage.  
 
Some studies had access to a pathology registry (Lash (171), Rasmussen (184)) and 
Ehrenstein (173) had access to lab reports for Prostate specific antigen (PSA), to help 
identify outcomes. All four papers from Denmark utilised additional clinical variables; no 
other countries utilised such variables. The Nordic countries are acknowledged for their 
population-based registries, which has enabled linkage of multiple longitudinal data 
sources across whole nations, hence the utilisation of such clinical variables in Denmark 
(192).  
 
The use of additional reports reduces the generalisability of the algorithm. For example, 
the algorithms developed in Denmark cannot be used in the United Kingdom if the 
databases are not international. Hence, these algorithms could not be used in an 





algorithms could be used internationally. One additional paper of interest (Haque (175)) 
only identified events that could not be identified from pathology reports. 
Eleven: Investigation into the activity of variables 
This analysis was to assess if the activity of variables was investigated, for example, 
frequency or clustering of events, as opposed to just presence of codes. 8/27 (30%) 
(figure 23) of the studies undertook activity analysis.  
 
Focussing on the presence of codes only can lead to missing events, due to the nature of 
routine data. Some routine data events may be excluded intentionally but there is also 
erroneously missing and inaccurate data. Investigation into the activity of these data 
may therefore enhance the detection of events. This is discussed and the papers 
critiqued, below, through a thematic analysis (section 4.7.4). This is also investigated 
further within chapter 4. 
4.7.3.3 Outcome weakness and bias 
Twelve: The methodology developed allowed the timing of outcomes to be identified 
Some papers purely sought to identify if a patient had experienced an event at any time 
and others sought to identify exactly when an event occurred. This was extremely 
important as the timing of event is vital for clinical trial analysis. 15/27 (56%) (figure 23) 
papers created an algorithm capable of identifying the time of event. A shorter delay in 
detection is sought after, especially if the algorithmically identified date is to be used for 
trial analyses. 
 
Earle (163) detected relapse a median of 6.5 days after the medical record; Lamont 
(165) identified the date of recurrence for disease-free survival analysis with a median 
difference to the trial of 40 days; Liu (47) created survival curves to compare the 
algorithmically generated date to the gold standard and 16/20 of these were seen to 
have acceptable agreement; Ricketts (172) created survival curves to compare the 
timings to the reference, including 4/21 to the correct date; Lash (171) plotted 
cumulative incidence of recurrence against clinical trial data, and the incidence was seen 
to ‘overlap significantly’; Ehrenstein (173) identified if the outcome was detected within 





date of subsequent breast cancer and for over 90% of patients the date differed to the 
reference by less than 60 days; Warren (176) identified the first indicator of recurrence 
and identified the median time to recurrence but no validation was undertaken; Hassett 
(180) created separate algorithms and identified where the code count peaked for 12 
categories and integrated the values to identify a single time of recurrence; Gupta (181) 
found a median difference of 27 days; Ritzwoller (182) correctly classified 14.3% and 
64.7% of events at three and six months, respectively; Wong (183) identified 4/16 within 
two weeks, 6/16 between four weeks and 100 days and 2/16 over 100 days; Rasmussen 
(184) found substantial concordance with the reference, 64% of events were estimated 
within 30 days; Uno (185) identified 75.3% within six months of the reference and 
Rasmussen (188) again found substantial concordance with a median difference of 17 
days.  
 
This highlights the non-standardised method of reporting the results, and the variable 
delays in detection. For example, Ritzwoller (182) only identified 14.3% of events within 
3-months of the reference, compared to Earle (163) detecting relapse at only a median 
of 6.5 days after the reference. This demonstrates the difficulty in identifying oncology 
events from routinely collected data. 
 
Where the timing of outcome is determined, it is possible to calculate surrogate 
endpoints for overall survival, for example PFS, for clinical trial analyses. In the two 
papers linked to RCTs (Lamont (165), Lash (171)), the timing of the outcome was 
assessed. Lamont identified the DFS and compared the individual events to the trial 
collected data to calculate the sensitivity at 2-years, 5-years and over the whole period 
of follow-up. Lash (171) plotted the cumulative incidence of recurrence against the 
clinical trial acquired data.  
 
Twelve studies did not develop an algorithm that could identify the timing of the event. I 
would expect the sensitivity of event detection to be higher if the algorithm is only 
required to identify if a patient has had an event, or not, over the whole disease 
trajectory. Despite this, this was not a clear trend in the studies identified. This is 





standardised definition to report the delays in detection, so that the summary statistics 
can be more comparable.  
Thirteen: Algorithm feasible for use with regards to accuracy  
The accuracy was investigated for the indirect algorithms in each study and the 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) were compared, where specified. Warren and Yabroff (189) judged algorithms 
against an 80% detection accuracy rate for the statistics (sensitivity, specificity, positive 
predictive value), hence 80% being used as a proxy marker for quality here. 
 
Using this definition for the published values, as opposed to the interpretation by the 
author, only 9/27 (33%) (figure 23) met these criteria. The larger studies tended to have 
lower accuracy, for example, Nordstrom (169), Hassett (180) and Ritzwoller (182), 
compared to the smaller cohorts such as, Lamont (165) and Liu (47). The single centres 
may have more complete and accurate coding, compared to the multiple site studies, 
possibly reflecting the difficulty in identifying events with larger samples (189). This 
highlights that, where possible, the analyses should be undertaken using multi-site data 
(as discussed above in criterion six), to confirm the integrity of the algorithms.  
 
Lower accuracy algorithms should be interpreted with caution, as events could be 
missed, or more false positives could be present. However, the accuracy measure of 
greatest importance (for example, sensitivity, specificity), depends on the desired 
algorithm use. For example, if the routine data is being used alone, then a high 
sensitivity is vital to detect the maximum number of events. However, if a reference 
data set is available in addition, then the sensitivity may not be quite as vital. Here the 
positive predictive value be more important to reduce the number of false positives 
being identified.  
4.7.3.4 General quality 
Fourteen: The reference data are of high quality 
In order to validate the accuracy of the algorithm-derived events, a quality reference is 





standard’ is not possible (147), but a more accurate reference than the routine data is 
vital for validation. I deemed registry data to not be a suitable source of reference data 
to validate events; this is due to the derivation of registry data as discussed in section 
1.2.3. Registries are often utilised as the routine data source to be validated and as such 
should not be used as the reference. 
 
23/27 (85%) (figure 23) of papers used a quality reference source. Those without a 
suitable reference included McClish (164), who used a registry plus a small record 
review; Warren (176) who used no reference and Rasmussen (184) who used a Danish 
bladder cancer registry in the first paper and in the second paper (188) again used a 
registry plus GP and small medical record review, where no event was identified in the 
registry. 
 
The accuracy statistics for these four studies should be interpreted with cation. If the 
reference itself has missed events, then events detected by the algorithm may actually 
be true positives and not false positives. Likewise, if the reference has false positive 
events, events missed by the algorithm may appear to be false negatives rather than 
true negatives. Inaccurate measures of algorithm performance may be generated with a 
low-quality reference; this leads to uncertainty of the algorithm performance. However, 
as mentioned above, there is no ‘true’ reference available (147) but the higher the 
quality of the reference, the greater the algorithm integrity. 
Fifteen: Table/figure comparing algorithm results and the reference data 
A table or figure outlining the accuracy of the event detection algorithm is important to 
allow these data to be more easily interpreted. Despite, this only 17/27 (63%) (figure 23) 
displayed these data in this format, for example, in a figure (Chubak (167)) or in a table 
(Lamont (165), Gupta (181)). 
 
Where algorithms are being assessed for clinical use, accessibility and transparency of 
results is vital. If reporting guidelines requested comparable items, then it would be 





Sixteen: Indexed by PubMed 
27/27 (100%) (figure 23) of the articles were indexed by PubMed. This was utilised as a 
proxy, although arbitrary, marker for quality of the journal of publication. This was used 
as an alternative to the journal impact factor, as this marker of quality has been 
previously questioned (193).  
 
No comparisons could be made for the quality of the papers here as all were indexed by 
PubMed. However, this suggests that all of these papers were published by journals that 
met ‘vigorous review or selection criteria’ (194). This, therefore, gives a proxy marker 
that the algorithms have been reviewed by an independent researcher. This suggests 
that the algorithm designs have been reviewed and therefore these algorithms may 
have higher integrity. 
Seventeen: Algorithm variables published (or summary)  
In order to replicate analyses, the variables used in each algorithm should be published. 
Despite this, only 19/27 (70%) (figure 23) published the variables.  
 
If the studies do not report the variables, it may not be possible to replicate the 
algorithm and validate or use it within your cohort. The algorithm is not generalisable if 
it is not possible to replicate. It may be possible to request the algorithms off the 
authors, but this is often also not clear. It may not be possible, or appropriate, to publish 
the entire algorithm but here it should be obvious that it is possible to request the code 
or variables off the author. This enables the algorithms to be replicated within similar, or 
different, cohorts for further validation and use. 
4.7.3.5 Overall weakness and bias assessment 
In assessing these criteria through analysing participant, intervention, outcome and 
quality factors, it was found there was a varying level of weakness and bias. Greater 
than 85% of studies fulfilled the following criteria: the cohort was accurately identified 
(criterion one); the events were compared to a reference (criterion seven); the 
reference data were of high quality (criterion fourteen) and the studies were indexed by 































In contrast, alarmingly less than 20% of studies used suitable patient exclusion criteria 
(using my defined criteria) or linked the routine data to an RCT. The patient exclusion 
criterion was deemed to therefore be the greatest source of weakness and bias, as the 
accuracy of event detection was hypothesised to be increased, due to excluding more 
challenging cases (figure 23). Within a real clinical setting, patients cannot be excluded 
from follow-up due to less favourable disease trajectories. The lack of RCT routine data-















Figure 23: The percentage of papers fulfilling each of the 17 criteria analysed during the content 
analyses. 
 
At a study level, the papers identified to score the lowest level of weakness and bias 
were by Haque (175) and Chubak (167), scoring 14/17, 82.4% of criteria. The papers 
identified to have the highest level of weakness and bias were by Hagberg (170), 
Deshpande (174) and Livaudais (177) (figure 24).  
 
The studies by Haque (175) and Chubak (167) also identified a maximum sensitivity of 

























































































































most feasible algorithms (both studies were in breast cancer using databases in the 
USA).  
 
The study by Livaudais (177) showed the highest sensitivity of event detection (1.0) but 
also scored the lowest in the weakness and bias assessment. This is potentially due to 



















Figure 24: The percentage of the 17 criteria fulfilled by each author.  
Where 0% and 100% = 0/27 and 27/27 of the criteria being scored, respectively. The total number 






4.7.4 Methodology analysis summary 
Further analysis was undertaken into the development of the algorithms for: 1) the type 
of variable utilised in the algorithm (outcome coding, procedure coding, clinical coding 
and activity coding) and 2) the algorithm design. 
4.7.4.1 Types of variable 










Cause of death or date of death 
End-of-life care indicator (hospice)  
Pathology codes 
Procedure Surgical Non-surgical (chemotherapy, RT, imaging, biopsy) 
Clinical* PSA 
Activity Number increase (visits, imaging) 
 
Table 44: The variable coding themes identified from the literature; outcome, procedure, clinical 
and activity. 
*: Algorithms developed to use clinical or outcome variables alone would be excluded, unless the 
algorithm was developed linked to RCT data (see the exclusion criteria in table 41). 
 
The most common design (table 44), was utilising both outcome and procedure coding 
(13/27, 48%) (table 45). The procedures were used as proxies to enhance the detection 
of events that would have been missed using outcome coding alone. The second most 
common technique was using procedure codes alone (7/27, 26%) without the outcome 
coding.  
 
Lamont (165) was the only paper to utilise outcome coding alone, due to the exclusion 
criteria (table 41). The study by Ehrenstein (173) was the only study to utilise clinical 
diagnostic test values as well as procedure codes. 5/27, 19% of papers investigated the 





still relied upon outcome coding. Not one algorithm using activity markers was designed 
without the use of outcome coding (table 45). 
 
Algorithms developed with outcome coding (especially alone) should be interpreted 
with caution. Many routine clinical datasets are collected for primary reasons that often 
do not include research. Hence, diagnoses coding if often not mandatory; this can lead 
to sporadic reporting. Therefore, these techniques may reduce the algorithm 
performance in detecting events. In the HES data, procedure codes are documented 
with a date (for example, date of the operation or the admission) but diagnoses codes 
are not reported with a date. Hence, if the diagnoses code was being used as an 
indicator of the event date, this could be delayed from the true diagnoses date. 
 










Earle (163)   + 
 
    
McCLish (164)     +     
Lamont (165) +         
Anaya (166)     +     
Chubak (167)         + 
Kimmick (168)   +       
Nordstrom (169)      +     
Liu  (47)   +       
Hagberg (170)     +     
Lash (171)     +     
 Ricketts (172)   +       
Ehrenstein (173)       +   
Deshpande (174)     +     
Haque  (175)         + 
Warren (176)     +     
Livaudais (177)   +       
Nordstrom (178)     +     
Joshy (179)   +       
Hassett (180)         + 
Gupta (181)   +       
Ritzwoller (182)         + 
Wong (183)     +     
Rasmussen (184)     +     
Uno (185)           + 
Xu  (186)     +     
Xu (187)     +     
Rasmussen (188)     +     
Total 1 7 13 1 5 
 
Table 45:  The methods utilised for algorithm development by the author.  
If one algorithm in a study was developed using procedure coding alone, the study was classified 






The five instances where activity of the variables were investigated were, Chubak (167), 
Haque (175), Hassett (180), Ritzwoller (182) and Uno (185). Chubak (167) and Haque 
(175) used the frequency of a single event (visits) to fulfill a categorical variable. For 
example, if four visits were met within a defined time period, the recurrence indicator 
was identified, flagging an event. The final algorithms contained a rule to flag outcomes 
that identified the presence of two visits, plus a code for a secondary malignant 
neoplasm within 60 days. Although not included in the final algorithm, the number of 
instances of breast imaging and diagnoses codes in certain time periods, for example, 
two visits for mammography within 60 days were also investigated. The final Haque 
(175) algorithm included identifying the number of oncology visits in 60 or 90 days (four 
visits within 90 days and three visits within 60 days) to flag an outcome of interest.  
 
In contrast, Hassett 2017 (180), Ritwoller 2017 (182) and Uno 2018 (185) (all papers by 
the same team) investigated the ability of using unique peaks in the code count to 
detect events. Hassett (180) initially developed an algorithm based upon twelve 
potential indicators of cancer recurrence to identify outcomes of interest and to identify 
the timing of the events.  
 
Indicators of recurrence were assessed to include the mean numbers of events, for 
example, imaging and inpatient events per year. Indicators were usually categorical 
variables, unless the absolute code count increased over time, in which these were 
classified as continuous indicators. To determine the timing of the event, the period 
when the code count peaked for each individual variable was assessed. Therefore, it was 
possible for a patient to have twelve different recurrence times. Subsequently a single 
time was statistically derived from the twelve dates to flag the outcome of interest. 
 
Ritzwoller (182) in the following year enhanced the Hassett (180) algorithm. Algorithms 
were separately developed to 1) identify events and 2) identify the timing of events. To 
identify events, the number of secondary malignant neoplasm codes were determined; 
if the absolute number reached the threshold (34 events), the probability of cancer 
recurrence was 100%. In those patients where 34 events were not identified and the 
threshold was not reached, indicator variables were utilised (as in the Hassett (180) 





recurrence included a mean increase in the imaging code count over the year and the 
total number of chemotherapy codes, radiotherapy codes, hospice codes and 
mastectomy codes.  
 
The timing of recurrence was based upon the Hassett (180) study, identifying where the 
code count peaked for each individual code group. Each variable held a weight, and this 
allowed a final estimate to be identified. An offset (difference between the time when 
the code count peaked and the gold-standard) was investigated in addition, to aim to 
identify a recurrence date nearer the ‘true’ value.  
 
The final paper by the team (Uno, (185)) also aimed to identify the timing of event. In 
addition to enhancing the previous timing model, a method was developed to infer the 
date of missing events. This was done by using the time halfway between diagnosis and 
the end of follow-up, as the date of recurrence.  
 
The use of activity variables may have enhanced algorithm performance; where 
sensitivity values were published (Chubak (167), Haque (175), Hassett (180), Ritzwoller 
(182)), the sensitivities ranged between 0.77 (Hassett (180)) and 0.99 (Chubak (167)). No 
studies investigated the cumulative sum of all cancer-related interactions, but instead 
looked at the individual variables in isolation. Due to the absence in the literature and 
routine data limitations, this cumulative method of identification was investigated 
further. The hypothesis was that events could be identified despite the absence of direct 
outcome coding in the routine data.  
4.7.4.2 Algorithm design 
As discussed above in section 4.7.4.1, different algorithms are designed to screen for 
different types of codes (the outcome, procedures and clinical variables). However, in 
addition, the algorithms are also designed in other ways. For example, the algorithms 
begin screening from different time points and often require treatment-free intervals. 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 27: Summary of the main concepts identified during full-text review of the 6/27 papers 
analysed in the review. 
Sx = surgery; Dx = diagnosis; Tx = treatment. RT = radiotherapy; HTx = hormone therapy; M1 = 






Secondary neoplasm codes, biopsies, imaging, 
chemotherapy, surgery, RT >10 weeks. Backdating 
was also used e.g. to biopsy date to optimize 
correlation to the manual data 
Wong  
Primary Tx (end date = 
cystectomy or last RT 
fraction (plus various 
rules) 
Ongoing disease indicators e.g. cystectomy (period 
of activity required) – during 90d post Sx or 180d 
post RT. Then indicators of recurrence: diagnoses 
codes for recurrence, distant metastatic disease, 
RT/chemotherapy, other codes (pathological, 
procedures and diagnostic) 
Rassmussen  
Dx 
Variables in the timing algorithm were secondary 
malignant neoplasm codes, chemo and imaging. 
Time estimates were combined from the multiple 
code group peaks. If no time of recurrence could be 
identified = estimate halfway between Dx and the 
end of follow-up Uno  
Primary Tx 
Various algorithms were developed including, new 
chemotherapy or RT >1y post primary Tx, death by 
cancer, 2nd mastectomy 1y post-Dx, type of surgery, 
2nd referral 1y post-Dx, TNM stage at Dx, cluster of 
visits to cancer centre 1y post-primary Tx 
Xu  
Primary Tx 
Various algorithms were developed including, age, 
surgery, chemotherapy & RT >180d after primary 
Tx, 2nd surgery 1y post-Dx, 2nd referral 1y post-Dx, 
death by cancer, surgery after Dx, clusters of visits 
(>4) 540d post Dx Xu 
Primary Tx (end date = 
lumpectomy/mastectomy 
or last RT/chemotherapy 
(plus various rules) 
Ongoing disease indicators e.g. stage, chemotherapy, 
RT, surgery (period of activity required) <90d post Sx 
or 30d post RT/chemotherapy. Then indicators of 
recurrence: morphology codes, RT, metastases codes, 







Treatment free intervals were often required to fulfil the algorithm rules to detect an 
event (for example, Earle (163), McClish (164), Chubak (167), Haque (175), Ritzwoller 
(182)). The aim of this is to enhance the identification of events, however, it is possible 
that this may restrict event detection; events may occur within that time window. For 
example, a patient that progresses very quickly after diagnosis may be excluded. This is 
in contrast to one study by Nordstrom (169) where the codes to identify events were 
required to be present in the first 60 days after diagnosis. This means that events 
occurring sooner can be identified, but events occurring during long-term follow-up 
would be excluded.  
 
Codes are also screened to identify events from different time points. For example, 
diagnosis (166), entering a trial (165), primary treatment (179) and specifically surgery 
(168) or chemotherapy (177). Where primary treatment is used as a marker to begin 
screening codes, this would exclude any patients that experienced an event prior to 
treatment. However, allowing screening to occur from diagnosis may increase the 
number of false positives (reduce the PPV) whilst enabling detection of earlier events. 
This may be illustrated by three low PPV performing studies (Ehrenstein (173), 
Nordstrom (178) and Chubak (167)) that screened from diagnosis. This can be compared 
to studies with high performing PPVs, such as by Rassmussen ((184), (188)) which 
screened from primary treatment (table 43, part 2). There is therefore a trade-off 
between developing an algorithm with a high sensitivity and a high PPV. Detecting 
events earlier at diagnoses may increase event detection (increase the sensitivity) but 
may lead to more false positives (reduce the PPV).  
 
In addition, to optimise the identification of events, Ricketts investigated optimum 
backdating time windows to find the ‘true’ date of event from the date of the proxy 
event (172). It is possible that the new backdated event may also not be the ‘true’ date. 
For example, the radiotherapy date may not flag the true date of the cancer event. 
 
Algorithms were designed differently to try to enhance event detection accuracy. 
However, what was shared across studies was that all codes were screened from an 






4.8 Systematic literature review: Conclusion 
This systematic review identified different methods to detect outcomes of interest, 
where the majority of outcomes were detected in non-trial patients. Worldwide, only 
two studies linked routine data to trial data, but the timing of the outcome was assessed 
in both of the papers. However, neither of these models were designed to detect 
outcomes without clinical databases containing details such as pathology or direct 
coding alone, limiting their generalisability. Only one study compared the cumulative 
incidence of algorithmic-detected outcomes to trial data collected outcomes but the 
ability to identify trial level surrogacy (treatment intervention efficacy, see section 4.9.5) 
was not assessed. In addition, this study only involved a small sample of 63 events in 
colorectal cancer. Hence, no studies worldwide have developed a clinically useable 
validated tool for trial use. It was also identified that no UK routine databases have been 
used to perform oncology clinical trial analyses. 
 
Therefore, this review confirmed there remains an unmet need to utilise routine 
datasets alongside clinical trial data, to identify oncology outcomes that could be used 
to perform surrogate endpoint analyses.  
 
In clinical trials, time to outcomes are a commonly collected trial measure and therefore 
a method to extract this information from routine data would uncover hidden but 






4.9 Materials and methods 
4.9.1 Approvals 
All STAMPEDE data, routine HES data (Public Health England (PHE) and National Health 
Service Digital (NHSD) sourced) and clinical noting data were sought with relevant 
ethical and regulatory processes in place; see the section 2.4 for the detailed list of 
approvals.  
4.9.2 Participants 
Participants were included across four cohorts (table 46); some patients overlapped 
between groups, but the number of novel participants in each cohort can be seen in 
table 46. Cohort one to three (including the cumulative cohort) included eligible England 
STAMPEDE participants recruited from the University Hospitals Birmingham Queen 
Elizabeth Hospital (UHB QEH), selected from STAMPEDE treatment arms A-F 
(introduction, 1.5.1) (72). The patients in cohort one were chosen by M. Gannon at the 
MRC CTU at UCL as a sample of patients that were known to have routine data available 
and at least one skeletal related event (SRE) instance (to also enable SRE outcome 
availability analyses), four of which had spinal cord compression (an SRE). The single-site 
data were utilised due to only having access to single-site routine data initially. There 
was no resource or regulatory access to perform validation from outside of UHB QEH. 
Cohort two and three patients were chosen as a random sample of the remaining 
STAMPEDE patients linked to the routine data for training and validation; these patients 
were not restricted by SRE occurrences. The largest (cohort four, N=1,695) validation 
study was undertaken in an England multi-site cohort. This included patients on 













Cohort number Stage Total cohort size Novel patients 
1 Model development (pilot/feasibility) 6 6 
2 Algorithm training 44 41 
3 Algorithm validation 1 46 46 
- Algorithm validation 2 (cumulative) (cohort 2 & 3 plus 3 from cohort 1) 93 0 
4 Algorithm validation 3 1,695 1,644 
 
Table 46: The number of patients (total cohort size and number of unique/novel patients at the 
time of the analyses) in each cohort by the stage of analyses.  
 
The number of patients in the entire STAMPEDE docetaxel comparisons can be seen and 




















Figure 28: Diagram illustrating the final cohort selection (cohort four), from the total in the 
docetaxel comparison in the STAMPEDE trial. 
*= This includes patients providing a name at randomisation, implicitly giving consent for 
flagging, who have not withdrawn consent or have a wrong NHS number. **= Those linked by 
PHE, with HES data available. 
 
4.9.3 Data extraction, outcome measures and processing 
Data were extracted from three separate sources: the STAMPEDE trial, the routine data 
and the clinical records. The records extracted from STAMPEDE included: date of 
randomisation, treatment allocation, trial visits and trial outcomes (for example, 
progression). These data for the six initial pilot cases were sourced directly from the 
478 excluded (not English sites) 
59 excluded (no consent or wrong NHS 
number) 
 
N = 2,291 (patients in the STAMPEDE docetaxel arm ACE comparison worldwide) 
N = 1,813 (patients in the STAMPEDE docetaxel arm ACE comparison in England) 
N = 1,754 (eligible patients for routine data linkage*) 
COHORT FOUR: N = 1,695 (analysed in cohort four)** 
59 excluded (not received from PHE- 





case report forms (CRFs) but for all other stages, data were extracted from the trial 
database. The required fields (table 47) to identify individual routine data interactions 
were linked to each unique STAMPEDE trial ID.  
 
The STAMPEDE data were also used to extract patient characteristics, including; 
treatment arm, broad disease grouping, age and PSA at randomisation (interquartile 
range (IQR), median, range) and tumour (T), node (N) and metastases (M) category at 
randomisation. I calculated the summary statistics using code that I wrote to extract the 
information from the STAMPEDE database. C.Brawley at the MRC CTU at UCL, extracted 
the age summary statistics for the largest multi-site cohort, because I did not have 
access to the non-UHB QEH date of birth (DOB) values. 
 
Variable  Code 
Date the patient was admitted to hospital/date appointment scheduled ADMIDATE/APPTDATE 
Date the patient was discharged from hospital DISDATE 
The specialty under which the consultant is contracted MAINSPEF 
The type of interaction – admitted patient care or outpatient event ADMITYPE 
Diagnosis codes - ICD-10 DIAG_01 – DIAG_12 
Operation codes - OPCS version 4.2 to 4.8 OPERTN_01 – OPERTN_12 
The organisation acting as the healthcare provider PROCODE 
 
Table 47: The routine data (HES) fields analysed during model development, to identify prostate 
cancer-related events. 
 
Case series of the clinical records were undertaken using the clinical noting data and this 
was considered the reference standard for all analyses, except for trial endpoint 
analyses where the STAMPEDE records were considered the reference standard.  
 
Records of interest extracted from both the routine data and the clinical records upon 
note review included: date, type of healthcare interaction (inpatient, outpatient) and 
diagnostic, treatment and follow-up details. In addition to this, progression outcomes 
were identified from the clinical records and defined as, local or nodal progression, 
distant metastases and/or skeletal-related events (SRE). Dates for outcomes were 
assigned as the date of objective detection, unless not specified, whereby the dates of 






During model development, for each participant, each clinical record and routine data 
interaction was manually inspected and tabulated to classify as 1) prostate cancer-
related record, or 2) non-prostate cancer-related record, which were removed. 
4.9.4 Data censoring 
Where the three data sources were being initially investigated individually (during 
model development – cohort one), each of the three data sources were analysed until 
the end of follow-up for each source. However, where comparisons were being made 
using multiple data sources, analyses of the data sources were undertaken from the 
date of randomisation into STAMPEDE until the last available mutual event, identified in 
either the routine data, the clinical records, or the STAMPEDE data, depending on what 
analysis was being undertaken.  
 
Throughout endpoint analyses during algorithm training (cohort two) and the small-
scale validation (cohort three), the STAMPEDE May-2015 dataset freeze for arms B, C, E 
and contemporaneously recruited arm A patients were used (data frozen 13/05/15). For 
the D, F and corresponding arm A patient analysis, the December-2015 data freeze was 
used (data frozen 15/12/15). This date was substituted for the last routine data or 
clinical record event if these events preceded the STAMPEDE censor date.  
 
In the large-scale validation (cohort four), more recent HES data (up to the 31/01/18) 
was available compared to the STAMPEDE data; hence, if no earlier outcome was 
identified using the HES model, or the HES outcome that was found occurred after the 
STAMPEDE censor (STAMPEDE arm A, G data freeze December 2017), the event was 
censored back at the individual STAMPEDE censor date (clinical noting analyses was not 
possible in the multi-site cohort four analyses). 
4.9.5 Requirements to develop a surrogate endpoint 
In order to validate the HES-derived endpoint (event/outcome of interest), previously 
published criteria were followed (195, 196). This involved testing the endpoints at an 
individual level and at a treatment level (195, 196). These criteria can be seen in practice 





study (98). These criteria require a two-stage validation model investigating validating 
that a surrogate can show a strong relationship between: 
 
1. Individual endpoint effects (patient level surrogacy) – association of the novel 
endpoint to standard endpoints, without reference to an intervention (98, 195, 196) 
(151). Within this study, the algorithm generated endpoints were compared to the 
standard STAMPEDE endpoints and correlation coefficient analyses were 
undertaken; further details can be seen below. 
 
2. Endpoint treatment effects (trial/treatment level surrogacy) - a strong correlation 
between treatment effects on the novel endpoint was required (98, 151, 195, 196). 
Hazard ratio analyses were conducted; further details can be seen below. 
4.9.6 Analytical methods 














Case series (interactions classified as prostate-cancer related 
or not) ü ü û 
Records of interest extracted from the routine data and the 
STAMPEDE data (classified as prostate-cancer related or not) ü ü û 
Routine data accuracy & SRE accuracy ü û û 
Clustering analyses (varying time intervals, varying 
thresholds, coding variations, removing early confounding 
events, removing overlapping codes, removing routine 
oncology appointments, assessment of continual 
progressive states) 
ü ü û 
Surrogacy analyses: Patient level surrogacy (association of 
the algorithm endpoint with the STAMPEDE endpoints) ± 
magnitude of the difference analyses ± Pearson’s correlation 
± Bland-Altman analysis 
ü ü ü 
Surrogacy analyses: Trial level surrogacy (comparing hazard 
ratios – comparing treatment effects) û ü ü 
 
Table 48: A summary of the methods used during the analyses. 
 
Firstly, routine data accuracy calculations were performed for: overall accuracy of 





feasibility of an indirect model, by investigating the effect of inferring missing HES 
events (inferred event analyses) and the effect of intentionally excluded codes on the 
data quality (excluded event analyses) (table 49). 
 
Accuracy 
analysis Aim Included events Excluded events 
Missing 
events  
Validate the HES 
against note 
review-derived 
records to assess 
the data accuracy  
All prostate cancer related 
events (inpatient and 
outpatient) 
Unconfirmed events that could 
not be validated, including, 
STAMPEDE nurse visits (CRF 
identifiable but often not 
documented in clinical noting) 
 
Did not attend or cancelled 




To assess if further 
events could be 
identified using 
alternative coding 
Events included in the ‘missing 
event’ accuracy calculation, 
plus: 
 
Inferred coding for events:  
• MAINSPEF 800 (clinical 
oncology outpatient 
event) = radiotherapy 
• MAINSPEF 960 (allied 
health professional 
outpatient event) = scans 
Those excluded from the ‘missing 
event’ accuracy calculation 
Excluded 
events 
To assess whether 
the HES accuracy 
(missing events) 
was due to missed 
or planned 
exclusions 
Events included in the ‘missing 
event’ accuracy calculation 
Those excluded from the ‘missing 
event’ accuracy calculation, plus: 
  
• X-Ray imaging 
• Trial treatments 
 
Table 49: The events included in the three accuracy calculations, for: missing, inferred and 
excluded events. 
MAINSPEF = a HES field which documents the speciality which the patient’s consultant is 
contracted to (table 47). 
 
During the model development (pilot), we hypothesised that if a patient was 
experiencing a clinically relevant outcome (for example, progression), the number of 
healthcare events (for example, contact with services, such as scans and visits) would 
increase, providing us with a clinical footprint. The aim was to capture periods of activity 
above routine oncology (197) and STAMPEDE trial monitoring (198) which could identify 
trial outcomes of interest, such as progression. To build a model to identify these 
outcomes of interest, the counts of records were generated from both the clinical 
records (initially) (see table 50 for included and excluded events) and the routine HES 





of activity. If the level of activity fulfilled the defined model rules (table 51), a routine 
data derived outcome was identified. The time to this HES-derived outcome was 
proposed as the ‘activity-free survival’, the AFS. 
 
Included events 
Medical oncology interactions (inpatient, outpatient) 
Clinical oncology interactions (inpatient, outpatient) 
Urology interactions (inpatient, outpatient) 
Nurse led STAMPEDE clinic visits 
Cancelled appointments 
Did not attend appointments 
Radiotherapy 
Trial chemotherapy (for example, docetaxel, zoledronic acid) 
Non-trial chemotherapy (for example, strontium, radium) 
Imaging (including X-rays) 
Admissions related to prostate cancer 
Excluded events 
Unplanned visits 
Outpatient or inpatient non-prostate cancer-related events (e.g. cardiology) 
Blood tests (e.g. prior to chemotherapy, PSA) 
Specialities related to side effects e.g. maxillofacial appointments - osteonecrosis jaw 
 
Table 50: The events that were identified during the pilot analyses and were included and 
excluded from the clinical noting data to build the HES-outcome detecting model. 
N.B This is not an exhaustive list of potential events (compared to table 52) as not all events could 
be identified within the initial six prostate cancer patient trajectories. 
 
Whilst triangulating the three data sources, model rules were refined for optimum 
outcome detection, to identify when a cluster of events was deemed to be a ‘routine 
data outcome’. This included varying time intervals to cluster the healthcare 
interactions, a threshold number of events to reach to identify the timing of the 
outcome (for first and subsequent outcomes) and coding variations to enhance the 
detection.  
 
For each of the candidate thresholds and time intervals (seven different time intervals 
were investigated, using both clinical and statistical assumptions) calculations included, 
true and false positive outcomes, sensitivity, PPV and false negatives. In addition, the 
mean difference in detection (the mean magnitude of the difference) was also 
calculated between the clinical noting derived outcome and the routine data outcome. 
The accuracy of detecting SRE outcomes directly from the routine data coding was also 
investigated in all six pilot patients (analyses also included splitting the cohort into the 





comparing the routine data-derived outcomes to the clinical noting and trial-derived 
outcomes. 
 
Subsequently, during algorithm training (cohort two), the model was automated within 
R v3.3.2 (109) with RStudio v1.0.136 (110) and applied to the routine data (code 
available on request). Two different sets of analyses were undertaken to assess patient 
level surrogacy and the magnitude of the difference in detection (weeks) for all true 
positive STAMPEDE and routine data endpoints were calculated. 
 
1) All reference clinical noting progression outcomes were compared to the 
routine data-detected outcomes and the STAMPEDE (PFS, MFS and FFS) 
documented endpoints (99) (the ability to detect the first two outcomes per 
patient, are presented). The clinical noting and STAMPEDE endpoints were also 
assigned to the algorithm time intervals to enable a direct comparison. 
 
2) The first routine data outcome per patient (the AFS) was compared to the 
STAMPEDE endpoints (MFS, FFS, PFS) (the reasons for the missed or delayed 
routine data outcomes were identified).  
 
The ability of the algorithm to correctly classify the overall outcome status over the 
whole of follow-up was also assessed (for example, identifying if the patient did or did 
not experience an outcome during the whole of the follow-up period). In addition, the 
total number of routine data-derived outcomes (AFS, SRE) was compared to the number 
of standard STAMPEDE detected outcomes (FFS, MFS, PFS, SRE). Subsequently trial level 
surrogacy was investigated by performing standard survival analyses and calculating 
descriptive statistics (see below for further details). 
 
Further rules were developed to confirm the optimum threshold and clustering time-
interval, to maximise the sensitivity and specificity for outcome detection. Analysis 
included: identifying all potential prostate cancer-related events of interest (table 52); 
removing early confounding trial events (initial outcome-free periods), removing 
overlapping codes (where events were counted more than once), assessment of 





continual progressive states, which later defined our analysis to the first two progressive 
outcomes. The rules can be seen in table 51. 
 
 
Table 51: The rules developed to detect the routine data-derived outcomes. 
^ = during model development the optimum thresholds required to trigger an event were 




4 Chemotherapy Chemotherapy assessment, blood sample, procurement and delivery, plus further potential chemotherapy codes 
5 Imaging 
Location specific, computerised tomography (CT), positron emission 
tomography (PET), magnetic resonance imaging (MRI), bone scan, X-ray, 
ultrasound, cystoscope, other imaging to specific areas, 
radiopharmaceutical imaging, non-prostate cancer scans (end-of-life care 
scans), scans related to SREs 
6 Radiotherapy RT planning, delivery, type, brachytherapy planning and delivery 
7 Biopsy Biopsy 
8 Surgery Surgery to prostate, bladder, lymph nodes, surgery for spinal cord compression and pathological fracture 
9 Other therapies, interventions 
Hormone therapy, immunotherapy, other drugs, blood transfusion including 
various interventions such as catheter insertion  
10 SRE direct detection 
SREs identified individually - Radiotherapy, surgery to bone, spinal cord 
compression and pathological fracture (identified through diagnoses and 
treatment codes) 
 
Table 52: The prostate cancer-related interactions of interest, for the algorithm to detect in the 
routine data, to flag an outcome of interest. 
 
Once the algorithm had been trained, validation could be undertaken, firstly, at a 
patient surrogacy level. During the single-site validation (cohort three, N=46), the 
number of STAMPEDE trial outcomes that were detected using the HES-algorithm were 
Model development rules (for first and subsequent events) 
1 Outcome triggered = when the number of prostate cancer-related events reached a defined threshold ^ 
2 8-weekly clustering intervals ^ 
3 Sustained increase above the threshold = the same outcome 
4 Subsequent outcomes: When the number of events reduced then raised above ≥5 or ≥6 events again 
5 An SRE could flag an outcome even if the threshold was not reached 
6 SREs in the outcome peak = the same outcome until the threshold was reached again 
Final algorithm training and validation rules (enhancing identification of 1st event) 
1 Outcome triggered = when the number of prostate cancer-related events reached the threshold (≥5) * 
2 8-weekly clustering intervals 
3 Sustained increase above the threshold = the same outcome 
4 Subsequent outcomes: When the number of events reduced to ≤4, then raised above ≥5 events * 
5 An SRE could flag an outcome even if the threshold was not reached 
6 SREs in the outcome peak = the same outcome until the threshold was reached again 
7 Remove outcome if identified in the first 15% of a patient’s history (likely to be trial treatments) * 
8 Radical radiotherapy should not flag an outcome, as a definitive Tx for prostate cancer * 





calculated and the time to the first algorithm-detected outcome (AFS) per patient was 
compared to the STAMPEDE endpoints (FFS, PFS, MFS). Detection accuracy was 
calculated using the magnitude of the difference in weeks. In this cohort (N=46), the 
false positive and false negative events were confirmed by note review. The total 
number of events detected using each endpoint (HES AFS and SREs, STAMPEDE MFS, 
PFS, FFS and SREs) (N=93) were also analysed and compared. 
 
To validate at a trial surrogacy level (cohort two onwards) the algorithm was reapplied 
to the routine data which was split by those receiving docetaxel (arms C, E) and those 
not (arms A, B, D, F; in the final validation stage, only arm A was utilised). Standard 
survival analyses (Kaplan-Meier) methods were used and Cox-proportional hazard 
models with 95% confidence intervals, to calculate the hazard ratios. This was to 
estimate and compare the treatment effects between the STAMPEDE outcomes (FFS, 
PFS, MFS and SREs), the clinical reference-derived outcome (progression) (where 
possible, during the single-site studies) and the routine data-derived outcome (AFS and 
SREs). These were defined as the time from trial randomisation to the first outcome per 
data source. The effect of grouping the outcomes into the 8-week intervals were also 
investigated, by assigning the STAMPEDE MFS into the routine data intervals, prior to re-
calculating the STAMPEDE MFS hazard ratio (HR). A HR below 1.00 favoured the 
research group (chemotherapy - docetaxel), as opposed to the control standard-of-care 
(non-chemotherapy hormone therapy, all patients were randomised prior to docetaxel 
becoming added to the standard of care). The median survival (in weeks) and the 2-year 
(104 weeks) and 5-year (261 weeks) proportion remaining estimates (%) were also 
calculated.  
 
In addition, during the multi-site validation (cohort four, N=1,695), Pearson’s correlation 
coefficients were calculated comparing the correlation of the algorithm endpoints (AFS 
and SREs) to the STAMPEDE MFS, PFS, FFS and SREs. The strength of correlation was 
defined as detailed in the literature (199, 200) (for example, 0.00-0.30 = negligible 
correlation; 0.30-0.50 = low correlation; 0.5-0.70 = moderate correlation; 0.70-0.90 = 
high correlation; 0.90-1.00 = very high correlation) (199, 200). Correlation coefficients 
were calculated for all endpoints for outcomes where patients experienced both a HES 





correlation coefficients were calculated: those where patients only experienced a HES 
outcome (but not necessarily an MFS outcome) and those where all HES and STAMPEDE 
MFS outcomes were included (including those censored without an outcome). Both of 
these measures included patients censored at mutual time points due to not 
experiencing an event. The initial correlation coefficient calculated for outcomes 
identified in both sources (HES and the trial) was undertaken to gain an unbiased 
coefficient. For the other measures, censoring would lead to a mutual outcome date 
being identified, biasing the results. Hence, these results were deemed inconsequential.  
 
Scatter graphs were created where appropriate to visualise the correlation, the line of 
perfect correlation was also present. Bland-Altman plots were also constructed to 
determine the quality of surrogacy for the HES outcome to the trial MFS and PFS. Limits 
of agreements were defined as the mean difference in the number of weeks between 






4.10 Results  
4.10.1 Participants 


























A 2 (33%) 9 (20%) 16 (35%) 27 (29%) 855 (50%) 
B 2 (33%) 8 (18%) 6 (13%) 14 (15%) - 
C 0 (0%) 6 (14%) 9 (20%) 15 (16%) 415 (24%) 
D 0 (0%) 6 (14%) 3 (7%) 9 (10%) - 
E 1 (17%) 9 (20%) 6 (13%) 16 (17%) 425 (25%) 
F 1 (17%) 6 (14%) 6 (13%) 12 (13%) - 
Broad disease 
grouping 
Newly diagnosed N0M0 0 (0%) 10 (23%) 7 (15%) 17 (18%) 343 (20%) 
Newly diagnosed N+M0 0 (0%) 3 (7%) 6 (13%) 9 (10%) 229 (14%) 
Newly diagnosed M1 6 (100%) 30 (68%) 32 (70%) 65 (70%) 1035 (61%) 
Previously treated M0 0 (0%) 1 (2%) 0 (0%) 1 (1%) 44 (3%) 
Previously treated M1 0 (0%) 0 (0%) 1 (2%) 1 (1%) 44 (3%) 
Age at 
randomisation 
Median (IQR) 60 (56-66) 63 (57-69) 65 (57-73) 
63 (57-
70) 66 (61 – 71) 
Range 54-68 48-80 41-81 41-81 42 - 82 
PSA at 
randomisation 




406) 66 (21 – 189) 
Range 19-478 10-5000 3-8028 3-8028 0.2 - 15747 
T category at 
randomisation 
T0 0 (0%) 0 (0%) 0 (0%) 0 (0%) 6 (0%) 
T1 0 (0%) 0 (0%) 2 (4%) 2 (2%) 16 (1%) 
T2 0 (0%) 4 (9%) 4 (9%) 8 (9%) 175 (10%) 
T3 3 (50%) 26 (59%) 21 (46%) 49 (53%) 1095 (65%) 
T4 2 (33%) 7 (16%) 7 (15%) 14 (15%) 282 (17%) 
TX 1 (17%) 7 (16%) 12 (26%) 20 (22%) 121 (7%) 
N category at 
randomisation 
N0 2 (33%) 13 (30%) 14 (30%) 29 (31%) 730 (43%) 
N+ 4 (67%) 21 (48%) 23 (50%) 45 (48%) 867 (51%) 
NX 0 (0%) 10 (23%) 9 (20%) 19 (20%) 98 (6%) 
Metastases at 
randomisation 
M0 1 (17%) 20 (45%) 19 (41%) 40 (43%) 616 (36%) 
M1 5 (83%) 24 (55%) 27 (59%) 53 (57%) 1079 (64%) 
 
Table 53: Patient characteristics, split by the analyses cohort (cohort 1 model development N=6; 
cohort 2 algorithm training N=44; cohort 3 algorithm validation N=46 & 93; cohort 4 algorithm 
validation N=1,695). 
C: cohort; TX: tumour cannot be measured; NX: nodal status cannot be measured; N+: node 
positive; N0: node negative. M1: metastatic; M0: non-metastatic. Due to rounding, percentages 
(%) may not add to 100%. 
4.10.2 Model development (pilot/feasibility) (cohort 1) 
58.6% (136/232) of all the prostate cancer-related interactions/events were identified in 





73.4%, 58/79). When inferring missing routine data records with alternative coding, the 
accuracy increased to 62.5% (145/232) and when assessing the accuracy for mandatory 
coded events only, the accuracy increased to 76.8% (129/168) (table 54). Therefore, 




events 1 2 3 4 
Missing event analyses 
Number of events identified in the HES  47 58 12 19 136 
Total number of events (reference)  77 79 19 57 232 
 Percentage of events detected (%) 61.0 73.4 63.2 33.3 58.6 
Inferred event analyses 
Number of events identified in the HES 51 59 12 23 145 
Total number of events (reference) 77 79 19 57 232 
  Percentage of events detected (%) 66.2 74.7 63.2 40.4 62.5 
Excluded event analyses 
Number of events identified in the HES 45 50 12 22 129 
Total number of events (reference) 61 53 12 42 168 
  Percentage of events detected (%) 73.8 94.3 100.0 52.4 76.8 
 
Table 54: The accuracy of the HES routine data coding for prostate cancer-related events, since 
randomisation, for the three different accuracy calculations (missing events, inferred events and 
excluded events) for four patients.  
Missing event analyses = assessing all prostate cancer related records; inferred event analyses = 
assessing records that can be identified using coding inferral; excluded event analyses = assessing 
the impact of coding that was planned to be excluded (see table 49 for further details). 
 
Graphically grouping/clustering the prostate cancer-related events, sourced from the 
note review data, optimally identified progression outcomes in 8-week intervals 
(identifying 11/11, sensitivity: 1.00, (table 55)).  
 
Patient Reference progression outcomes 
Detected 
with model 
% of outcomes 
detected 
1 3 3 100 
2 3 3 100 
3 1 1 100 
4 2 2 100 
5 2 2 100 
Total 11 11 100% 
 
Table 55: The number of progression outcomes identified in the clinical noting that were detected 
using the clustering of events model. The patient numbers do not necessarily correspond to those 









For example, in figure 29, from analysing the case history, three progression outcomes 
were identified which reflected the completion of the two STAMPEDE CRFs (week 24, 
month 24), plus another CRF not completed (for progression 3); only the 1st instance has 
to be documented by the trial. The three progressions can be seen as three peaks (figure 
29), with the highest point reaching week [16-24), [72-80) and [112-120). The patient 
developed increasing bone pain and a bone scan (week 16) confirmed progression, 
alongside a PSA increase (biochemical failure). This was noted in the STAMPEDE CRF as 
objective, biochemical, symptomatic and SRE progression. Subsequently another 
chemotherapy trial was initiated but the pain continued to worsen; the bone scan (week 
66), confirmed objective progression. This led to cessation of the trial treatment. The 
pain again continued to worsen, and the PSA indicated progression, which was 
confirmed on a bone scan (week 102). A CRF (month 24) was completed for biochemical, 
objective and symptomatic progression, subsequently second line chemotherapy was 
initiated. The patient continued to progress further without any treatment response. In 
addition, multiple SREs were experienced throughout the disease history.  
 
The events that were identified and included in the model as prostate cancer-related, 
can be seen in table 49. The analyses validating the 8-week intervals can be seen in the 






Figure 29: An example of the 8-weekly clustering of the note review sourced prostate cancer-
related events, for one patient, from randomisation (t=0) until death.  
Red circles = progression outcomes; ‘[‘ = inclusive of nearest value; ‘)’ = exclusive of nearest value; 
w = week; # = number. 
 
As shown, clustering the note review sourced prostate cancer-related interactions, 
enabled the identification of major trial outcomes (progression). Next the model had to 
be tested on the routine data, despite the data quality limitations highlighted in table 
54. When this model was applied to the routine data, progression outcomes were also 
identified by the peaks of activity (figure 30).  
 
Next a threshold had to be chosen, in which the number of prostate cancer-related 
events needed to reach, to flag an outcome of interest. Whilst considering the number 
of true and false positives, the optimum number of prostate cancer-related events in 
which to exceed (threshold) to identify an outcome per 8-week interval (in the five 
patients) were: ≥6 (identifying 12/13 outcomes, sensitivity: 0.92, PPV: 0.75) and ≥5, 
(identifying 13/13 outcomes, sensitivity: 1.00, PPV: 0.72) (table 56) (figure 30). Further 
detail into the number of events detected, by patient, at both the five and six event 






































































Progressed (w16) on STAMPEDE arm 



























Figure 30: Clustering of the routine HES prostate cancer-related events (for the patient in figure 
29) to identify outcomes of interest (progression = red dots). 
The dashed lines correspond to the two optimum thresholds (≥5 and ≥6) required to trigger that 
an outcome of interest was met; ‘[‘ = inclusive of nearest value; ‘)’ = exclusive of nearest value; w 









(% extra events) Sensitivity 
False 
negatives PPV 
≥3 13 8 0.62* 1.00 0 61.9 
≥4 13 6 0.46* 1.00 0 68.4 
≥5^ 13 5 0.38 1.00 0 72.2 
≥6^ 12 4 0.31 0.92 1 75.0 
≥7 10 2 0.15 0.77* 3 83.3 
≥8 9 2 0.15 0.69* 4 81.8 
≥9 8 2 0.15 0.62* 5 80.0 
≥10 7 1 0.08 0.54* 6 87.5 
≥11 5 0 0.00 0.38* 8 100.0 
≥12 2 0 0.00 0.15* 11 100.0 
 
Table 56: Analyses into the optimum threshold to identify outcomes of interest. The threshold 
was chosen as a compromise between sensitivity and PPV. Specificity values were not possible to 
calculate, nor the NPV, due to an infinite number of false negatives.  
(*) = the number of false positives were assessed to be too high, or the number of true positives 
too low to be clinically useable; (^) = the two intervals chosen as a compromise between 
sensitivity and PPV. The thresholds are demonstrated in figure 30. The number detected, by 
patient, at the chosen thresholds (5, 6) can be seen in the appendix, table 84. 
 
The three data sources (trial data, clinical noting and routine data) were triangulated to 
compare the ability to identify the outcomes (figure 31). At both thresholds (≥5 and ≥6 










 Threshold ≥6: False negative outcome 



























data or by using routine data model (or both). False positives were identified; the trial 
data identified one outcome not present in the other data sources and the routine data 
identified four or five outcomes not present in the other sources (depending on the 
threshold). 
 
The trial documented 9/13 of the outcomes detected using the clinical noting 
(sensitivity: 0.69, PPV: 0.90). At both thresholds, the 4/13 (30.8%) events not 
documented by the trial were identified using the routine data model (figure 31) 












Figure 31: The number of progression outcomes identified by the data source at,  
(A) threshold ≥6 events and (B) threshold ≥5 events, corresponding to the data in table 56. 
 
The mean difference in detection (mean magnitude of the difference) between the 
routine data identified outcomes and the clinical noting was 4.5 weeks, at both 
thresholds (range; -4 to +14 weeks) (appendix, table 86). At both thresholds, the model 
identified 8/13 outcomes within the same 8-week interval, 2/13 within one interval (± 8 
weeks) and 2/13 within two intervals (± 16 weeks). The extra remaining outcome (1/13) 
identified by the ≥5 threshold (but not using the ≥6 threshold) was also detected within 
one interval (± 8 weeks) (appendix, table 85) (appendix, table 86). The analysis of the 
thirteen events can be seen in the appendix 8.2.5. 
 
20 SREs were identified during note review, independent of thresholds (figure 32); 
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SREs were identified using the routine data model (after inferral, by identifying further 













Figure 32: A Venn diagram showing the number of SREs identified in the trial data, the note 
review (clinical data) and the routine data.  
The results are shown when inferring missing routine data radiotherapy events with routine data 
identified clinical oncology outpatient visits. 
 
When splitting the patients into subgroups, by time (the earliest and latest patients 
randomised into the STAMPEDE trial), the sensitivity of detecting events increased from 
0.69 (detecting 9/13 SREs) to 1.00 (detecting 7/7 SREs) (table 57) (see appendix: 8.2.6). 
 
Data source Total number of SREs 
Number of SREs (3 
earliest patients) 
Number of SREs (3 
latest patients) 
Reference data 
Note review (reference) 20 13 7 
Trial data 10 7 3 
Routine data 
HES (without inferral) 8 4 4 
HES (with inferral) 16 9 7 
HES sensitivity (HES vs. note review) 
HES (without inferral) 0.40 0.31 0.57 
HES (with inferral) 0.80 0.69 1.00 
 
Table 57: Accuracy of the routine data and the trial data for identifying SREs, in comparison to the 
note review reference, split by date randomised. The number of SREs correspond to figure 32. 
Inferral = enabling clinical oncology outpatient events to flag radiotherapy regimens. 
 
At the end of the pilot study, the optimum rules to detect outcomes of interest were 





additional outcomes plus a threshold of five events. These were further tested during 
algorithm training. 
4.10.3 Algorithm training (cohort 2) 
Further sensitivity analyses (cohort 2, N=44) were undertaken to identify the optimum 
number of true positive progression outcomes, with the lowest number of false 
positives (prior to the first outcome (the AFS)). The 8-week clustering interval, with the 
threshold of ≥5 events was confirmed. In addition, a threshold of ≥4 events in an interval 
was required to be reached before a subsequent outcome could be triggered (or the 
peak would be classified as the same outcome). The inclusion of oncology outpatient 
events was also confirmed to enhance outcome detection and removal of the first 15% 
of events per patient was required to remove confounding trial randomisation activity.  
 
At an individual trial outcome level (assessing patient level surrogacy), these optimum 
rules identified the majority of the first two progression outcomes or classified that no 
outcome had occurred for 59/64 (92.2%) outcomes. In the 53 patients that progressed, 
42/53 (sensitivity: 0.79) of the first two progression outcomes were identified, with 
three false positives prior to the first. When restricting analyses to the first progression 
only (as the time to the first outcome was proposed to be used as the trial endpoint, the 
AFS), 34/44 (77%) were identified in any time interval (progressed or did not progress). 
However, upon restricting detection to within 16 weeks (≤2 intervals), fewer 
progressions were identified, 28/44 (63.6%). At an individual patient level, the algorithm 
correctly classified the majority of patient’s disease states as, 1) progressed (31/33, 
sensitivity: 0.93) or 2) did not progress (9/11, specificity: 0.82). The reasons for the 








Description Number  
False negatives 
Non-trial events were not coded (missed), for example, radiotherapy 1 
Hormone therapy was initiated/continued and was not in the HES 6 
The number of events did not reach the threshold to trigger an outcome 1 
Trial therapy was initiated and was not in the HES 2 
Delay >2 intervals 
There was a delay in starting treatment for progression 2 
Hormone therapy was initiated/continued prior to other treatment/scans 3 
The progression was identified clinically at a delay 1 
Trial therapy was initiated prior to other scans/treatments 2 
False positives 
Detected death from a non-prostate cancer cause (although constituting the trial MFS) 1 
Investigation for a suspected progression but progression was not confirmed 1 
 
Table 58: Reasons for the algorithm-missed/delayed outcomes.  
Sometimes an outcome was missed/delayed for more than one reason. 
 
When comparing the first routine data outcome to the documented STAMPEDE 
endpoints (MFS, PFS and FFS), a mixture of the traditional endpoints were being 
identified. Within any time-interval, the routine data algorithm identified 10/32 FFS 
(31.3%), 13/24 PFS (54.2%) and 15/25 MFS (60%) of the STAMPEDE outcomes, with a 
mean magnitude of the difference of two intervals (9.7 weeks) (range; -8 to +44 weeks). 
Restricting the acceptable delay in detection reduced the number of endpoints that 
were detected.  
 
In addition, four outcomes not documented by the trial, were identified by the HES 
model (confirmed via note review). Three of these outcomes were missed from the trial 
data erroneously. Of these, the HES model identified one outcome one week early and 
one outcome two weeks late (compared to the date of objective progression in the 
clinical noting). The third was identified 90 weeks late, once chemotherapy was 
initiated. The fourth outcome not documented by the trial was excluded from the 
subsequent analysis due to the censoring (the progression outcome occurred in the 
same week as the STAMPEDE censor) and hence was not yet documented in the trial 
data. Excluding these four events, 29 patients fulfilled at least one STAMPEDE endpoint 
and the routine data algorithm identified 21/29 (72.4%).  
 
The total number of outcomes detected using the HES algorithm (27 events) was most 
comparable to the number of STAMPEDE MFS (25 events) and PFS (24 events) outcomes 





were not comparable to the number detected in the STAMPEDE data (18 events) (table 
59). 
 
Data/Outcome Total outcomes detected 
Note review PFS 33 
STAMPEDE PFS 24 
STAMPEDE MFS 25 
STAMPEDE FFS 32 
HES AFS 27 
STAMPEDE SRE 18 
HES SRE 7 
 
Table 59: The number of outcomes identified during the note review (note review PFS), those 
documented in the trial (STAMPEDE PFS, MFS, FFS, SRE) and those identified using the HES 
algorithm (HES AFS, SRE), from randomisation, until the mutual censor date.  
See the appendix table 88 for the number of outcomes detected, split by treatment. 
 
Endpoint treatment effects were then investigated for trial level surrogacy. The routine 
data algorithm was capable of separating the docetaxel treatment benefits in line with 
the standard trial endpoints and the clinical reference data (table 60) (figure 33). The 
routine data hazard ratio was most similar to the trial PFS, with both hazard ratios at 
0.41 (HES AFS 0.41, 95% CI 0.16-1.02; STAMPEDE PFS 0.41, 95% CI 0.15-1.10) (table 60). 
An example from the time to event analyses can be seen in figure 33 (HES vs. the 
STAMPEDE MFS). The number of events that were identified for each endpoint, by the 
trial treatment, can be seen in the appendix (8.2.7). 
 
Data/Outcome Hazard ratio (95% CI) 
Note review PFS 0.51 (0.23 - 1.13) 
STAMPEDE PFS 0.41 (0.15 - 1.10) 
STAMPEDE MFS 0.46 (0.18 - 1.16) 
STAMPEDE FFS 0.47 (0.21 - 1.01) 
HES AFS 0.41 (0.16 - 1.02) 
SREs 
STAMPEDE SRE 0.72 (0.25 - 2.05) 
HES SRE 0.58 (0.11 - 3.00) 
 
Table 60: The hazard ratios and 95% CIs comparing the HES model output for the HES AFS and 
SREs, compared to the trial-derived endpoints (FFS, PFS, MFS and SRE) and the note review 





















Figure 33: Kaplan-Meier analyses for STAMPEDE chemotherapy (C, E) and non-chemotherapy (A, 
B, D, F) treatment arms, comparing the algorithm output with the STAMPEDE trial MFS.  
Numbers at risk are shown (including those remaining = not censored or no outcome of interest 
reached). 
 
The median survival time using the routine data algorithm (HES AFS) for the non-
chemotherapy arms was 108 weeks; this value was most comparable to the STAMPEDE 
MFS and PFS (92 and 89 weeks). The routine data algorithm (HES AFS) median was not 
reached for the chemotherapy arms. The STAMPEDE PFS did not reach the median 
either (table 61).  
 
The 2-year event free rate using the routine data algorithm (HES AFS), for non-
chemotherapy arms was 57%, most similar to the STAMPEDE PFS (49%). The 2-year 
event free rate for the chemotherapy arms using the HES AFS was 93%, most similar to 
the MFS (79%) and PFS (79%). In addition, the 5-year event-free rates for the HES AFS 
were most comparable to the STAMPEDE PFS and MFS (Table 61). 
 
MFS HR: 0.46 (95% CI: 0.18 – 1.16) 











group STAMPEDE_CE_MFS HES_CE STAMPEDE_ABDF_MFS HES_ABDF
29 25 24 16 13 12 11  9  6  5  4  4  4  4
15 14 13 12 12 12 10  7  6  6  4  3  3  1
29 26 25 21 17 12 11 10  6  5  5  4  4  4
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Data Endpoint 2y (104w) event-free rate (% remaining) 
5y (261w) event-free 
rate (% remaining) 
Median time to 
MFS (weeks) 
Non-chemotherapy arms (ABDF) 
HES AFS 57 30 108 
STAMPEDE 
PFS 49 30 89 
FFS 29 17 65 
MFS 45 32 92 
Chemotherapy arms (CE) 
HES AFS 93 55 NR 
STAMPEDE 
PFS 79 63 NR 
FFS 67 47 127 
MFS 79 59 321 
 
Table 61: The median (weeks) and 2-year and 5-year event free rate (%) comparing 
chemotherapy and non-chemotherapy arms using the STAMPEDE endpoints and the HES-derived 
endpoint. 
NR = not reached. 
4.10.4 Algorithm validation 
4.10.4.1 Small scale validation (N=46, N=93) 
At a patient surrogacy level, the routine data algorithm identified 14/33 (42.4%) FFS, 
23/29 (79.3%) PFS and 22/28 (78.6%) MFS endpoints. The routine data identified three 
events missed in STAMPEDE and identified one progression outcome that may not have 
been correct to document in the trial (a false positive routine data and trial-detected 
outcome). When removing these four patients from the analyses, 30/36 (83.3%) of one 
or more of the MFS, PFS or FFS endpoints were identified using the routine data model. 
Excluding false positive and negative STAMPEDE and HES-detected outcomes, there 
were 26 patients that experienced an outcome; of these, the mean delay in detection 
was 17.2 weeks. 
 
Upon analysis of the cumulative cohort (N=93), despite the least FFS outcomes being 
identified using the routine data model, the total number of first outcomes (AFS) 
detected by the HES algorithm (66 events) were most comparable to the number of 
STAMPEDE FFS outcomes (67 events) (table 62). The number of SREs detected using the 
HES data (15 events) were again not comparable to the number detected in the 






Data/Outcome Total outcomes detected  
STAMPEDE PFS 56 
STAMPEDE MFS 56 
STAMPEDE FFS 67 
HES AFS 66 
STAMPEDE SRE 34 
HES SRE 15 
 
Table 62: The number of outcomes documented in the trial (STAMPEDE PFS, MFS, FFS, SRE) and 
identified using the HES algorithm (HES AFS, SRE), from randomisation, until censor date.  
See the appendix table 89 for the number of outcomes detected, split by treatment. 
 
At a treatment surrogacy level, the routine data algorithm was again capable of 
separating the docetaxel treatment benefits in line with the traditional trial endpoints 
(figure 34) (table 63). The FFS hazard ratio, on this occasion, was the closest of the 
STAMPEDE endpoints to the HES-derived AFS endpoint (table 63). The number of events 
that were identified for each endpoint, by the trial treatment, can be seen in the 
appendix (8.2.7). 
 
Data/Outcome HR (95% CI) 
STAMPEDE PFS 0.36 (0.18 - 0.72) 
STAMPEDE MFS 0.47 (0.25 - 0.89) 
STAMPEDE MFS (+ interval grouping) 0.47 (0.25 - 0.89) 
STAMPEDE FFS 0.51 (0.29 - 0.89) 
HES AFS 0.59 (0.33 - 1.03) 
SREs 
STAMPEDE SRE 0.46 (0.20 - 1.05) 
HES SRE 0.64 (0.20 - 2.00) 
 
Table 63: The hazard ratios and 95% CIs comparing the HES model output for the HES-derived 
outcome and HES detected SREs, with the trial-derived endpoints (FFS, PFS, MFS and SREs). 
 
To assess the impact of the time interval grouping on the routine data-derived outcome 
hazard ratios, the STAMPEDE trial data MFS outcomes were allocated to the 
corresponding intervals, prior to recalculating the hazard ratios. This did not change the 
STAMPEDE MFS hazard ratio, suggesting that the grouping of routine data events did 









Figure 34: Kaplan-Meier analyses for STAMPEDE chemotherapy (C,E) and non-chemotherapy 
(A,B,D,F) treatments, comparing the routine data outputs with the (A) exact trial PFS and (B) with 
the trial MFS grouped into the corresponding time-intervals used in the algorithm.  














group STAMPEDE_CE_PFS HES_CE STAMPEDE_ABDF_PFS HES_ABDF
62 52 46 34 28 25 24
31 27 25 24 21 20 16
62 58 51 40 33 26 23
















group STAMPEDE_CE_MFS HES_CE STAMPEDE_ABDF_MFS HES_ABDF
62 53 47 35 30 27 26
31 27 25 24 22 21 16
62 58 51 40 33 26 23





MFS HR: 0.47 (95% CI: 0.25 – 0.89) 
HES HR: 0.59 (95% CI 0.33 – 1.03) 
MFS -chemo HES -chemo 
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PFS HR: 0.36 (95% CI: 0.18 – 0.72) 
































The median survival times using the routine data algorithm for non-chemotherapy and 
chemotherapy arms were 108 and 148 weeks respectively. For the non-chemotherapy 
arms, this was most comparable to the STAMPEDE MFS and PFS (MFS, PFS: 92 weeks; 
HES AFS: 108 weeks). For the chemotherapy arms, the HES-derived estimate was most 
similar to the STAMPEDE FFS (FFS: 169 weeks; HES AFS: 148 weeks) (table 64).  
 
The 2-year event free rate using the routine data algorithm (HES AFS), for non-
chemotherapy arms was 51%, most similar to the STAMPEDE MFS (45%). For the 
chemotherapy arms, the HES-derived estimate rate was 79%, equal to the STAMPEDE 
PFS (79%). In addition, the 5-year event-free rates can also be seen (table 64).  
 
Data Endpoint 2y (104w) event-free rate (% remaining) 
5y (261w) event-free 
rate (% remaining) 
Median time to 
MFS (weeks) 
Non-chemotherapy arms (ABDF) 
HES AFS 51 26 108 
STAMPEDE 
PFS 44 28 92 
FFS 32 21 62 
MFS 45 32 92 
Chemotherapy arms (CE) 
HES AFS 79 39 148 
STAMPEDE 
PFS 79 65 321 
FFS 68 39 169 
MFS 59 59 321 
 
Table 64: The median (weeks) and 2-year and 5-year survival (%) comparing chemotherapy and 
non-chemotherapy arms using the STAMPEDE endpoints and the HES-derived endpoint. 
4.10.4.2 Large-scale validation (N=1,695) 
The total number of progression outcomes detected using the HES algorithm (833 
events) was most comparable to the number of STAMPEDE MFS (748 events) and PFS 
(754 events) outcomes (table 65). STAMPEDE identified more SREs (411 events), 






Data/Outcome Total outcomes detected  
STAMPEDE PFS 754 
STAMPEDE MFS 748 
STAMPEDE FFS 1028 
HES AFS 833 
STAMPEDE SRE 411 
HES SRE 323 
 
Table 65: The number of endpoint events documented in the trial (PFS, MFS, FFS, SRE) and 
identified using the HES algorithm (AFS, SRE), from randomisation, until censor date.  
See the appendix table 90 for the number of outcomes detected, split by treatment. 
 
The HES-derived endpoint was capable of showing treatment benefits across the multi-
site cohort (N=1,645), with a hazard ratio closest to the STAMPEDE MFS (HES AFS HR: 
0.88, 95% CI 0.77 – 1.01; STAMPEDE MFS HR: 0.82, 95% CI 0.71-0.95) (figure 35, A). The 
HES detected SRE hazard ratio was also comparable to the STAMPEDE SRE hazard ratio 
(HES SRE HR: 0.68, 95% CI 0.55-0.85; STAMPEDE SRE HR: 0.61, 95% CI 0.50-0.74) (table 
66) (figure 35, B).  
 
Data/Outcome HR (95% CI) 
STAMPEDE PFS 0.74 (0.64 - 0.86) 
STAMPEDE MFS 0.82 (0.71 - 0.95) 
STAMPEDE FFS 0.67 (0.60 - 0.76) 
HES AFS 0.88 (0.77 – 1.01) 
STAMPEDE SRE 0.61 (0.50 – 0.74) 
HES SRE 0.68 (0.55 – 0.85) 
 
Table 66: The hazard ratios and 95% CIs comparing the HES model output for the routine data 
derived-outcomes and HES identified SREs, compared to the trial-derived endpoints (STAMPEDE 




















































Figure 35: Kaplan-Meier analyses (without censor lines) comparing docetaxel (+chemo) with the 
standard-of-care arm (-chemo). The HES AFS and SRE endpoint are compared to, A) the 
STAMPEDE MFS, B) the STAMPEDE SREs. The steps in the HES curves = the clustering intervals. 
 
MFS HR: 0.82 (95% CI: 0.71 - 0.95) 
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SRE HR: 0.61 (95% CI 0.50 – 0.74) 





The median (weeks) and 2-year and 5-year event free rate (% remaining) comparisons 
can be seen in table 67, as an example comparing the HES-derived and STAMPEDE MFS 
endpoints.  
 
Endpoint 2y (104w) event-free rate (% remaining) 
5y (261w) event-free 
rate (% remaining) 
Median time to 
MFS (weeks) 
Non-chemotherapy arms (A) 
HES AFS 64 37 172 
STAMPEDE MFS 67 45 224 
Chemotherapy arms (CE) 
HES AFS 67 38 188 
STAMPEDE MFS 76 49 250 
 
Table 67: The median (weeks) and 2-year and 5-year survival (%) comparing chemotherapy and 
non-chemotherapy arms using the STAMPEDE endpoints and the HES-derived endpoint. 
 
To further investigate the relationships between the endpoints, the strength of the 
correlation between the HES-derived endpoints (AFS and SREs) and the STAMPEDE-
derived endpoints were next compared (MFS, PFS, FFS and SREs). The correlation 
coefficients where both the HES and STAMPEDE endpoints identified an event can be 
seen in table 68. The coefficients between the HES-derived outcomes (AFS and SREs) 
and the STAMPEDE MFS, PFS and SREs showed high correlation (AFS vs. MFS = 0.74 (95% 
CI: 0.70 – 0.77); AFS vs. PFS = 0.73 (95% CI: 0.69 – 0.77); HES SREs vs. STAMPEDE SREs = 
0.81 (95% CI: 0.75 – 0.86)) (table 68). In contrast, the HES AFS showed low correlation to 
the STAMPEDE FFS (table 68). 
 
Data comparisons Number of outcomes identified by both HES & STAMPEDE 
Correlation 
coefficient (95% CI) 
HES AFS vs. STAMPEDE MFS 565 0.74 (0.70 - 0.77) 
HES AFS vs. STAMPEDE PFS 580 0.73 (0.69 - 0.77) 
HES AFS vs. STAMPEDE FFS 699 0.67 (0.63 - 0.71) 
SREs 
HES SREs vs. STAMPEDE SREs 178 0.81 (0.75 - 0.86) 
 
Table 68: The correlation coefficients calculated to compare the HES endpoints to the standard 
STAMPEDE trial endpoints. 
 
Correlation scatter plots comparing the HES-derived AFS outcomes and the STAMPEDE 
MFS and FFS (the highest and lowest correlation, respectively) can be seen in figure 36. 
The scatter plot comparing the HES and STAMPEDE SRE endpoints can be seen in the 


















Figure 36: A scatter plot showing the correlation between the HES endpoint and the STAMPEDE, 
A) MFS and B) FFS. 
Black line through the origin = a line illustrating 100% correlation. The vertical plotting of the lines 
is due to the 8-week clustering intervals on the x-axis.  
 
A Bland-Altman plot, comparing the HES AFS and the STAMPEDE MFS and PFS outcomes 
can be seen in figure 37. The mean difference between the HES AFS and STAMPEDE MFS 
was -13 weeks. Hence, the HES outcomes were identified a mean of 13 weeks prior to 
the trial MFS. For the trial PFS, the mean difference was -3 weeks; hence, the HES 







The limits of agreement were wide at -112 and 87 weeks (HES AFS vs. MFS); it was 
therefore identified that 95% of the HES-detected outcomes were expected to lie 112 
weeks before and 87 weeks after the STAMPEDE MFS (figure 37, A). These wide limits of 
agreement (199 weeks), may highlight the identification of a novel endpoint. When 
comparing the HES endpoint to the PFS, the limits of agreement were marginally 
narrower (187 weeks), at -97 and 90 weeks; 95% of the HES-detected outcomes were 
expected to lie 97 weeks before and 90 weeks after the MFS (figure 37, B). Again, 
potentially highlighting, that as with the MFS, a novel endpoint was being identified.  
 
Plot patterns for both the MFS and PFS comparisons suggest that outcomes occurring in 
the first 100 weeks, generally lay within two standard deviations of the mean (figure 37). 
However, as time increased, a larger number of events lay outside the limits of 
agreement, suggesting that the HES endpoint may be more comparable to the trial 
endpoints for earlier events (occurring within the first two years of randomisation into 








































Figure 37: Bland-Altman plots between the HES AFS and the STAMPEDE A) MFS and B) PFS. 
Blue line = the mean difference in detection of the HES and the STAMPEDE outcomes (weeks). Red 
lines = the limits of agreement, which are defined as the mean difference ± 1.96 times the 
standard deviation (SD) of the difference between the HES and the STAMPEDE outcomes. Grey 
points = single outcomes; black points = where greater than one outcome overlaps. 
 
For SRE detection, the mean difference between the HES detected endpoint and the 
STAMPEDE endpoint was 18 weeks. Hence, the HES events were identified a mean of 18 
weeks after the trial SREs. The limits of agreement were at -53 and 89 weeks.
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Figure 38: A sum
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There is an increasing consensus that the use of routine healthcare records can aid the 
growing challenges of trial conduct and improve the quality of trials. The hypotheses is 
that this alternative trial follow-up design may: increase recruitment (63); reduce costs 
enabling funds and resources to be redistributed elsewhere (63, 103); reduce patient 
and trial staff burden (103); and subsequently enable patients more expedient access to 
novel treatments (201). However, as discussed and shown, there are well known 
concerns of missing data or inadequate outcome fields to enable this (201). Despite this, 
it has been proposed that routine data could be used to validate objective cancer 
progression and investigate subsequent treatments, explore progression characteristics 
and explore alternate progression endpoints (202). Routine data offers opportunities to 
develop endpoints for oncology trials, but practically, I found little evidence of previous 
attempts to identify non-survival endpoints and no evidence using HES data linked to a 
RCT.  
 
Both administrative and registry data have the potential to identify outcomes (as 
discussed in the introduction, section 1.2.3). Registry data, despite often enabling 
collection of required outcomes of interest, often requires manual input for data 
collection. For example, during the completion of this PhD, the cancer outcomes and 
services dataset (COSD) has been developing its documentation of trial-related 
endpoints (such as, recurrence and progression); data were first collected in July 2015 
and a new specification for enhanced collection was released in April 2018. However, 
these data on outcomes are manually generated at multiple disciplinary meetings (MDT) 
and thus relies upon clinician input, leading to missing data and loss to follow-up. Hence, 
I proposed that routine mandatory administrative data could, although not providing a 
direct source of outcomes, indirectly identify these. Hence, routine administrative data 
were the data source of choice during this chapter. 
 
Standard trial non-survival endpoints (for example, FFS, MFS, PFS and SREs) present 
clinically different timepoints but still provide similar differences in intervention and 
function (to compare treatment efficacy) as surrogates for overall survival. However, 





proposed to be inadequate (203). This chapter set out to identify clinically useable non-
survival endpoints using routine administrative healthcare data.  
 
The three data sources (routine data, trial data and clinical noting data) each had their 
own limitations. For example, the clinical reference obtained during note review meant 
that events occurring outside of the hospital were often not accessible, early events 
were missing due to the transition from paper to electronic noting and wrongly 
recorded events may have been present due to incomplete or lost data (204). Hence, 
routine data events assumed to be false positives may indeed have been true positives. 
In the absence of the possibility to query back to the individual sites within this study, 
this was not possible to investigate. However, this study revealed initial evidence that 
events missed by the trial could be identified using routine data (for example, figure 31) 
and hence, it may suggest that routine data could be identifying further events that 
were missed in the clinical noting. Further to this, clinical note review was also 
extremely resource intensive and time consuming. This meant that a second reviewer 
could not audit my data collection process. This could mean that events thought to be 
true positives or negatives in the reference were not, impacting the algorithm accuracy 
statistics.  
 
The trial data also had limitations; the STAMPEDE trial is only required to collect the first 
instance of events, for example, progression on treatment, so analyses of subsequent 
events is not possible, this is a common feature of trials. In addition, as illustrated in 
chapter 3, new hypotheses arise that were not previously appreciated, for example, 
response to subsequent treatments, and it is thus not traditionally possible to 
retrospectively collect these outcomes to enable the analyses. Trial data are also 
commonly known to have problems with loss to follow-up, where outcomes are missed. 
Hence, desirable characteristics of a routine data model would be to reduce loss to 
follow-up and enable analyses of events not routinely collected in the trial. The two data 
sources used as a reference, the clinical noting and the trial data were hence, not a true 
gold standard, as there is no known truth (147), making validation challenging.  
 
As previously stated, assessment of the routine data within the other chapters (chapter 





availability of key outcome data fields (for example, progression). In addition, this study 
identified that some events are not required to be collected (not mandatory) in the 
administrative data due to the payment function of these data and thus cannot be 
analysed, for example X-rays. Again, this resulted in missing operational procedures and 
diagnostic codes (table 54).  
 
Erroneously coded data were identified; for example, when SREs were not being 
detected (figure 32), which was also highlighted in the varying hazard ratios compared 
to the STAMPEDE SRE measure. Despite these missing data, in the largest analyses, 
when the effect of docetaxel on skeletal related events (SRE) was compared to the 
standard-of-care, the benefit of the intervention was still maintained using the HES-
detected SRE measure (figure 35, B) (table 66). Although SRE events were shown to be 
missed from the routine data, events were identified that were not documented in the 
trial data, hence leading to the frameshifted but comparable hazard ratios seen (table 
66). HES SREs were identified a mean of 18 weeks after the trial documented date. SREs 
are well defined events; for example, if a patient has had radiotherapy to the bone. 
Hence, this delay is implying that the HES data were often missing the trial detected 
events but may be identifying downstream SREs not collected in the trial. This 
hypothesis is supported as HES and STAMPEDE identified a different number of SREs 
(323 and 411 respectively) (table 65); with only 178 instances where an event was 
identified in both datasets. Hence, it is possible that the estimated correlation is high, as 
we are excluding events that were only reported by one dataset or are not correctly 
matched. This is difficult to assess as there is no known ‘truth’. 
 
For all the prostate cancer-related interactions, 23% of events were missed in the 
routine data when compared to the reference datasets (clinical noting and trial data). 
However, these were patients randomised earlier in the STAMPEDE trial and the SRE 
accuracy was seen to increase over time (table 57), in the very small sample. This was to 
be further investigated in a larger sample in chapter 5. 
 
There is a continual drive for cleaner data to enhance reimbursement for the NHS (205) 
but cleaner data are also proposed to aid secondary analysis (206). In addition, it was 





descriptions. For example, radiotherapy sessions were often coded as clinical oncologist 
outpatient visits and scans were often coded as allied health professional visits, but the 
procedure was not documented. Hence, to detect as many events as possible, it was 
essential that these codes were also included in a model.  
 
As predicted, the inadequate availability of key outcome data, missing and excluded 
coding, meant that these data could not be directly used for endpoint analyses. This 
meant that a model had to be created, based upon a set of rules, to indirectly infer when 
trial outcomes of interest occurred.  
 
To account for these limitations, I developed a model using event clustering to flag 
absent outcomes from diagnosis and procedure patterns. This model was proposed to 
allow events to contribute, indirectly, even if they were coded using alternative 
descriptions. The model was designed to identify ‘clinically relevant outcomes’ that had 
been experienced. The aim was to identify the time to the first major clinical outcome. 
The hypothesis was, does an increase in HES activity correlate with clinically relevant 
outcomes? This significant increase in ‘disease-related activity’ was made up from 
various prostate-cancer related events; for example, an increased number of 
oncology/urology outpatient visits, diagnostic tests, treatments, admissions and SREs. 
Thresholds and clustering intervals were developed to identify the outcomes of interest. 
 
In order to develop a clinically useable surrogate endpoint tool for RCTs, criteria were 
used for validation (section 4.9.5) (195, 196). A surrogate needed to show a strong 
relationship between endpoints (patient level surrogacy) and also show endpoint 
treatment effects (trial/treatment level surrogacy). Therefore, as undertaken in the 
ICECaP studies, association to existing endpoints and treatment effects were assessed.  
 
In the early stages of training, where the clinical reference was available, the algorithm 
identified most reference-identified progressive outcomes, including some not 
documented in the trial (4.10.3). However, outcomes were also classed as erroneous if 
they were, 1) missed, or 2) incorrectly located either before (identified early) or after 
(delayed) the reference. The first type of these absent outcomes were typically due to 





However, outcomes were also missed if the observed number of events did not reach 
the threshold to detect events. Most local biochemical failures were missed due to 
absent routine data events. This was either due to clinical factors, resulting in an absent 
routine data footprint, or the limited routine data coding, both leading to activity below 
the threshold. For example, local prostate cancer management commonly involves the 
initiation of a surveillance programme or the addition or alteration of hormone therapy, 
neither of which are identifiable in the routine data.  
 
Subsequent outcomes were also masked (and hence missed) due to a sustained level of 
activity above the threshold for several intervals. Upon analysis of these periods, the 
algorithm was actually found to be detecting the same progression event, with no 
treatment response, and so identifying when the patient had entered a continual 
progressive state. I therefore restricted any analysis of subsequent outcomes to the first 
two progressions, as subsequent clinical advantage of identifying further outcomes was 
deemed inconsequential, during which events became less distinct.  
 
The second type of erroneous outcomes - those delayed or found early, occurred due to 
the algorithm clustering design (discussed below) and the clinical pathway for 
progression, reflecting the clinical difficulty in defining the events. Although, arbitrary 
dates are often assigned to outcomes because assigning the true date is often not 
possible (207). 
 
For maximum detection of these outcomes, 8-week time-intervals were chosen to 
cluster the interactions. This reduced noise from non-important outcomes whilst still 
detecting significant outcomes. Narrower time intervals resulted in uninterpretable data 
noise, in contrast to wider intervals which presented a clinically unusable output (table 
82). Consequently, an outcome could have occurred at any point during an 8-week 
period, resulting in a lower level of precision in comparison to standard trial data 
collection. However, when assessing the impact on the hazard ratios by grouping the 
STAMPEDE MFS into the intervals (figure 34, B), the results remained consistent, 
suggesting clustering the events had a smaller than expected clinical impact. However, 
due to this grouping, identifying true negatives at an individual outcome level was not 





to the sustained periods of activity and delays in detection. Therefore, specificity was 
not calculated at an individual outcome level.  
 
Additional algorithm rules were developed to enhance the detection of significant 
outcomes of interest, whilst reducing the noise from unrelated events. This involved: 
filtering out unrelated non-prostate cancer related interactions; prioritising events such 
as SREs due to the significance of these events on patient outcomes enabling the 
flagging of outcomes despite not reaching the threshold; including routine outpatient 
appointments (excluding them led to a reduction in the number of outcomes being 
identified); removing early confounding trial randomisation interactions and choosing 
the optimum threshold to detect an event. The optimum threshold that was identified, 
required the presence of greater than or equal five prostate cancer-related events to 
trigger an outcome, reducing to less than or equal four events, to enable the detection 
of a subsequent outcome. These rules were specific to prostate cancer and often unique 
to the STAMPEDE trial. However, these rules may be generalisable (or modifiable) in 
other oncology settings and trials.  
 
There are also temporal issues with the coding. The algorithm was designed to identify 
International Statistical Classification of Diseases (ICD) 10 codes and Office of Population 
Censuses and Surveys Classification of Interventions and Procedures (OPCS) 4.2 to 4.8 
codes. However, the coding schemes are continually updated, for example, ICD-11 and 
OPCS 4.9 are pending release. New classification releases can change how events are 
coded for. Hence, upon utilising algorithms such as those presented here, on novel data, 
additional codes will have to be included to capture all events of interest. This was a 
limitation during the development of the chapter 4 algorithm (proxy endpoint); all the 
relevant OPCS codes needed to be included to capture events across a wide patient 
timeframe but codes did change and subsequently could be used for alternative 
procedures. Hence, there was a potential for codes that were not relevant to have been 
included. This will remain a limitation where coding structures are continually updated. 
This may have implications on the algorithm threshold to detect events. If more prostate 
cancer-related interactions are being identified, the threshold may need to be raised, to 







Another limitation of the study included the small cohort used to develop (6 patients) 
and train (44 patients, 41 novel) the algorithm (table 46). An overall STAMPEDE cohort 
of less than one hundred patients was available from the single-site QEH UHB that were 
linked to routine data. Hence, small subsets were only available to develop, train and 
then validate on this single-site cohort, prior to the validation at a multi-site level. 
Different trusts will code differently which has implications on the routine data. It is 
therefore possible that the algorithm performs differently at other sites. The differences 
in performance are assumed to be minimal due to the comparable hazard ratio analyses 
during the multi-site study (discussed below) but this cannot be confirmed in the 
absence of multi-site note review. 
 
We have shown that our routine data algorithm was able to show a strong relationship 
between endpoints (patient level surrogacy) and endpoint treatment effects (trial level 
surrogacy). I found that the algorithm was not directly detecting a single standard trial 
surrogate; however, the model was detecting a combination of the standard surrogates 
(for example, 4.10.4.1) and the hazard ratios were comparable to those identified using 
the trial data (table 63).   
 
As mentioned above, some trial endpoints are more clinically driven than others; for 
example, the FFS, is often clinically arbitrary, compared to the PFS. The HES endpoint 
was proposed to be a more clinically driven endpoint, due to identifying hospital 
interactions. Thus, it was hypothesised that the HES endpoint would identify outcomes 
more similar to the MFS and PFS. This was confirmed, the algorithm was able to identify 
more of the MFS and PFS endpoints, than the FFS (section 4.10.4.1). This was due to the 
difficulty in identifying biochemical failure, often triggering the FFS endpoint. A prostate 
specific antigen (PSA) rise often precedes other endpoints and is therefore a more 
expeditious surrogate (FFS), (151) but patients can experience an FFS event but not die 
from prostate cancer (9) and often these events are not clinically significant. A rise in 
PSA may lead to surveillance or hormone therapy change, in contrast to clinically 
significant events, including those that constitute the PFS, where the patient is often 
experiencing clinical progression. Although outcomes most similar to the clinically driven 





and hence a novel outcome was proposed. It would be valuable to test the algorithm in 
another oncology setting that does not involve biochemical PSA failure, for example, 
breast cancer. To my knowledge there is currently no systematic way to extract UK 
multi-site patient laboratory results to aid the identification of FFS events. This is in 
contrast to Denmark, where it is possible to extract multi-site (for Northern and Central 
Denmark) PSA readings, hence enabling the analyses of this (173, 208). The number of 
STAMPEDE endpoints met could only be identified in the patients that had their clinical 
noting reviewed, hence the number identified were not calculated for the final large-
scale validation. 
 
My routine data surrogate was detecting the first significant increase in disease-related 
‘activity’, thus allowing time to ‘clinically relevant outcome’ to be calculated in endpoint 
analysis – the ‘activity-free survival’ (AFS). This is the first most intensive period of 
healthcare service interaction, which I proposed to reflect the disease state of the 
patient. These periods are often treatment intensive and time consuming and therefore, 
lengthening the time to this outcome, has clear implications to patient quality of life; 
this correlation with quality of life is proposed to be investigated. Quality of life has been 
proposed to be one of the most important measures for patients with cancer (152). 
However, although quality of life audits for patient cohorts with cancer have been 
undertaken and these data are available through routine data providers (209, 210), this 
is not currently the standard; although there is currently a drive for routine NHS quality 
of life data collection. Hence, although these measures are not directly available in these 
data, an endpoint such as the AFS may provide a proxy measure for quality of life. 
 
The correlation coefficient of the HES-derived endpoint compared to the STAMPEDE 
MFS and PFS (table 68), for the largest multi-site analyses, highlighted that a novel 
endpoint was being identified that was different to standard trial endpoints. However, 
there was still a strong correlation between the HES and the STAMPEDE MFS and PFS 
endpoint (table 68) (199, 200). In the correlation plots (figure 36), it can be seen that 
when compared to the standard endpoints, the HES-identified outcomes were often 
being found early or delayed (confirming what was identified in the early analyses). For 
example, more frequently, the HES endpoint was identified prior to the MFS (early). This 





assessment, rather than the interventions post-progression. The correlation plot 
comparing the HES-detected outcomes and the trial FFS (figure 36, B), illustrated the 
difficulty in identifying FFS events, that was discussed above. The majority of the 
outcomes lay below the line of perfect correlation. Hence, HES often identified the 
outcomes later than the FFS, potentially highlighting that the early FFS outcomes were 
being missed and a later event was being identified.  
 
The Bland-Altman analyses (figure 36) were undertaken because measures can be 
correlated but it does not mean they agree. The limits of agreement for the endpoints 
were very wide, highlighting the difference between the novel HES AFS endpoint and the 
standard endpoints. However, as previously highlighted no true gold standard is 
available to validate the events. However, Bland and Altman stated that how far apart 
measurements can be without causing difficulties is a question of judgement (211). 
Thus, although a different measure may be being identified, the utility of this novel 
measure remains in question until further validation has been undertaken in the trial 
setting.  
 
It was not clear if a clinical pattern was being identified with the plotted outlier events, 
due to being outcomes that could not be validated by note review. However, the plot 
suggested that the HES endpoint was more comparable to the standard endpoints (MFS, 
PFS) for earlier outcomes (occurring within the first year of randomisation into the trial), 
than the later ones (figure 36). One suggestion for this could be, if a patient experiences 
a trial event early (near randomisation), during more frequent trial follow-up visits (for 
example, every six weeks), these visits may increase the total hospital interaction 
number above the algorithm threshold and enable earlier event detection.  
 
Trial surrogacy was investigated; as more clinically driven endpoints are reached, such 
as the PFS, the effect size shown when comparing treatments often reduces. Hence, as 
the HES endpoint was proposed to be more clinically driven due to identifying hospital 
interactions, it was hypothesised that the treatment effects would be more similar to 
MFS and PFS, rather than the FFS. This is what was seen in the largest multi-site 
validation (table 66), with the HES-derived hazard ratio splitting docetaxel treatment 





STAMPEDE MFS and the algorithm was capable of identifying treatment benefits, in line 
with standard endpoints. In the early stages, the confidence intervals for the hazard 
ratios were wide due to small patient numbers. However, upon the large-scale multi-site 
validation the confidence intervals became narrower, although the HES AFS comparing 
treatments did cross one (table 66). 
 
Despite the efforts to create a validated endpoint with consideration to the ICECaP 
criteria, this study was only able to assess proof of concept and prior to consideration 
for acceptance as a validated endpoint within trials, much further work is required. For 
example, it would be necessary to perform further statistical tests of surrogacy and to 
compare the AFS to the OS for the same cohort of patients (151). This routine data 
model could also be used to compare trial to non-trial patients to test ‘real-world’ 
intervention effects and assess whether a trial result has been truly implemented in 
practice. However, the algorithm would also need validating within this different 
population. 
 
Another thing to consider is when the results from this algorithm would be 
communicated to patients; this depends upon the use of the algorithm. If the algorithm 
was being used to capture additional events, validate standard trial collected events or 
be used to conduct survival analyses, then I would envisage any results to be 
communicated at the same time as the dissemination of the trial results. However, the 
algorithm could be utilised for other purposes, for example, detecting if a patient has 
entered a palliative care stage. I envisage the method of communicating this to the 
patient would be directly at the point of detecting the event (dependent on the 
timeliness of the routine data), as the aim would be to enhance their care. 
 
Finally, to tie the results of this study into the current available literature, this study was 
assessed for weakness and bias using the developed systematic review criteria. All 
criteria were fulfilled (see table 81 in the appendix); however, it was not appropriate to 
assess the accuracy of the endpoint, compared to standard endpoints, due to the 
identification of a novel routine data outcome, the AFS. Although I developed the 
criteria, these were created to appraise the literature, prior to conducting this study, 






Further work is currently being undertaken to further validate the algorithm within 
different settings; for example, testing the surrogate within another drug setting 
(hormone therapy). Further projects are also being set up to develop the algorithm, 
including, for outcomes not routinely collected in a trial, for example, to assess time to 
subsequent treatment outcomes. Validation has also been discussed in a low-risk 
prostate cancer setting, an alternative prostate cancer RCT and within other oncology 
settings. Breast cancer would be an exciting validation, due to the disease similarities 
with prostate cancer (212) and radical treatment options, which are identifiable routine 
data healthcare interactions, as presented here. Projects are underway at the MRC CTU 





4.12 Conclusion  
In conclusion, routine data were again identified as having potential to improve 
standard clinical trial frameworks. The main aim of enhancing trial design is for patient 
benefit. Hence, prior to contrary belief, if routine data are used with caution, they may 
be a rich source of trial outcomes and may provide an alternative overall survival 
surrogate endpoint, for prostate cancer trials. 
 
These two chapters have illustrated the retrospective feasibility of using routine data for 
trial follow-up, to identify outcomes, 1) that were directly identifiable within the routine 
data, and 2) that were not directly identifiable within the routine data. The next chapter 
describes a study undertaken to assess the feasibility of using routine data to 
prospectively acquire data for trial follow-up, with consideration to the evidence 






5 CHAPTER FIVE: Direct RCT data collection (prospective follow-up model) 
5.1 Disclosure 
Work from this thesis chapter was submitted to the Pilot and Feasibility journal and is 
pending peer review. Work from this chapter was also presented at the Trials using 
Cohorts and Routine Health Data: International symposium on their Efficiency and 




This chapter documents the development of a novel data collection technique for trial 
follow-up, based upon routine National Health Service (NHS) data. Traditionally, 
oncology trial patient follow-up can involve patient-health care professional contact, 
where trial data are collected on case report forms (CRF). A novel methodology was to 
be developed, if deemed feasible, using data from routine administrative sources, that 
could provide a robust system feasible for use in a trial. To develop this, a case study 
was set up in the BladderPath trial. BladderPath is a bladder cancer randomised 
controlled trial (RCT) evaluating an alternative pathway for diagnosis and treatment, 
aiming to improve outcomes. This chapter reports the development and validation of a 
method enabling routine data use in a recruiting trial. 
5.2.2 Methods 
Using routine data, an algorithm was developed to identify the delay from diagnosis to 
treatment (number of days, time to correct treatment (TTCT)), for muscle invasive 
bladder cancer (MIBC) patients treated at the single site University Hospitals 
Birmingham Queen Elizabeth Hospital (UHB QEH). The routine data were also validated 
by extracting events of interest algorithmically and comparing the events to reference 
datasets, for example, clinical noting, to determine detection sensitivity. Subsequently, 






There was greater than a 3x increase in the number of days for the TTCT (68-day 
increase) for MIBC patients when compared to the NHS target diagnoses to treatment 
time target of 31 days. Overall, a total of 829/1042 events were detected using the 
hospital routine data. There was an increase in data quality from 2011 (41/117, 35%) to 
2017 (104/109, 95%). Varying sensitivities were identified for events. A method was 
developed to utilise routine data using additional datasets, a querying framework and 
further rules. 
5.2.4 Conclusion 
The time from diagnosis to treatment for MIBC patients was increased compared to the 
NHS target, which is in line with published literature. BladderPath hypothesises that this 
may highlight why outcomes for MIBC are poor. The restrictive nature of the coding to 
identify confirmed MIBC cases, meant that events were missed. However, using routine 
data was shown to be a feasible method for trial follow-up. It was identified that very 
high sensitivities can be achieved with targeted data queries to further enhance these 
data. Routine data currently is not of high enough quality to solely perform follow-up 
without a querying framework in place. However, I believe routine data to offer a robust 







5.3.1 Direct clinical trial analysis 
The previous chapter (chapter 4) explored the concepts surrounding the use of routine 
data to perform retrospective analysis of outcomes not collected using standard clinical 
trial data collection techniques. The chapter found that missing, erroneous and lack of 
detail in these data were limitations to performing such analysis. Despite this, it was 
highlighted that routine data are a powerful resource for analysis for outcomes not 
collected within a clinical trial, but due to the limitations it was found that ‘raw’ 
(unprocessed) routine data may not be ready as a source of clinical trial data alone.  
 
Standard clinical trial activities, such as data collection and follow-up, have been 
approached via face-to-face techniques (213) with patients and health care 
professionals. Trial data can be collected manually on case report forms (CRF) during 
patient follow-up visits (214) but substantial time is often required for this (215). Thus, 
moving to using a routine data framework would be a radical departure from usual 
methods.  
 
This chapter outlines the feasibility for the design and implementation of a novel clinical 
trial methodology using routine data for patient follow-up. If the methodology was 
deemed feasible to provide a robust system for a trial, the next aim was to implement a 
clinically useable method for an RCT, with BladderPath as the example. BladderPath is 
funded by NIHR HTA (National Institute for Health Research, Health Technology 
Assessment) (see introduction, 1.5.2). The overall aim of BladderPath is to conduct an 
RCT achieving broad patient recruitment with the least clinical, cost and resource 
disruptions.  
 
As mentioned in the introduction, the TTCT for all patients (both non-muscle invasive 
bladder cancer (NMIBC) and MIBC) are collected as a primary outcome for the 
BladderPath trial (see introduction 1.5.4) (73). This is to compare the standard 
treatment pathways with the split enhanced pathway. Overall survival and recurrence 
are also to be collected in the final clinical stage, to assess if a reduced time to correct 





5.3.2 Chapter rationale 
Using the BladderPath trial as an example, in this chapter, I report the development and 








5.4.1 The dawn of routine data in UK RCTs 
The idea of using routine data to enhance RCTs is not new. In 2000, Lewsey (11) 
published a report performing studies to explore how routinely collected data could be 
used to ‘complement or supplement RCTs’ (11). Scottish morbidity records were 
analysed for hospital episodes and death (1981 to 1995) but these data were not linked 
to an RCT. The aim of the individual studies were to answer questions that would not be 
appropriate to perform using standard RCT designs (as in the chapter 3 study). For 
example, the procedure would be considered unethical through randomisation, or the 
sample size would not have been large enough through traditionally recruited studies 
(11).  
 
The study supported the conclusion that ‘routinely assembled NHS data might have 
value as a complement or alternative to RCTs in certain circumstances’ (11). However, 
the authors noted limitations to conducting such studies, concluding, ‘studies based on 
routine data fall short of the rigour that one expects in RCT designs when comparability 
between the different arms of a trial is fundamental to the assessments that are made’ 
(11). At this time, the scope of routine data was identified but the quality made it not 
feasible to consider using these data in an RCT.  
 
In 2003, Williams reported that ‘routinely captured clinical data have real potential to 
measure patient outcomes, particularly if the detail and precision of the[se] data could 
be improved’ (216). But it was not until 2005, that the Health Technology Assessment 
(HTA) then recognised that there was a vicious circle, ‘as the[se] data are poor, they 
cannot be used; lack of use ensures they remain limited and of poor quality’ (217). 
Hence, the HTA provided proposals to enhance data quality with the aim to make these 
data a useable resource for RCTs (217).  
5.4.2 Validating UK RCT routine data 
Since 2005, many studies have linked routine data to RCT data, however, not for trial 
conduct but for validation purposes (46, 103, 105). For example, Wright-Hughes 





harm outcomes for trials (105). This was a validation study as data were first collected 
via standard researcher visits to site. They concluded that ‘further targeted data 
collection through researcher site visits’ was required for supplementary information 
(105). Kilburn (103) explored the use of routine data by linking trial data from an 
oncology trial (TACT) to routine data, however, did not use routine data for follow-up. 
The four breast cancer trials under investigation within this study are, TACT2, POETIC, 
IMPORT HIGH and FAST FORWARD, which are completed trials; analysis is also being 
undertaken into identifying endpoints in the routine data (218). Powell also validated 
the use of routine data in an epilepsy RCT setting (219). 
 
Routine data have also been used frequently for epidemiological outcome generation. 
For example, in prostate cancer, the trial PHONIC, used routine data to determine rates 
of osteoporotic fracture, but routine data were not used for patient follow-up (102). The 
Cluster Randomized Trial of PSA Testing for Prostate Cancer (CaP) team also performed 
retrospective linkage for a health economics study (220).  
 
All of these studies performed retrospective analysis of routine data linked to trials. The 
aims were either to identify an outcome, or for validation purposes: no study used 
routine data to provide an alternative method of RCT data collection. However, there 
has been an increase in the number of RCTs using routine data to supplement or replace 
traditional trial data collection and is discussed below (5.4.3). 
5.4.3 Routine data supplementing follow-up in UK RCTs 
Trials have been using routine data to supplement standard outcomes collection. For 
example, mortality records are commonly accessed to supplement trial data collection 
(156). The Knee Arthroplasty Trial (KAT) (221) used routine English HES data in addition 
to the Scottish equivalent (ISD) to supplement the trial data (221). Admissions and other 
surgical events were identified in the routine data, upon which, the clinical noting was 
queried (221). Trials have also used routine data for long-term follow-up of outcomes. 
The REACT (Randomised Evaluations of Accepted Choices in Treatment) trials were 
developed to use General Practice Research Database (GPRD) primary care data (2010). 
Patients were monitored as usual in clinical practice, then the general practice (GP) 





for side effect monitoring. The trial database was then compared to the GPRD database 
and the routine data used for long-term follow-up (222). The two REACT trials detailed 
were Retropro (a cardiovascular study, ISRCTN33113202) and eLung (a chronic 
obstructive pulmonary disease study, ISRCTN72035428) (222-224). 
 
In an oncology setting; Bhattacharya is investigating the use of routine data to 
supplement the recruiting breast cancer study: PRIMETIME (218). They aim to download 
NCRAS routine data at six-monthly intervals for follow-up. However, PRIMETIME also 
uses traditional patient follow-up for ten years, so is not using routine data exclusively 
(218, 225). Fitzpatrick (35) also investigated the use of routine data for long-term RCT 
follow-up. Fitzpatrick found 113 trials worldwide had been extended by record linkage, 
including 25 in the UK, concluding that routine data linkage is an underused approach 
which may add insight compared to traditional data collection methods (35). 
5.4.4 Routine data as the basis for follow-up in UK RCTs 
Two cluster primary care RCTs were designed to utilise routine data for follow-up, one 
for antibiotic prescribing for acute infection (226) and the other looking at prevention 
after first stroke (227). It was identified that both RCTs could be performed efficiently 
using electronic healthcare records (CPRD) and were identified as being among the first 
cluster RCTs to be ‘performed exclusively’ using electronic health records. The electronic 
health records were populated from the information recorded by the clinician during the 
visits (228). No secondary care RCTs or oncology RCTs were identified to use routine 
data as the basis of data collection. 
 
In summary, the scope for routine data use in RCTs has been recognised for two decades 
(11), however, until recently RCTs only used these data for validation (103) or outcome 
generation (102). More recently, routine data have been used to supplement RCT data 
collection (221). However, no secondary care RCTs have been identified to use routine 
data sources as the basis for patient follow-up, including none identified in oncology. A 
method was therefore to be designed, if feasible, to utilise routine data as the method 





5.5 Materials and methods 
5.5.1 Summary methods 
5.5.1.1 Approvals 
All data were sought with relevant ethical and regulatory processes in place (section 
2.4). Both the time to correct treatment analysis and the data validation were registered 
as audits at UHB QEH. Routine Hospital Interactions Data (HID) (a HES data equivalent) 
were provided by the informatics department at UHB QEH. The audits conducted for this 
validation study are also referenced in the BladderPath trial protocol (see section 2.4 for 
further details) (73).  
5.5.1.2 Summary participants 
Two different analyses were undertaken, time to correct treatment (TTCT) and data 
quality analyses. All participants included were patients that underwent cystectomy 
surgery (bladder removal) to the bladder (not exclusively for bladder cancer) or bladder 
radiotherapy (radical or palliative) at UHB QEH. This included 206 patients that had 
bladder cystectomy surgery (not exclusively for bladder cancer) between 08/01/10 – 
07/04/17 identified in the manual surgical reference group and 525 patients identified 
from a radiotherapy reference (radical and palliative), that were treated between 
01/01/11 – 11/06/18. The surgical reference was designed to collect the desired cohort 
and therefore did not require further cohort extraction. However, the radiotherapy 
cohort were extracted by using the ICD (32) bladder cancer code C67X.  
 
The data quality validation cohort was not restricted by bladder cancer and as such, the 
whole cohort of unique patients were eligible for analyses. In contrast, the patient 
analysis profile for the TTCT can be seen in figure 39, where a diagnosis of MIBC was 
required.  
 
The programming language SQL was used to extract the patient characteristic 
information from the hospital interactions/informatics routine data (note that these 
data were extracted by A. Dosanjh, in table 72, for the data quality analysis cohorts 





Comorbidity Index scores (‘Charlson scores’) (143). The Charlson scores were calculated 
if the patient had experienced an inpatient procedure. The score was calculated at the 
time of the surgery to the bladder or if the patient had not had surgery, the nearest 
inpatient admission to the start date of the radiotherapy was identified. In addition, the 
median, Interquartile range (IQR) and range was identified for age. For the data quality 
analyses, age was chosen as, the age at first treatment identified in the routine data and 
in the TTCT analysis, the age was identified as the age at flexible cystoscopy (a proxy for 
diagnosis) identified in the routine data. I calculated the patient characteristics for the 
TTCT analyses manually from the clinical noting and therefore Charlson scores were not 
identifiable (table 72). 
5.5.1.3 Data sources 
The data source used in both analyses were the local routine HID. As these data are 
returned centrally to National Health Service Digital (NHSD) to form the HES, they were 
assumed to be an equivalent to the HES data (2). No data linkage was required as 
linkage to a clinical trial number was not necessary. Comparison to reference data sets 
was possible via unique hospital identifiers.  
5.5.2 Joint methods 
The algorithms to extract events of interest from the routine HID were written and run 
in R (109) using RStudio (110) for both the TTCT analyses and the data quality validation 
(code available on request).  
5.5.3 Time to correct treatment (TTCT) analysis 
5.5.3.1 Participants 





















Figure 39: The study profile for the cohorts utilised in the TTCT analyses.  
* = 17 patients were excluded when the routine data-identified diagnosis dates (flexible 
cystoscopy) were queried with the clinical noting; these patients were suspected to not have 
bladder cancer. The 17 exclusions included: The upfront diagnosis was missed (N=9); flexible 
cystoscopy was used for a previous renal condition (N=4); incorrect routine data (N=2) or bladder 
cancer was not yet formally diagnosed (N=2). ** = The final cohort consisted of 35 patients being 
given radiotherapy and 22 surgery for MIBC (patients without bladder cancer were excluded using 
the algorithm and note review). ^ = Also identified upon note review. 
5.5.3.2 Analytical methods 
The algorithm was developed to apply proxy rules to the routine HID to extract patients 
with suspected de novo (newly diagnosed) MIBC following the standard pathway. The 
time to the following events (in days) was calculated for: 
 
1) Diagnosis (flexible cystoscopy) to transurethral resection of bladder 
tumour (TURBT) (defined by the NHS as the first definitive treatment for 
bladder cancer) (see introduction figure 4; time X),  
2) TURBT to correct treatment (see introduction figure 4; Y) and  
N = 647 excluded (not identified as 
MIBC patients using the algorithm) 
N = 5 excluded (duplicates) 
N = 17 excluded (not bladder cancer*) 
N = 731 (total patients) 
N = 84 (algorithm identified MIBC patients) 
N = 79 (unique patients) 
N = 62 (patients with confirmed bladder cancer) 
N = 57 (confirmed MIBC: 35 radiotherapy, 22 surgery)** 





3) Overall time from diagnosis to treatment (see introduction figure 4; 
X+Y).  
 
The codes to identify events from the routine data can be seen in section 8.3.1 
(appendix, table 91). These time to event values were calculated using R, and the mean, 
minimum and maximum values calculated using Excel. The difference in the time to the 
correct treatment of surgery and radiotherapy were also compared. 
 
For each patient, each of the routine data identified flexible cystoscopies were 
confirmed via note review to confirm a bladder cancer diagnosis. If the flexible 
cystoscopy was not performed to identify de novo bladder cancer, the patient was 
excluded from the analysis. A random sample of 10 patients’ pathways (30 events, 10 
flexible cystoscopies, 10 TURBTs, 10 subsequent treatments) were confirmed against the 
clinical noting to confirm the accuracy of the routine data in detecting individual events. 
All patients were assessed in the clinical noting for MIBC diagnosis to calculate 
sensitivity and positive predictive value (PPV) accuracy of MIBC detection using the 





1 Extract the first flexible cystoscopy event for each patient 
2 Extract the first TURBT event for each patient 
3 Keep only the events where patients have 1) both a flexible cystoscopy and a 
TURBT event, 2) the flexible cystoscopy must come before the TURBT 
4 Extract the first definitive treatment event (radiotherapy, surgery, 
chemotherapy) per patient 
5 Keep only the events where patients have had 1) a flexible cystoscopy, a TURBT 
event and definitive treatment, 2) the flexible cystoscopy must come before 
the TURBT which both must come before the definitive treatment 
6 Time to event calculations: Time to the TURBT minus flexible cystoscopy, 
definitive treatment minus TURBT, definitive treatment minus flexible 
cystoscopy 
 
Table 69: The algorithm process to extract suspected MIBC patients to enable time to definitive 
treatment calculation.  
5.5.4 Data quality assessment 
5.5.4.1 Data sources 






1) Radiotherapy data: Consisting of radiotherapy machine prescription data.  
 
2) Manually collected surgical data: Used to identify the surgical cohort. This is a 
dataset maintained by the surgical team to collect manual data on all surgical 
patients (for example, from data extracted from the clinical noting). In addition, 
the manually collected data were enhanced with data from the national British 
Association of Urological Surgeons (BAUS) dataset (229, 230).  
 
3) The routine HID (HES-equivalent) with inpatient and outpatient interactions 
(206). These data were extracted by the informatics team at UHB QEH using the 
NHS number and the hospital number which were both identified in the 
reference cohorts. In order to capture events prior to the manually documented 
date of cystectomy, the routine HID for the cystectomy cohort were extracted 
one year before the documented reference date of surgery. These data were 
censored at 31/03/18. To extract the routine HID for the radiotherapy cohort, 
data were extracted from the first radiotherapy event that was documented in 
the radiotherapy reference which was the 01/01/11. These data were censored 
at 31/05/18.  
 
4) UHB QEH clinical note review data, for example, correspondence and clinical 
noting. 
 
Reference data were assumed to be the ‘gold standard’ to compare to the routine data 
to enable accuracy of detection to be calculated. Reference data consisted of three 
sources: 1) the manually collected surgical data, containing procedure and date, used to 
validate the surgical routine HID events, 2) the radiotherapy administrative data, used to 
validate the radiotherapy routine HID events, 3) the note review extracted data from the 
clinical portal, used to validate the following routine HID events: Chemotherapy, Bacillus 
Calmette-Guérin (BCG), cystoscopy, and censor (date of last known clinical visit – a 






Test data were the routine data that were being validated for accuracy against the 




Reference  Test  
Radiotherapy administrative data ü û 
Surgical data (manually collected) ü û 
Routine HID (inpatient and outpatient interactions) û ü 
Clinical note review data ü û 
BAUS national dataset (surgical data enhancer) ü û 
 
Table 70: The data sources utilised for the validation study. 
5.5.4.2 Participants and events of interest 
For the data quality assessment, a total of 707 patients had at least one event of interest 
validated across the surgical and radiotherapy cohorts. For surgical event accuracy, the 
whole cohort of 206 patients was used, and random subsets of events that were 
identified in the routine HID were used to check other events. The number of events by 
participants that were validated can be seen in table 71. In addition, the whole 






Number of regimens 
validated 
Number of individual 
events (procedure or 
administrations) 
validated 
Surgery to bladder 206 NA 206 
Chemotherapy 40 47 - 
Cystoscopy 29 NA 106 
BCG 30 15 114 
Censor date 100 NA 100 
Radiotherapy 525 568 7894* 
 
Table 71: The number of patients, number of regimens and number of individual events 
(administrations, radiotherapy fractions), validated by event type. 
Patients were able to have multiple regimens and each regimen could include multiple 
administrations (for example, BCG and radiotherapy but individual administrations were not 
assessed for chemotherapy); * = the number of radiotherapy fractions in the 568 regimens; NA = 
not appropriate; ‘-‘ = not calculated. 
5.5.4.3 Processing and outcome measures 
To identify the events of interest from the routine data (seen in table 71), the algorithm 





Surveys Classification of Interventions and Procedures (OPCS) codes version 4.4 – 4.8) 
(33). In addition, the censor date was extracted from the NHSD main speciality 
(MAINSPEF) coding in the informatics data (231) (see appendix 8.3.2 for the codes that 
were extracted, appendix table 92). The events of interest were:  
 
• Surgery to the bladder to remove the tumour: Including cystectomy, 
cystoprostatectomy and exenteration procedures. 
• Radiotherapy - Including radical (for curative effect) and palliative (for pain 
relief) regimens. 
• Cystoscopy: Including all types of cystoscopy, including but not limited to flexible 
procedures (cystoscopy or urethroscopy) or rigid TURBT (therefore events could 
be both before or after cystectomy). 
• BCG immunotherapy therapy. 
• Chemotherapy: Including treatment for any cancer, as it is not possible to 
identify what the chemotherapy was administered for in the outpatient routine 
HID. 
• The last known interaction that the patient had, either with urology or oncology 
departments. These events were identified as inpatient or outpatient events. 
5.5.4.4 Analytical methods 
The events that were identified using the algorithm were manually compared, by date, 
to the reference events to calculate the PPV and sensitivity. Events were also grouped 
by year to assess if the sensitivity changed over time. Assessments were undertaken 
where, 1) the event was required to be detected on the exact reference date, 2) the 
event was not required to be identified on the exact date. The exact diagnostic code was 
not required to detect the events, but the correct type of code was required. For 
example, if the wrong banding of chemotherapy was identified in the routine data, the 
chemotherapy event was still classified as being identified. This was due to the 
restrictive nature of the coding identified in chapter 3 and 4.  
 
For outpatient events, for example, flexible cystoscopy, the date of appointment was 
validated against the reference data. Operation dates were validated for inpatient 





chemotherapy events, only one event per regimen was therefore required to be present 
in the routine data to correctly identify that the regimen had been administered. 
5.5.4.5 Follow-up design outcomes 
Using the results from the studies, if deemed feasible, a framework was to be designed 








The patient characteristics for all cohorts analysed in this chapter can be seen below in 
table 72.  
 
  TTCT analysis Data quality analysis cohorts 
All cohort All radiotherapy Surgical 
N=57 N=525 N=206 
Number of patients (%) 
Age at 1st 
treatment 
Median (IQR) 72 (64-79) 75 (68-94)  66.5 (56-73) 
Range 50-94 31-96 22-85 
Gender 
Male  36 (63%) 380 (72%) 147 (71%) 
Female  21 (37%) 144 (27%) 59 (29%) 
Ethnicity 
White 47 (83%) 401 (76%) 191 (93%) 
Asian/Asian British 2 (4%) 18 (3%) 9 (4%) 
Black/Black British 2 (4%) 5 (1%) 3 (2%) 
Mixed 2 (4%) 7 (1%) 0 (0%) 
Other 1 (2%) 2 (0%) 2 (1%) 
Unknown 3 (5%) 91 (17%) 1 (1%) 
Charlson 
score 
<1 - 253 (48%) 116 (56%) 
1-5 - 73 (14%) 45 (22%) 
6-10 - 39 (7%) 23 (11%) 
11-15 - 21 (4%) 10 (5%) 
16-20 - 11 (2%) 5 (2%) 
>20 - 8 (2%) 3 (2%) 
Unknown - 119 (23%) 4 (2%) 
 
Table 72: Patient characteristics for the TTCT assessment and the data quality analyses for the 
cohorts.  
In the data quality analyses, the patients without an inpatient event in the routine data have an 
unknown Charlson score. (-) = The Charlson scores could not be identified from the clinical noting 
for the TTCT analyses and hence are not presented in the table. The percentages in the table may 
not sum to 100% due to the rounding. 
 
In the total surgical cohort (N=206), 106/206 (51%) patients were diagnosed with MIBC, 
64/206 (31%) had NMIBC and the remaining 36/206 (17%) did not have cystectomy for 
bladder cancer. All patients in the radiotherapy data were extracted upon the condition 







5.6.2 Time to correct treatment (TTCT) analysis 
29/29 (100%) events (flexible cystoscopy, TURBT and subsequent correct treatment) 
that were queried to the reference clinical noting were correctly identified in the routine 
data (one event could not be confirmed). The routine data identified one event one-day 







Flexible cystoscopy 10 10 
TURBT 10 10 
Correct MIBC treatment 9 9 
Total 29 29 
 
Table 73: Validating the routine data algorithm coding to identify the correct events in a small 
cohort. 
 
The algorithm proxy rules to identify MIBC were investigated. Compared to the surgical 
cohort, where it was known that 106/206 had MIBC, only 35/106 (sensitivity: 0.33) 
patients were identified to have MIBC using the algorithm rules using the direct coding. 
 
Across both cohorts (surgical: 35, radiotherapy: 44), the algorithm identified 79 unique 
patients (figure 39) as having MIBC, two of these had obvious inaccurate routine data 
outcomes, so the accuracy of detection before exclusions was calculated for 77 patients. 
57/77 routine data events were true MIBC events and there were 20 false positives 
(PPV: 0.74) (figure 40, A). Hence, before exclusion of non-bladder cancer patients using 
the reference, many events were being missed and many false positives were present. 
After non-bladder cancer patients were excluded using the reference, 62 patients were 
identified with the proxy. 57/62 were confirmed as MIBC events (PPV: 0.92), hence 






   MIBC reference    
 A   Yes No     
Algorithm proxy test 
Yes 57 20 77 74.0 
No NA NA NA   
    57 20     
 
   MIBC reference    
 B   Yes No     
Algorithm proxy test 
Yes 57 5 62 91.9 
No NA NA NA   
    57 5     
 
Figure 40: The PPV for identifying the MIBC patients.  
A) The routine data extracted events prior to excluding non-bladder cancer patients using the 
reference (bladder cancer and non-bladder cancer patients present); B) after excluding non-
bladder cancer patients (only bladder cancer patients present). 
 
Using confirmed MIBC patients, the routine data acquired time from diagnosis to 
starting TURBT was 27 days but for these MIBC patients where further correct treatment 
was required, there was over a 3x increase (99 days in total) in the number of days to 
treatment than the 31-day target. Post-TURBT it was quicker to have surgery than 
radiotherapy, with a mean difference of 11 days (radiotherapy = 75 days, surgery = 64 
days). 71 further days were required from TURBT until correct treatment was given 




Figure 41: The time to definitive treatment for MIBC patients. 
X = time from diagnosis to correct treatment for NMIBC; Y = further time to correct treatment for 
MIBC; X + Y = total time from diagnosis to treatment for MIBC. 
5.6.3 Data quality assessment 
In total, the algorithm utilising the routine data detected 829/1042 events (sensitivity: 
0.80) across the ten data years (2008-2018) (table 74).  
 























Cystectomy 206 202 98.1 
Radiotherapy regimen 568 391 68.8 
Censor 100 89 89.0 
BCG regimen 15 14 93.3 
Cystoscopy 106 89 84.0 
Chemotherapy regimen 47 44 93.6 
Total events detected 1042 829 76.9 
 
Table 74: The total number of events that occurred (identified in the reference), compared to the 
total number of events that the routine data were able to identify.  
A variation of this table is in a publication in submission. 
 
The number of events split by year from 2011 can be seen in table 75. The data quality 
improved 60.4% from 2011 to 2017 (the years where greater than 100 events were 
identified in the reference) (table 75). 
 





2011 117 41 35.0 
2012 144 56 38.9 
2013 139 118 84.9 
2014 146 142 97.3 
2015 149 145 97.3 
2016 149 148 99.3 
2017 109 104 95.4 
 
Table 75: The number of events identified in the routine data and compared to the reference 
(2011-2017). The sensitivity is displayed as a percentage (%). 
 
Over the last five full data years (2013-2017) years, the routine data had a sensitivity of 






Figure 42: The number of events identified in the last five full data years (2013-2017).  
 
In the surgical cohort, a 100% linkage rate of the reference data to the routine HID was 
present, 206/206 patients had a routine HID event documented (any inpatient or 
outpatient interaction, not exclusive to those analysed). In the surgical cohort, using the 
whole ten-year data period, when the exact date of surgery to bladder was required to 
correctly identify an event, the sensitivity was calculated as 96%; with 198/206 events 
correctly identified. When not restricting the routine data event detection to a date, a 
sensitivity of 98% was present with 202/206 surgical events identified (table 74). These 
four additional events were detected less than two weeks from the date of procedure as 
identified in the reference. Two 1-day, one 4-day and one 13-day delay in event 
detection were identified. In addition to this, a PPV of 96% was calculated, as eight false 
positives were also detected. This was due to duplicate events, unrelated events (for 
example, TURBT) and procedures that were not undertaken. The quality of the routine 
data was consistently high across all data years.  
 
Chemotherapy regimens could be identified with a sensitivity of 94% (44/47 events were 
detected) (table 74). The PPV was 94% for detecting chemotherapy regimens, the three 
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treatment (table 76). 100% of chemotherapy regimens were identified from 2012 
onwards.  
 
A sensitivity of 84% was present for detecting cystoscopy events (89/106 were detected) 
(table 74). 100% of TURBTs were identified (32/32) and 77% of flexible cystoscopy 
events (41/53 were detected). The PPV for detecting cystoscopy events was 94% (table 
76). The six false positives were due to: duplicate records (three events), an extirpation 
of bladder lesion (one event), a nephrostogram plus insertion of stent (one event) and 
cystodiathermy (one event). Cystoscopies are also often undertaken during the three 
false positive procedures identified, hence a potential reason for the detection of these 
events. 
 
At a regimen level for BCG (only one administration was required to be identified), 
14/15 regimens were identified (sensitivity: 0.93) (table 74). In contrast, when assessing 
the routine data accuracy to identify all individual administrations in each regimen, 
114/149 administrations were identified (sensitivity: 0.77). The majority of the false 
positive regimens that were detected (20 regimens), which reduced the PPV to 41%, 
were due to Mitomycin C administration (due to a similar method of administration) 
(table 76).  
 
Finally, the only event to show a reduction in data quality over two consecutive years 
post-2014, was the censor follow-up event. A total sensitivity of 89% was present 
(89/100 events were detected) (table 74). 
 
A 100% linkage rate was not present for the radiotherapy cohort. Of the 525 patients in 
the reference, only 524 patients had an event in the routine data. Only 69% of regimens 
were identified (391/568) (table 74). The PPV was high at 95%, with only 20 false 
positive regimens being detected (table 76). The data quality improved from 2011 to 
2017. In 2011 a sensitivity of 1.4% was present (1/74 events detected) to 100% in 2017 
(68/68 events detected) (figure 43). 7894 individual fractions were administered across 
the 568 regimens; of these, 5121 were identified in the routine data (sensitivity: 0.65). 
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The accuracy of the routine data algorithm to detect the correct MIBC treatments 
(surgery, radiotherapy and chemotherapy) can be seen in figure 43. As previously 
stated, the TTCT is a BladderPath primary outcome measure. 
 
 
Figure 43: Accuracy of the routine data to detect the BladderPath primary outcome measure. 
5.6.4 The framework 
Due to the false positive and false negative events identified during these studies, plus 
the knowledge gained during chapter 3 and 4, I believed directly using coding to identify 
events for a trial using the hospital administration data alone, was not feasible. 
However, I propose three techniques may enable the feasibility of this, 1) additional 
routine datasets, 2) a querying framework and 3) additional rules. 
 
The overall proposed schema designed to enable the feasibility of using routine data as 
the basis for trial follow-up, can be seen in figure 44. An algorithm to extract events, 
such as the one presented here, could be run down the routine data at frequent 
intervals, to identify the events of interest. These events could then be incorporated 
into a CRF which could be electronically verified at the sites using queries to either 









































Figure 44: The methodology developed for the BladderPath trial 
 
 
The results presented within this chapter suggest that routine data may not be of high 
enough quality for a trial without implementing additional measures. The results are 






verified at site 
Incorporated into 




As identified in the literature, although clinical trials have used routine data to 
supplement standard clinical trial data collection for many years, there is limited 
evidence of studies using routine data to replace these standard follow-up techniques. 
Standard techniques may include patients visiting a trial clinic for consultation and CRF 
completion to document any trial events. This method of data collection is resource and 
time intensive and of financial burden. In this thesis I assessed the feasibility of using 
routine data to strive to provide an alternative methodology to alleviate these 
complications. 
5.7.1 Time to correct treatment (TTCT) study 
The time from diagnosis of bladder cancer to the TURBT (the correct treatment for 
NMIBC but incorrect treatment for MIBC) was three days less than the published NHS 
target value of 31 days. This suggested that although the sample of patients analysed in 
this TTCT study were a MIBC cancer cohort, the NMIBC would be treated within the 
target. However, for the MIBC patient cohort, where further treatment is required post-
TURBT, there was over a 3x increase in the number of days to treatment (with an 
additional 71 days from TURBT to correct treatment (surgery or radiotherapy), when 
compared to the 31-day target. The delay in time to treatment for MIBC were 
comparable to other studies across many different countries (225), giving confidence 
that the results identified by the routine data are representative of the population. It 
was also identified that there was a mean 11 day decrease in the TTCT if surgery was 
given, when compared to radiotherapy.  
 
A limitation of this TTCT study is that only single-site data (from UHB QEH) were used. 
This meant that the routine data could not be validated across multiple sites nor could 
the delay to treatment be assessed in more depth. As discussed previously, different 
sites will have differences in their coding but also there will be differences in the clinical 
pathway, impacting waiting times. Hence, multi-site analyses would allow comparisons.   
 
To confirm patient inclusion in the time to event analyses, the routine data detected 
flexible cystoscopy events per patient were confirmed by note review to include only 
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patients with MIBC. In the majority of the excluded cases, the routine data did not 
identify the initial flexible cystoscopy diagnosis due to the timeliness of the routine data 
provided. For example, when diagnosis occurred many years previously and the 
surveillance cystoscopy was identified as the event of interest. Patients were also 
excluded where the routine data identified exploratory diagnostic events, led to an 
uncertain or non-bladder cancer diagnosis. In this study, the ability to confirm events 
using the note review enabled these false positive MIBC events to be excluded from the 
sample. This enhanced the integrity of these data in this case. However, in the absence 
of a reference, these events would have been erroneously included in the analyses. 
Therefore, it was necessary to validate these routine data events prior to inclusion in the 
analyses. When only MIBC patients were included in the analyses, by restricting the 
cohort during the note review, the number of false positives reduced and there was 
therefore a large increase in PPV (figure 40).  
 
As seen in previous chapters, it was hypothesised that MIBC patients were being falsely 
excluded (missed) from the analysis due to missing/erroneously coded routine data 
events. This can be illustrated by the number of patients in the surgical cohort that were 
identified as having MIBC using the algorithm proxy routine data rules, when compared 
to a MIBC cohort reference. In the reference, 206 patients underwent cystectomy, 
170/206 patients had a radical cystectomy for bladder cancer and 106/170 (62%) of 
these patients had MIBC. However, the algorithm proxy only identified 35/106 (33%) of 
eligible MIBC cases.  
 
These missing patients are hypothesised to be due to the, 1) routine data coding, or 2) 
patients following a different treatment pathway. Due to routine data coding, the 
extraction of single codes to detect individual bladder cancer events restricted 
detection. As also identified in the chapter 3 analyses, broader coding needed to be 
algorithmically extracted to increase the sensitivity of event detection; however, this 
technique would reduce the specificity. MIBC patients may have also been missed that 
did not follow the same treatment pathway as that used to extract the patient cohort, 
due to clinician preference or patient illness. Although not present in this cohort, due to 
all patients being known to receive a correct treatment (surgery or radiotherapy), it is 
possible that when using this model more widely this would exclude patients that never 
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received the correct treatment, for example, due to illness. As time goes on, the 
implications of the BladderPath trial (replacing TURBT with MRI imaging for MIBC 
patients) could also change the pathway and therefore not enable detection of these 
patients using the model developed here. Hence, in order to capture more patients, 
additional pathway rules should be added to the algorithm to aim to capture further 
events (an adaptive design is required). A sample of the 71 MIBC patients that had a 
cystectomy, that were missed from the analyses, could be studied to identify why they 
were missed; the routine data should be compared to the clinical noting. 
 
A small sample of all events of interest were also validated to confirm the accuracy of 
the routine data events being detected. For example, that the OPCS codes M459 
(unspecified diagnostic endoscopic examination of bladder) and M421 (endoscopic 
resection of lesion of bladder) were identifying flexible cystoscopy and TURBT 
respectively. 100% of flexible cystoscopy, TURBT, and subsequent correct treatment 
(surgery, radiotherapy) events were identified (table 73).   
 
To reduce the problems identified with missing (reducing the sensitivity) and false 
positive data (reducing the positive predictive value), it was hypothesised that 
increasing the number of included codes to identify the outcome could increase the 
number of events identified. However, an additional data query technique would be 
required to increase data quality to reduce the number of false positives. This method of 
data query was tested when querying the flexible cystoscopies above. The benefit of 
increased accuracy of these data outweighed the burden of the querying. This burden 
was low due to the ability of the routine data to pinpoint individual events with a time 
stamp, enabling direct identification by date and procedure in the clinical noting. This 
again suggested that due to routine data quality limitations, a querying mechanism 
would be required to enable the feasibility of routine data in trials where routine data 
are the primary data source. The quality of the routine data was assessed further during 
the data quality validation study.  
5.7.2 Data quality validation study 
The Hospital Interactions Data (HID), the HES-equivalent, was seen to be a suitable 
dataset, in the absence of HES data. The quality of the HES data, if anything, would be 
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higher due to the further processing of this SUS data prior to becoming HES (206) (figure 
2). Therefore, it was deemed a suitable alternative for the analyses. 
 
As seen in table 76, events were found to be missing but the proportion of missing 
events reduced over time. In fact, the quality of all of these data items except the date 
of the last visit (censor) reached 100% in the last year available for analysis (2017) (table 
76). The radiotherapy events historically had the lowest coding accuracy, however, this 
accuracy increased in 2013/2014 and was sustained, although small fluctuations were 
present (figure 43). I investigated this increase in accuracy; anecdotally it occurred due 
to a coding review at the trust. During this reporting period, increased checking 
procedures were implemented to ensure correctly coded events. Due to the impact on 
remuneration to the hospital (232), the accuracy has remained consistently elevated 
since. In parallel to this, an NHS audit was undertaken in 2013/2014, across 50 trusts. 
This audit was specifically looking into the coding of co-morbidities, as only those 
relevant to the period of care are required to be documented. It also identified a trust 
with a maximum primary procedure code error rate of 26%. A report was released 
following these audits, including, a ten-step checklist to enhance data quality. The 
function of reports are to increase data quality, the results of which could be seen 
during the data validation study (233). Due to the primary payment function of these 
data (232) and central initiatives to increase data quality (233), I hypothesised that 
recent data across other sites (not just limited to the UHB QEH site) would also reflect 
this pattern with more recent data being more accurate. However, as discussed above 
for the TTCT study, the validation of only single-site data did not enable the routine data 
quality to be analysed across sites which is a limitation. Another limitation in the TTCT 
and data quality study was that neither the specificity nor the negative predictive values 
could be calculated; I did not have access to a reference documenting the patients that 
did not have a particular event.   
 
Missing data had implications on the Charlson scores, as some were scores missing. This 
is because the inpatient admission events often occur at different sites to where 
radiotherapy was administered and therefore would not be identifiable in the local 
routine data. Another limitation is that although it is proposed that routine data could 
be enhanced using other datasets, only in-depth validation was undertaken using the 
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routine HID (the HES-equivalent). However, it is proposed that more events could be 
identified using additional sources.  
 
Limitations were also identified regarding the reference data. Events can be missed from 
manually reviewing clinical noting data, for example if the event occurred in another 
hospital without transfer of the patient noting. A further limitation was that the 
radiotherapy reference data documented radiotherapy fractions that were prescribed 
and not those that were delivered. In contrast, the HID identified events that had been 
delivered and not prescribed. I queried the relationship between fractions prescribed 
and delivered to see if this would have implications on the accuracy results. Upon query, 
I found anecdotally at UHB QEH, the relationship between the fractions prescribed and 
delivered is extremely close, therefore implying that there would have been little impact 
on the sensitivity values identified. However, even if misclassified, the impact of this was 
deemed small. The sensitivity would increase if regimens that were thought to be 
missed in the routine data, due to being documented as being prescribed in the 
radiotherapy data, were never actually delivered; the number of false negatives in the 
routine data would reduce, increasing the sensitivity.   
 
In summary, limitations were again identified for using routine data for RCTs, including 
missingness, inaccurate coding and limited clinical variables, and it is therefore of no 
surprise that previously there has been hesitation to using such a resource and 
therefore, limited evidence of such. However, I propose many of these limitations can 
be overcome. 
5.7.3 Implications to RCT conduct 
As presented in the results (5.6.4), directly using coding to identify events for a trial 
using the routine hospital administration data alone, was not feasible and as stated, this 
can be reflected by the lack of literature for trials being performed solely using routine 
healthcare data. However, as proposed (section 5.6.4) various techniques may enable 
the feasibility of this, 1) additional routine datasets, 2) a querying framework and 3) 




The aim was that additional datasets that have data derived from alternative sources 
would enhance the collection of events. A querying framework would enable the 
screening of a broader coding set, therefore, enabling the capture of additional but 
confirmed events. Additional rules may also enable the detection of missing routine 
data events that were still not identifiable using additional datasets or captured through 
weaker coding restrictions. These three techniques are detailed below. The BladderPath 
trial data collection framework is currently being designed to incorporate these 
techniques, with the aim to be regarded as the first secondary care or oncology RCT to 
use routine data as the basis for data collection.  
5.7.3.1 Additional datasets 
To aim to capture the maximum number of events, I proposed additional datasets would 
be required. In particular, radiotherapy events were of the highest concern due to the 
historically poor accuracy seen in figure 43. Hence, to further ensure that radiotherapy 
events could be captured nationally across multiple sites, I proposed the 
supplementation of the hospital interactions data (for example, HES) with data from the 
national radiotherapy dataset (RTDS). These data are collected directly from the 
radiotherapy treatment machines and these data are therefore derived from an 
alternative source to the EHR generated HES data (introduction 1.2). The RTDS is 
proposed to be automatically generated upon administration of radiotherapy (24). 
 
In this study the RTDS-equivalent was used as a reference to validate the quality of the 
HES-equivalent. This was due to the hypothesised high quality because of the 
automatically generated method of collection. However, the RTDS-equivalent was also 
investigated by performing survival analyses with data from the Office of National 
Statistics (ONS) Spine (234) (death data). Note that A. Dosanjh performed this separate 
analysis, hence the results are not shown. This work undertook analyses of the impact of 
radiotherapy on overall survival in a bladder cancer cohort (utilising many of the 
patients within the cohorts presented during this study). The results generated by 
A.Dosanjh during the analyses revealed results comparable to published clinical trials 




In addition to enhancing HES-detected (27) radiotherapy events with the RTDS (235), the 
HES chemotherapy data can also be supplemented with the systemic anti-cancer 
therapy data set (SACT) (52) and imaging data can be supplemented with the Diagnostic 
Imaging Dataset (DID) (236). Cancer registration data (49) can also be requested to 
further enhance general event detection and also date of death (for overall survival 
calculation) can be requested (table 77). Additional datasets, derived from alternative 
sources, are proposed to enhance trial data quality and reduce missingness (table 77). 
 
Outcome to be 
extracted Database Implication from validation 
Surgery to 
bladder 
• Hospital Episode 
Statistics (HES) 
• Historically high quality 
• HES data alone sufficient 
Chemotherapy 
regimens 
• Hospital Episode 
Statistics (HES) 
• Systemic Anti-Cancer 
Therapy (SACT) 
• Historically high quality to detect regimens 
• The exact date of administrations can additionally be 
found in the SACT data (and clinical noting if required) 
• HES data alone sufficient 
Radiotherapy 
regimens 
• Hospital Episode 
Statistics (HES) 
• National Radiotherapy 
Data set (RTDS) 
• More recent high quality (since 2014) to detect 
regimens 
• Due to the validation of the radiotherapy data, the 
RTDS could be used to supplement missing events 
Cystoscopy 
• Hospital Episode 
Statistics (HES) 
• Diagnostic Imaging 
Data set (DID) 
• Recent high quality (since 2016) 
• Consistent high quality TURBT coding 
• Historically lower quality of flexible cystoscopy coding 
• Prior to trial data confidence, a database query 
process may be necessary (check flag = if no flexible 
cystoscopy is identified prior to TURBT) 
• To confirm identification of subsequent surveillance 
flexible cystoscopy events, the DID could be used as a 
supplement 
BCG regimens 
• Hospital Episode 
Statistics (HES) 
• Systemic Anti-Cancer 
Therapy (SACT) 
• More recent high quality (since 2013) 
• SACT data could supplement missing administration 
details 
Censor 
• Hospital Episode 
Statistics (HES) 
• Data quality historically high, but reduced recently 
(post-2016) 
• Therefore, upon query at site, the most recent event 
in the clinical noting could be confirmed 
Date of death 
(overall 
survival) 
• Various sources, 
including, the ONS 
spine and PHE NCRAS 
data 
• The utility of such was demonstrated by A.Dosanjh 
using data from the ONS Spine 
• The collection of death data is mandatory and as such 
data quality should be high (to be confirmed) 
 
Table 77: An example for the BladderPath trial of how additional datasets can aid event 
identification.  
I have also submitted this table in a submitted paper pending publication. 
 
However, a limitation to this approach is that the more data sets that are required, the 
more resources are needed to: 1) apply for these data, 2) safely receive these data 
(potentially from multiple routine data providers), 3) merge these data, 4) validate these 
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data and 5) process these data. More data sets therefore require additional time to 
undertake the steps listed above and hence, increase the costs associated with using 
routine data follow-up. However, the question remains as to if the costs associated with 
these methods remain lower than the costs associated with standard follow-up 
techniques. 
 
Additional datasets will only help where the outcomes required by the trial are 
obtainable in these data. As presented in chapter 3 and 4, the routine data coding can 
be restrictive, including with the lack of clinical or pathological details. Outcomes are 
only feasible to be collected for trials if the particular outcomes of interest are directly 
identifiable (such as presented here) or indirectly identifiable (such as in chapter 4). 
5.7.3.2 Querying framework 
As mentioned above, in order to capture as many trial events as possible a methodology 
was developed which involved the querying of the algorithmically detected events 
(figure 44). Due to this proposed querying technique, the algorithm was developed to 
identify a broad coding list (as many events as possible), which could then be confirmed 
at trial sites. Hence, a very high sensitivity is required to detect as many events as 
possible, but a lower specificity would be acceptable. This is because each individual 
event would be queried at site. Hence all false positives would be removed, so by 
definition the specificity would become 100%. Therefore, a lower PPV would be 
acceptable, as the benefits from identifying additional events for an RCT outweighs the 
additional burden on site staff from validating further (potentially false positive) events.  
 
A balanced approach will be required using this method; the broader the acceptable 
coding, the higher the burden on trial staff to query these additional events. Care also 
has to be taken with the documentation of the clinical noting. This is to ensure that 
routine data true positive events are not rejected (upon query) due to being missed in 
the clinical noting. 
5.7.3.3 Additional rules 
I proposed that additional rules could be utilised to flag missing events of interest. For 
example, I identified that flexible cystoscopies could me missed from the routine data 
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and therefore could be flagged using rules (cystoscopy, table 77); if a TURBT is 
identified, but no flexible cystoscopy prior to this, a flexible cystoscopy event could be 
queried in the clinical noting. This would enable identification of initial flexible 
cystoscopies, however, not later surveillance events. Similar rules could be adapted to 
increase the sensitivity of detecting the last censor events. 
 
Limitations include the potential for misclassification, increasing site staff burden (103) 
from querying the additional events. In addition, further rule creation increases the 
complexity of the data collection and therefore may increase resource use and cost. 
 
However, even in the absence of these additional methods to enhance the data 
integrity, the routine informatics data were seen to be of recent high quality for trial 
conduct; a level of missingness is also expected using conventional trial data (149, 237). 
Therefore, data quality is estimated to have minimal impact on the trial data integrity, 
especially if these additional methods are employed. 
5.7.4 Further considerations for using routine data in trials 
There are further considerations and potential caveats for using routine data in trials 
which must be considered whilst developing a routine data framework. Timeliness of 
accessing routine data is a limitation of using such methods in trials. This was illustrated 
during the data validation analyses. The three missing radiotherapy events in 2018 were 
not due to erroneous data but due to the delay in data access. Often data are provided 
at a delay and therefore the data censor limits identification of the most recent events. 
If the time lag between the event occurring and the routine data being received by the 
trial is too great, techniques such as these proposed here are futile. 
 
However, I propose, although a time lag would be present through acquiring routine 
data, the time lag may be overall less than with standard collection methods. For 
example, in the STAMPEDE trial, initially follow-up is undertaken every six-weeks but at 
six years follow-up can occur at less frequent intervals of 12-months (72). Hence, using 
STAMPEDE as an example, obtaining data from routine providers, would reduce the 
mean delay in event detection over the whole follow-up period. Discussion is currently 
underway with the routine data providers to identify the optimum frequency and delay 
 
 243 
in data release (by the data provider) for the lead BladderPath site to receive these data; 
the frequency is proposed to be 12-weekly and the delay in data collection is currently 
under discussion. Hence, in terms of data frequency, in comparison to the STAMPEDE 
trial, initially there would be a 6-week delay in event collection using the routine data 
but from 9-months, where follow-up become less frequent, the timeliness of event 
collection would increase using the routine data, compared to the standard methods. 
However, this is also dependent on the delay in data release by the data provider. 
 
Consent and access to data is of further consideration when using these data in trials. 
This study was undertaken using non-trial audit patients; hence, consent was not 
required. However, for a trial, patients are required to consent to routine data access, 
which enables the acquisition of personally identifiable event data. The patient consent 
forms for the BladderPath trial were designed to enable this, including clauses such as 
(excerpts taken directly from the BladderPath consent forms):  
 
• I give permission to the Trials Office to access relevant data collected via the NHS 
Hospital Episode Statistics (HES). I understand this may include relevant data prior to 
the date of consent. I give permission for my personal details e.g. full name, date of 
birth, gender and NHS number to be sent to the University Hospitals Birmingham 
NHS Foundation Trust Informatics Team via a secure system to be able to obtain the 
relevant data. I understand that this transfer of my personal details will only occur 
once. 
 
• I understand that the Trials Office, may access information held by Cancer Registries, 
Cancer Intelligence Unit, NHS Digital, National Cancer Registration and Analysis 
Service (NCRAS) and other similar data sources kept by the NHS or related 
organisations, to keep in touch with me and to follow-up on my health status. 
 
I have been leading the acquisition of the routine data for the trial. Initially an 
application was submitted to NHSD to acquire the HES, DID and ONS data and I was 
completing, in parallel, an application to PHE for the SACT, RTDS and cancer registration 
data. However, limitations of acquiring data from NHSD were present, including 
costings. This technique of using routine data for follow-up aims to reduce the cost of 
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follow-up compared to standard trial data collection methods. However, if the costs are 
too high to receive frequent data sets from these providers, then techniques such as 
these become futile. Where providers charge the same data linkage fee per extract, the 
costs can make these methods non-accessible by trials (see further details in 6.1.1.3).  
 
Due to reasons such as costings, an application was being completed to hope to acquire 
all data from PHE. However, due to the importance of receiving timely data, discussions 
remain with NHSD and hence, a combination of acquiring data from both PHE and NHSD 
may be the optimum. 
 
As discussed, due to the querying methodology proposed, all events will be queried for 
accuracy. Therefore, I am currently liaising with PHE regarding the development of a 
continual data quality feedback mechanism. The overall aim is to enhance routine data 
quality for future trials, where the requirement for querying events would be negated. 
Working closely with the routine data providers during trial set up is necessary to design 
a smooth mutually beneficial application. 
 
It is vital that these caveats are taken into consideration whilst designing a routine data 
framework. However, if these concerns can be resolved, I believe in certain settings, 




5.8 Conclusion  
Although clinical trials have used routine data to supplement standard data follow-up 
methods for many years, I believe there to be limited evidence of using routine data as 
the basis to conduct a UK trial. Once the methodology has been implemented, I believe 
this will be the first non-primary care UK RCT and the first oncology UK RCT, using 
routine data with no standard clinic follow-up.  
 
Due to the data limitations identified across all the thesis studies, a methodology was 
developed to ensure maximum data integrity. This enables us to continually monitor 
data quality throughout the trial and if the quality is seen to be reliable, the necessity for 
querying may be removed (or at least for trials in the future). I believe to have 
demonstrated the feasibility of this approach despite the current routine data 
considerations. I hope this novel methodology may impact how future trials are 
conducted. To reiterate, there are many proposed benefits to using these data and 
hence, implications to patients. This includes, reducing burden, saving resources, 
reducing costs, increasing efficiency, all whilst collecting high quality rapidly updateable 
easily auditable data, enabling real-time data monitoring. These implications aim to be 




6 CHAPTER SIX: Overall discussion and conclusion 
6.1 Discussion 
The main aim of this PhD was to answer the question: ‘Can routinely collected data be 
used to inform randomised controlled trial outcomes in oncology’? To answer this, the 
feasibility of using routine data for trial follow-up was assessed and where possible 
clinically useable instruments were developed, to detect trial outcomes. To identify 
outcomes, methods were developed to directly and indirectly utilise the coding, to 
undertake retrospective trial analyses and in addition, assess the feasibility of using 
routine data for prospective trial follow-up. 
 
Within the literature, I identified no United Kingdom (UK) randomised controlled trials 
(RCT) in secondary care or oncology which had been designed to conduct follow-up 
using routine data alone. Hence, I investigated the feasibility of this. In parallel, I 
explored if existing follow-up could be replaced or supplemented within an existing trial. 
Examples for this included: assessing the feasibility of detecting trial non-survival 
endpoints and assessing the feasibility of answering a question not previously possible 
with the standard trial data. There was limited evidence in the literature of routine 
healthcare data being used to identify non-survival endpoints within trials (165, 171) 
and no evidence within the UK. In addition, the research question that was not 
previously possible to answer using standard trial data was chosen due to lack of 
evidence in the literature from a single RCT. 
 
Although the results of this thesis have been discussed individually within chapter 3, 4 
and 5, this chapter discusses the thesis as a whole, including the implications of the 
results. Of necessity, the results were presented in a linear fashion, however, all 
chapters informed each study and were largely undertaken in parallel. Hence, despite 
individual chapters identifying different outcomes using alternative methods, the 
overlapping principles are discussed below. Cumulatively the results, I believe, enabled 
me to answer the research question.  
 
In the introduction, I proposed the potential of such methods but also the concerns 
(table 1) that needed addressing in order to make clinically useable instruments for trial 
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follow-up. Hence, these are discussed below, in the context of the proposed thesis aims 
(section 1.8.1). 
6.1.1 Routine data concerns 
Both practical and regulatory concerns for using routine data for trial follow-up were 
explored in table 1. In practice, the true nature of these concerns and how these were 
overcome during these studies are presented below. The concerns included; outcome 
availability, data accuracy, data linkage, cost, timeliness, bias, patient privacy, security 
and consent and length of data retention (table 1). Data outcome availability and 
accuracy were the two greatest limitations which I identified during my studies, both of 
which are significant barriers to using these data in practice (63).  
6.1.1.1 Routine data outcome availability 
Firstly, all three studies were limited by the availability of outcomes in the routine data. 
In chapter 3, a standard neutropenic sepsis event outcome, such as febrile neutropenia, 
seen in the cross-study comparisons presented in the literature review, was not 
available in the routine data (Hospital Episode Statistics, HES). Hence, a proxy for the 
standard trial definition of sepsis events had to be created, utilising the coding that was 
available (admission for sepsis or neutropenic event). Proxies to classify the events by 
hormone-sensitivity (hormone-sensitive prostate cancer (HSPC), castrate-resistant 
prostate cancer (CRPC)) also had to be developed, using relative timing of events to 
classify the sepsis and chemotherapy events (table 21). When compared to the clinical 
noting (section 3.12.3), all events were correctly classified by hormone-sensitivity. 
However, the use of proxies was expected to lead to misclassified events during the 
other analyses. This is further discussed below, with regards to identifying a bladder 
cancer cohort. The use of proxies have implications in practice if exact definitions of 
events are required to be collected; for example, trial protocol specified definitions of 
sepsis events are required for CRF collection.  
 
Although a different definition for toxicity events was identified using the routine data 
proxy, this model did enable comparison, by chemotherapy timing, within a single RCT 
population. This was not previously possible using the case report form (CRF) collected 
STAMPEDE data, as the outcome was not explicitly collected in the trial CRFs to perform 
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the new analyses. These data, therefore, enabled hypotheses to be analysed that were 
not previously envisaged when the CRFs were being designed. However, to reiterate, 
the results were not conclusive, for example, the study did include some patients 
prescribed both HSPC and CRPC chemotherapy regimens (partially paired data) and 
hence may have had implications on the rates in the CRPC group. 
 
In chapter 4, the routine data (HES) could also not be used directly to identify trial 
outcomes. Trial-based disease outcomes, such as progression endpoints were not 
identifiable in the routine data due to the inadequate availability of key outcome data 
fields (section 4.3). Specific protocol defined progression outcomes cannot be identified 
in the HES data and therefore ‘time to events’ such as the progression-free survival (PFS) 
could not be derived directly. Hence, a model was created to indirectly infer when trial 
events of interest had occurred. I developed this model based upon the clustering of 
routine data cancer-related events, from the HES procedure and diagnostic coding 
(figure 30). The aim was to allow patterns of cancer-related coding to contribute to the 
model directly, to flag absent outcomes.  
 
The routine data model was not able to detect individual protocol defined non-survival 
endpoints (PFS, metastases-free survival (MFS), failure-free survival (FFS)), but a 
composite was in fact being identified (section 4.10.4). The model identified the first 
peak in clinically relevant activity and thus the time to event calculations using the 
model constituted the ‘activity-free survival’ or AFS. This was defined to be the time to 
the first most intensive healthcare interaction period for a patient. Although the model 
was not able to identify the protocol defined non-survival endpoints directly, I proposed 
the AFS as an alternative novel non-survival endpoint, subject to further validation.  
 
Standard non-survival endpoints such as the FFS, MFS and PFS present clinically 
different timepoints; some endpoints are less clinically relevant than others (for 
example, the FFS) but to function as a surrogate endpoint for overall survival, criteria for 
surrogacy are required (chapter 4, 4.9.5). The algorithm was identifying the more 
clinically relevant protocol defined outcomes (MFS, PFS), compared to the FFS (a less 
clinically relevant endpoint) (section 4.10.4). Although a novel endpoint was being 
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identified, similar treatment effects (hazard ratios) were seen in line with the protocol 
defined non-survival endpoints (table 60) (table 63) (table 66).  
 
A model such as the above, has implications in practice; routine data could be used to 
perform trial time to event analyses, and the algorithm derived outcomes could be used 
to validate trial outcomes. This may supplement the trial with additional data that was 
previously lost to follow-up (due to trial under-reporting). There are also non-trial 
implications; the model could be used to perform audits on ‘real-world’ data. The aim 
would be to test new hypotheses prior to trial set up. In addition, this model could be 
used to compare trial to non-trial patients to test ‘real-world’ intervention effects and 
confirm that the same impacts occur in the non-trial setting. In addition, the models 
could be used to assess whether a trial result has been truly implemented in practice.  
 
I propose that, alongside further validation, this endpoint could be used in addition to 
(and not in replacement of) the standard trial endpoints. I also propose that this routine 
data-based outcome may provide a particularly clinically relevant endpoint (section 
4.11). However, I believe further validation of the utility of the AFS as a surrogate 
endpoint is strictly mandatory, for example, within other treatment settings. Examples 
of other settings include, patients being treated with abiraterone hormone therapy and 
a prostate cancer cohort with a low risk of progression. Upon further validation, the AFS 
may pose a novel way to collect outcomes data to negate, reduce or supplement the 
requirement of standard data collection methods.  
 
Further to this, HES also intentionally did not document some investigations, such as 
simple radiography (X-rays), as opposed to complex radiography (for example, magnetic 
resonance imaging (MRI)). Hence, these were not available to detect in these data. This 
is likely due to the function of the administrative data, which does not seek to capture 
interactions of relatively low price.  
 
The lack of detailed clinical outcomes in the routine data also had implications within 
chapter 5. Identifying a cohort of patients was problematic. Here, within a non-trial 
bladder cancer cohort, a muscle invasive bladder cancer subset (MIBC) was required for 
analyses. However, this MIBC cohort was not directly identifiable in these data; hence a 
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proxy outcome was developed using procedure patterns to identify the cohort to enable 
the timing between events to be calculated. Using this proxy, a large number of 
potential MIBC patients were missed (section 5.6.2). However, I believe this to have 
minimal impact within a standard RCT setting, if cohorts are being identified using 
standard methods. However, this is reflective of the potential for misclassified events 
using indirect proxy techniques. 
 
In contrast, during the chapter 5 bladder cancer data quality validation study, the events 
of interest were directly available in these data. This included treatments and the last 
known follow-up indicator; hence, I developed a simple algorithm to extract these.  
 
To summarise, to identify outcomes of interest in the routine data that were not present 
directly in these data, proxies had to be created to indirectly identify the outcomes. 
Novel event definitions were created, where possible; however, when novel outcomes 
could not be generated, when particular defined outcomes were required, it was clear 
that outcomes were being misclassified (for example, the MIBC cohort). In both chapter 
3 and 4, novel outcomes were identified, to fit the outcome to these data to enable 
detection. Of particular interest is the model developed in chapter 4, based upon the 
clustering of events. These techniques appeared to enable trial event detection from 
routine data sources. However, whether these models work in practice, within a 
different population or setting are yet to be investigated and all events require 
validation on a study-specific basis. If the outcomes of interest are not available in the 
data sets, nor is it appropriate to utilise a proxy, then routine data would not be a 
suitable source of outcomes. 
 
Summary implications for practice: Routine data outcome availability meant that some 
outcomes of interest were not directly available in these data. However, in this study 
proxies were developed to enable identification of such events. There is limited literature 
available that seek to extract clinically useable outcomes from routine data. For 
example, there is a lack of studies developing models to identify non-survival endpoints 




6.1.1.2 Routine data accuracy 
Accuracy was investigated in depth throughout the studies. For example, during chapter 
3, chemotherapy regimens were often not being coded for in the routine data and 
hence, not being detected. However, models were successfully created to account for 
the missing routine data chemotherapy regimens (inferral). This enabled detection of 
more true positive chemotherapy and sepsis events (for example, table 33). However, 
there was an increase in false positives that were unrelated to chemotherapy (table 27).  
 
Further to this, to identify additional events of interest that were potentially miscoded, 
in all studies (except cystoscopy events within the chapter 5 time to correct treatment 
analyses), the eligible coding list to screen was broadened. This was to identify events 
that may have been documented using a similar, but incorrect, procedure code. 
Although enabling the identification of additional events of interest, this led to an 
increase in false positives (misclassification) being identified (for example, chapter 3 and 
5); in chapter 3, admission events coded exclusively for neutropenia-only, may not have 
been infection admission events. In contrast, during chapter 5, the algorithm only found 
a small proportion of eligible MIBC patients for analyses. This is hypothesised to be due 
to the restrictive cystoscopy coding proxy. However, in the sample of the MIBC patients 
that were confirmed, 100% sensitivity for detection of events of interest was achieved. 
Despite the restrictions, false positive MIBC patients were also still identified but by 
confirming each event against note review these were excluded from the time to correct 
treatment analyses.  
 
Further to this, it was identified that some HES procedures were coded with alternative 
descriptions to what was expected, for example, imaging events were coded as allied 
health professional consultations. Hence, although it would appear that events were 
missing, sometimes they were present but coded by alternative descriptions. 
 
To identify further events, the routine administrative HES data were supplemented with 
additional datasets. This included the STAMPEDE data to identify HSPC chemotherapy 
regimens and the Systemic Anti-Cancer Therapy Dataset (SACT) data to identify 
chemotherapy events, including drug name. Linking the routine data to both the 
STAMPEDE and the SACT enhanced the identification of events. HES identified 
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admissions for infection events (sepsis plus or minus neutropenia coded events) with 
high accuracy when compared to the STAMEPDE data (figure 18, B).  
 
In all three studies the false positive events identified using the routine data may have 
actually been true positives, that were unreported in the reference data sets (the clinical 
noting and the STAMPEDE trial data). Hospital clinical noting data may miss events 
occurring at other hospitals or events occurring prior to electronic recording of patient 
notes. Trial data are also known to suffer from loss to follow-up (under-reporting) and 
therefore some events could remain unreported, for example, due to recall bias, or 
patient relocation. Hence, routine data could be used to identify events missed using 
the standard trial data collection framework. 
 
In chapter 4, HES was seen to miss prostate-cancer related events including skeletal-
related events (SRE) (for example, table 57), due to the direct coding requirement. This 
is of utmost concern if the raw data are being used to collect such events. However, HES 
was able to identify outcomes that were missed in the trial data (for example, 
progression events, figure 31 and SREs, figure 32). This included identifying outcomes 
not required to be documented, but also some missed (section 4.10.3). Missing data in 
trials are a common feature but leads to great concern (149, 237). The HES detected 
outcomes were therefore able to complement the trial detected outcomes to enhance 
overall event collection. Although prostate-cancer related events were missed, the 
accuracy did increase over time (for example, identifying SREs in table 57). This increase 
in coding quality was reflected in the chapter 5 study, where the majority of the more 
recent events of interest were captured (table 75). In addition, the use of a clustering 
model to identify events in chapter 4, meant that single missing, wrongly coded or false 
positives would have minimal overall impact on the outcomes detected. 
 
To reduce the impact of using broader event inclusion, where specific events were 
required to be detected, it was identified that it was necessary to query events (such as 
in the time to correct treatment analyses). Hence, to build a model to enable the 
feasibility of using routine data as the basis of RCT follow-up, a querying framework was 
designed (chapter 5). The principle was that all events of interest could be extracted, 
using a broader coding list, to capture further events but the false positives could then 
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be further excluded from the analyses. Within the RCT framework, each individual 
extracted routine data event, marked with a timestamp was proposed to be queried at 
the site where the event occurred, using the clinical noting (figure 44). Implications of 
this in practice include, both the identification of more follow-up events and also 
improved accuracy. There is potential that the clinical noting will be missing events, for 
example those occurring at other sites, and as such when the query is run from the 
routine data, the event could be rejected as a suspected false positive. If the event 
occurred at a different site, this is estimated to have little impact, as the query can be 
sent to the correct site based upon location codes in the routine data. However, 
incorrect clinical noting may lead to wrongly rejected events.  
 
One aim of conducting a trial using routine data is to reduce burden on trial staff (103). 
However, event queries to the sites are necessary due to the data quality issues 
highlighted here. It is therefore vital to come to a compromise for maximum data quality 
but minimal staff burden. The ability to flag a suspected event to search for within the 
clinical noting is hypothesised to reduce the time taken to read all clinical noting entries, 
especially upon long-term follow-up. I have been trying to develop the most durable 
method for data flow, from receipt from the routine data provider to the validated data 
point being entered into the trial database. For example, consideration of temporal 
changes to the data are required. The data providers can continually send data updates 
for events already queried. Due to this, I am liaising with the data programming team to 
incorporate a timestamp into the database and a method to identify where data 
updates have been made to account for this. However, if the event has already been 
confirmed in the clinical noting data then any updates to the routine data may not be 
necessary to query again and duplicated events could greatly increase the burden on 
staff. In addition, the event coding may change when new coding classifications are 
released. Therefore, the algorithms and the trial database would have to be updated to 
enable the query of these new events (see discussion, section 4.11 for further details). 
 
Due to the improvement in accuracy achieved, along with the additional processes 
developed for further integrity, I believe these data to be of sufficient accuracy for trial 
follow-up. As discussed, I am in the process of applying the framework developed in 
chapter 5 to the new trial, BladderPath, where I am part of the Trial Management 
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Committee. I am liaising with routine data providers to set up a continual data quality 
feedback mechanism. Due to querying every event of interest in the clinical noting, prior 
to being incorporated into the trial database, a direct measure of real-time data quality 
can be fed back to the routine data providers for service improvement. The aim is to 
enhance these data for future trials, where potentially the need for query will be 
negated. 
 
Summary implications to practice: Data accuracy was seen to be improving over time. 
However, techniques had to be developed to enhance the quality of the routine data to 
enable feasibility of use for trial data collection. Additional data processing techniques 
(such as those presented) are required before there is evidence of high-quality reliable 
coding. There is limited literature documenting the use of routine data for oncology RCT 
follow-up. This may be due to the accuracy concerns detailed within these studies. 
6.1.1.3 Other 
In addition, there are other concerns for using routine data for trial conduct that were 
investigated during this project, for example, cohort linkage. I successfully completed a 
data application to Public Health England (PHE), in which STAMPEDE linkers were sent to 
the data provider so these data could be returned to us attached to the trial number. 
However, due to inaccurately documented trial linkers in the trial database, such as NHS 
number, a small proportion of patients failed to be linked. Errors can occur in the 
documentation of identification numbers, for example, NHS numbers. Upon telephone 
randomisation from the clinical trials unit to the site, these numbers can be 
misinterpreted. Hence, these patients were lost to follow-up using the routine data. I 
have informed the Medical Research Council Clinical Trials Unit at University College 
London (MRC CTU at UCL) that they need to query the identified inaccurate NHS 
numbers at site and prospectively collect these with more care. This is of utmost 
importance if follow-up is to be undertaken using routine data. In addition, this has 
highlighted how important it is to document linkers correctly for a trial using routine 
data as the main source of follow-up data; for example, the BladderPath trial. If the 
linkers are not documented correctly for BladderPath, these patients could be 




Another concern is the cost of routine data; costing is variable across providers. For 
example, NHSD charge a new linkage rate for each extraction, per dataset, of £2,060 
(238) (in addition to other costs). If long-term follow-up at frequent intervals is required, 
as necessary in clinical trials, the use of these data are restricted. For example, a cost of 
£247,200 would be quoted for monthly follow-up over ten years, using only one linked 
dataset, just to acquire these data. This is in comparison to PHE sourced data, from 
anecdotal evidence, alongside the evidence gained from the STAMPEDE PHE application; 
it is suggested that PHE charge an initial linkage fee to develop an algorithm to extract 
and link these data. However, it is suggested that this fee is not re-billed for subsequent 
extractions. This can lead to a large difference in costing frameworks and can be the 
difference between feasibility and non-feasibility of this framework in a trial. I am 
liaising with the providers currently, for the BladderPath trial, to create an arrangement 
that may enable the trial to save resources and benefit from reduced running costs. 
 
Regulatory concerns are also common. During this PhD I have successfully completed 
one data application and I have another underway. The completed application 
(STAMPEDE) was requesting retrospective data for patients that were randomised from 
when the trial began in 2005. This is in contrast to the pending application (BladderPath) 
which is prospectively requesting frequent drops of data. Both applications have crossed 
the timeline of GDPR initiation and therefore both applications had requirement 
changes during the application process. The benefit of the BladderPath design is that we 
are able to apply for these data in parallel to setting up the trial. This is in contrast to 
applying for retrospective data within the STAMPEDE trial.  It is vitally important to liaise 
with routine data providers during the application (ideally during trial set-up) to enable 
the acquisition of data to be as quick and smooth as possible. It takes a long time to 
apply for routine data and therefore, as soon as the trial team decide they may like to 
use this data source, the application process should start. 
 
Despite having successfully completed an application for routine data, when applying for 
retrospective trial data it is vitally important that the trial teams actively track those that 
do not give consent and withdraw from the trial; problems were experienced during the 
completion of this thesis. Patients that were identified initially as a consenting cohort, 
which were sent to the provider for linkage, were then actually identified as not having 
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given consent. These patients were excluded from future analyses and where possible 
removed from existing analyses, which were re-run. Once the MRC CTU at UCL reported 
these concerns, I frequently kept the team informed. I also informed the Warwick 
Medical School team who were happy with the measures taken. However, review of the 
patient consent is continually underway and additional patients may be identified that 
never consented. The MRC CTU at UCL are also currently seeking advice into what 
specific consent is required for such analyses. It is possible that due to the use of these 
data these particular studies may only require standard STAMPEDE trial follow-up 
consent, meaning only those withdrawing from the trial would be ineligible for the 
analyses. It is vitally important that trials remain vigilant with such consent data and 
efforts are being made by the trial team to enhance their documentation processes to 
increase integrity. Review of patient consent and enhancing the documentation of this is 
currently underway by the MRC CTU at UCL. 
 
Routine data retention is also a concern; trials require data to be kept for audit 
purposes, often after trial closure. I am currently liaising with the routine data provider 
(PHE) for the BladderPath trial, to agree a length of time that the trial team can keep 
these data, however additional applications for retention can be made. We are currently 
in discussions with PHE to keep the data for ten years, however, during this time it will 
be necessary to apply for data retention. 
 
Summary implications to practice: Other concerns such as linkage, cost, regulations, and 
data retention are limitations to utilising routine data in trials and are widely 
acknowledged (63). These concerns were encountered during the conduct of these 
studies. However, all were resolved in principle, and I therefore believe these concerns, 
previously believed to be barriers, can be overcome. 
 
These limitations reflect why minimal research has been done into the feasibility of 
using routine data as the main source for trial follow-up. However, as described, 
frameworks can be developed to overcome these issues, to enable feasibility. Although I 
believe these studies to have shown great scope in using routine data, there is a 
potential that in practice, such resources are not yet ready for current clinical trial use. 
For example, although data quality has been seen to improve, there is a chance that the 
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quality could remain variable across different trusts and hence, not reduce burden on 
site staff. It is also possible that this technique many not reduce costs and that these 
data cannot be retrieved as soon as required. However, until trials are designed to test 
the feasibility of this, we will not know. 
6.1.2 Routine data trial potential 
There are also many potentials for using routine data to conduct trials (introduction 
section 1.7, table 3). These are discussed in relation to the results presented in this 
thesis. These include the potential of investigating new hypotheses, event validation, 
identifying further events for example, those lost to follow-up (63), reducing burden 
(103), reducing costs (63), and increasing timeliness (63), which all have potential 
impacts on patients, discussed below. 
6.1.2.1 New hypotheses 
New hypotheses not previously possible to answer using standard trial data were 
investigated. In chapter 3 the routine data mitigated the need for cross-study 
comparisons and enabled the new clinical rationale to be investigated using a single 
randomised group. In addition, the routine data outcomes identified in chapter 4 were 
developed with the purpose of answering clinical hypotheses not previously possible 
with standard trial data. These include those such as, investigating time to subsequent 
events. Only the first event is required to be collected by STAMPEDE, so this would 
enable comparisons of subsequent treatment responses. In addition, in chapter 5, the 
routine data enabled us to use a non-randomised population to identify MIBC treatment 
outcomes.  
 
However, due to the limitations of the routine data described above, routine data would 
not be appropriate to answer all new hypotheses. The data restrictions mean that both 
suitable and feasible research questions have to be proposed. For example, I am 
currently working on a project that seeks to investigate cardiovascular events on 
hormone therapy. These events are directly available in these data and thus I assessed 
that routine data analyses would seem a feasible method to undertake this. 
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6.1.2.2 Validation of trial events and identifying events lost to follow-up 
The routine data were also able to validate trial collected events. HES validated 
STAMPEDE neutropenic events (chapter 3) and trial endpoint events (chapter 4). In 
addition, more events could be identified using routine data than were identified using 
the standard trial data. In chapter 3, additional neutropenic events were identified than 
in the trial, confirmed by note review. However, these were events that were not 
required to be collected by the trial. However, in the large analyses a low PPV of HSPC 
events was identified, compared to the HSPC STAMPEDE events. It is proposed that 
many of these events may actually be true positives, missed by the trial. Therefore, I am 
in discussion with the MRC CTU at UCL to confirm a sample of these events for 
verification at individual sites. Further to this, in chapter 4, outcomes were identified 
that were missed by the trial, as confirmed in the note review. Some were missed due to 
loss to follow-up and others due to the requirement for STAMPEDE to only document 
the first outcome. I recommend that any additional routine data identified events, that 
are potentially missed by the trial, should be queried at the individual sites and upon 
confirmation, subsequently be added to update the trial database. It is also possible that 
the proxy model developed in chapter 4 could be used to flag at risk patients, for 
example, those entering a palliative care stage. Therefore, I believe, routine data can be 
used to validate or enhance trial data. 
 
In terms of maximising clinical trial data event collection, I believe that the use of 
routine data detected outcomes to supplement trial detected outcomes is a superior 
method of data collection. Aside from the potential for increased resource use by using 
both methods of collection, I believe that the additional events found by the routine 
data models could be used to enhance outcome collection (once these events have 
been validated at site).  
6.1.2.3 Other 
The benefits of reduced costs, burden and timeliness of collecting events (63) are yet to 
be confirmed upon the acquisition of the BladderPath routine data. However, the 
proposed framework is hypothesised to aid these, when compared to standard patient-




I have presented here studies investigating the feasibility of using routine data to 
identify oncology trial outcomes. I investigated the ability to reduce/replace standard 
follow-up and the use of routine data as the basis of follow-up. One overarching 
limitation to this study was that the algorithms (chapter 3, 4 and 5) were developed 
using small cohort single-site data only. The model in chapter 4 (proxy endpoint) was 
validated, where possible, using multi-site trial data but for chapter 3 (neutropenic 
events study) and 5 (the BladderPath framework) multi-site validation was not possible. 
Where clinical results were presented (chapter 3), these should be interpreted with 
caution, are inconclusive and require further validation. As discussed previously, the 
algorithms may respond differently to data generated from different sites, impacting the 
ability to detect events and therefore the integrity of the algorithms. 
 
If I were to choose one result from this study to present to funders to persuade them to 
use in practice, I would choose figure 38. Although, the novel surrogate endpoint 
developed was only investigating proof-of-concept, I believe that there is potential that 
we may be able to isolate a routine data-based proxy that may correlate with standard 
clinical trial outcomes. I also believe that this may have the biggest impact on patient 
care. The clinical trial framework may be enhanced if events missed using standard 
methods could be identified, if at risk patients could be flagged, if an alternative method 
to collect time-to-event data was available (that may correlate with quality of life) and if 
methods could enable analyses of real-world treatment effects. I believe all of these 
could impact patients directly, hence, I chose this figure. 
 
I believe this study to have shown that routine data are a feasible data source for trial 
follow-up; however, extensive quality control techniques are required. I also believe 
standard trial data collection methods and routinely collected healthcare data to be 
complementary and their symbiotic relationship enables an enhanced trial framework.  
 
I believe that a routine data framework can aid the analyses of new hypotheses, enable 
trial outcome validation and identify outcomes lost to follow-up. Potential implications 
may include: reduced burden on health care professionals and patients (103, 104), 
reduced costs (63, 103), resources (63, 103) and increased timeliness of collecting trial 
events (63). Further potential uses of these data include cross comparing treatments to 
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real world outcomes to identify how treatments behave in a non-trial population. The 
final implication of utilising such techniques would be, enhanced trials, enabling more 
interventions to be available to patients, to enhance length and quality of life. 
6.2 Future work 
Future work is required that was beyond the scope of this thesis. The ‘activity-free 
survival’ (AFS) outcome rules need to be enhanced for use in an alternative setting to 
that in which it was designed. The optimum thresholds and weekly intervals need to be 
re-confirmed. The model may work differently with different classes of treatment; 
hence, further validation is required. I have also discussed with various organisations, 
such as, pharmaceutical companies, universities and hospitals, the validation of the AFS 
outcome in different oncology settings. Also, within the same prostate cancer setting, I 
have discussed testing the model in a low risk (of progression) prostate cancer trial. I am 
currently in discussions with a pharmaceutical company regarding potential projects, 
such as, assessing how the deoxyribonucleic acid (DNA) damage repair status may affect 
the response to chemotherapy, using routine models such as those outlined in this 
thesis. 
 
The model is also planned to be used to answer hypotheses not possible using the 
protocol collected STAMPEDE data, such as response to subsequent treatments. A PhD 
proposal is currently being developed which includes enhancing the algorithm 
developed here and using it to answer other clinical questions. I am having input into 
the research proposal and suggesting various techniques that were sadly beyond the 
timescale of this thesis. These include, additional modelling techniques.  
 
New protocols are currently being written to answer new hypotheses using the routine 
data I acquired. For example, assessing fractures and cardiovascular events whilst on 
abiraterone hormone therapy within the STAMPEDE trial; I am involved with this work.  
 
In addition, the data collection framework, presented in chapter 5, is currently being 
implemented in the BladderPath trial. Hence, the feasibility in practice is yet to be 
determined, including the overall impact on efficiency and costs. The applicability in 




Routinely collected healthcare data are a feasible and potentially useful data source for 
trial conduct. During this proof of principle study, a method was developed to identify a 
novel surrogate endpoint for trial effectiveness studies. I believe this to be the first 
oncology routine data non-survival endpoint developed, and the first instance where 
these outcomes have been used to perform trial treatment effectiveness analyses. In 
addition, I believe this thesis to present a novel framework developed to perform 
oncology trial analyses using routine data as the basis of follow-up. I believe this to have 
not previously been done in an oncology or secondary care setting in the United 
Kingdom (UK).  
 
However, the integrity and clinical feasibility of these models need further validation on 
a trial by trial basis, as many limitations were identified during this proof of principle 
study. Despite this, methods were developed with the aim to overcome these 
limitations, to produce clinically useable tools. I believe routine data have potential to 
increase trial efficiency, with the aim to have access to more patient interventions 
across the whole of healthcare. As routine data continues to improve, perhaps in the 
future routine data led trial follow-up may become the standard. 
 
Finally, can routinely collected data be used to inform randomised controlled trial 
outcomes in oncology? 
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8.1 Chapter three 
















Reason event missed without inferral Chemotherapy identifiable in SACT? 
1 û Chemotherapy HES data missing Prior to SACT collection 
2 û HES event 12 weeks after last HES chemotherapy  - 
3 ü - - 
4 û 
Two instances; HES event 18 weeks after and 102 
weeks before last HES chemotherapy 
- 
5 ü - - 
6 ü - - 
7 ü - - 
8 ü - - 
9 û Chemotherapy HES data missing ü 
10 û Chemotherapy HES data missing Prior to SACT collection 
11 ü - - 
12 û Chemotherapy HES data missing Prior to SACT collection 
13 û HES event 40 weeks after last HES chemotherapy - 
14 ü - - 
15 ü - - 
16 ü - - 
17 û Chemotherapy HES data missing ü 
18 û Chemotherapy HES data missing ü 
19* ü* - - 
20* ü* - - 
21* ü* - - 
22* ü* - - 
 
Table 78: The 22 patients that experienced a neutropenic event identified using the HES algorithm 
with inferral. Whether or not the algorithm could identify these events without inferral is also 
present. The reason for the missing data is also described, including whether the chemotherapy 
data could be identified using the SACT data.  
* = Occurring at HSPC. If not specified, then the event occurred at CRPC; û = missed; ü = 
identified. 
8.1.3 PHE application 
  
287 








                    
 
 290 
Figure 46: Project summary and data specification excerpt from the PHE application that I 
completed for the STAMPEDE routine data. 
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Figure 47: Copy of the document of the variables provided by PHE, upon application. 
 
8.2 Chapter four 
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8.2.5 Outcome analyses 
Event Detection 
Progression outcome (weeks) 
Routine data model output Note review 






midpoint  Event date 
Interval 
midpoint  Threshold 6 episodes Threshold 5 episodes 
1 Bone scan Missed Missed [8,16) 12 16 20 Y 
2 Bone scan [64-72) 68 [64-72) 68 66 68 N 
3 Bone scan [96-104) 100 [96-104) 100 102 100 Y 





[136-144) 140 [136-144) 140 138 140 Y 
6 SRE - radiotherapy [216-224] 220 [216-224] 220 218 220 Y 
7 MRI scan [8-16) 12 [8-16) 12 11 12 Y 
8 Bone scan [16-24) 20 [16-24) 20 17 20 Y 
9 CT scan [32-40) 36 [32-40) 36 36 36 Y 
10 Bone scan [96-104) 100 [96-104) 100 92 92 Y 
11 MRI [128-136) 132 [128-136) 132 118 116 N 
12 Bone scan [152-160) 156 [152-160) 156 154 156 N 
13 MRI [176-184) 180 [176-184) 180 166 164 N 
 
Table 85: Comparative analyses for the five and six event thresholds for the routine data model, 
compared to the note review (also grouped into the corresponding 8-week interval) and the 
STAMPEDE trial.  
 
Event 
Difference routine data 






data midpoint & 




Threshold = 6 events Threshold = 5 events 
1 NA NA -4 -1 
2 2 0 2 0 
3 -2 0 -2 0 
4 -4 -1 -4 -1 
5 2 0 2 0 
6 2 0 2 0 
7 1 0 1 0 
8 3 0 3 0 
9 0 0 0 0 
10 8 1 8 1 
11 14 2 14 2 
12 2 0 2 0 
13 14 2 14 2 
 
Table 86: The difference in the model detected-events (shown in table 85) and the note review 


























































































































































































































Table 87: Table calculating the accuracy of the routine data to identify SREs. RT = radiotherapy; SCC = spinal cord com
pression; Blue = note review
, HES and trial data; 
yellow
 = note review
 and HES; green = note review





Data/Outcome Non-chemotherapy arms, ABDF (n/N) (%) 
Chemotherapy arms, 
CE (n/N) (%) 
Note review PFS 24/29 (83%) 9/15 (60%) 
STAMPEDE PFS 19/29 (66%) 5/15 (33%) 
STAMPEDE MFS 19/29 (66%) 6/15 (40%) 
STAMPEDE FFS 24/29 (83%) 9/15 (60%) 
HES AFS 21/29 (72%) 6/15 (40%) 
SREs 
STAMPEDE SRE 13/29 (45%) 5/15 (33%) 
HES SRE 5/29 (17%) 2/15 (13%) 
 
Table 88: The number of cohort two outcomes detected, split by treatment, for each endpoint. 
n = total number of events; N = total number of patients. 
 
Data/Outcome Non-chemotherapy arms, ABDF (n/N) (%) 
Chemotherapy 
arms, CE (n/N) (%) 
STAMPEDE PFS 46/62 (74%) 10/31 (32%) 
STAMPEDE MFS 44/62 (71%) 12/31 (39%) 
STAMPEDE FFS 50/62 (81%) 17/31 (55%) 
HES AFS 50/62 (81%) 16/31 (52%) 
SREs 
STAMPEDE SRE 27/62 (44%) 7/31 (23%) 
HES SRE 11/62 (18%) 4/31 (13%) 
 
Table 89: The number of cohort three outcomes detected, split by treatment, for each endpoint. 





standard-of-care arms, A 
(n/N) (%) 
Chemotherapy 
arms, CE) (n/N (%) 
STAMPEDE PFS 417/855 (48.8%) 337/840 (40.1%) 
STAMPEDE MFS 400/855 (46.8%) 348/840 (41.4%) 
STAMPEDE FFS 567/855 (66.3%) 461/840 (54.9%) 
HES AFS 439/855 (51.3%) 394/840 (46.9%) 
SREs 
STAMPEDE SRE 249/855 (29.1%) 162/840 (19.3%) 
HES SRE 189/855 (22.1%) 134/840 (16.0%) 
 
Table 90: The number of cohort four outcomes detected, split by treatment, for each endpoint. 




8.2.8 SRE scatter plot 
 
Figure 49: A scatter plot of the correlation between the HES detected SREs and the STAMPEDE 
detected SREs. 
Includes only patients where a HES outcome and a STAMPEDE outcome were both identified. The 
black line through the origin is a line to illustrate perfect correlation.  
8.3 Chapter five 
8.3.1 Time to correct treatment (TTCT) event coding 
Flexible cystoscopy 
M459 Unspecified diagnostic endoscopic examination of bladder 
Rigid cystoscopy (TURBT) 
M421 Endoscopic resection of lesion of bladder 
Surgery to bladder 
M341 Cystoprostatectomy 
M342 Cystourethrectomy 
M343 Cystectomy NEC 
M344 Simple cystectomy 
M348 Other specified total excision of bladder 
M349 Unspecified total excision of bladder 
M358 Other specified partial excision of bladder 
M359 Unspecified partial excision of bladder 
X141 Total exenteration of pelvis 
X142 Anterior exenteration of pelvis 
X148 Other specified clearance of pelvis 
X149 Unspecified clearance of pelvis 
Radiotherapy: Radiotherapy planning 
X671 Preparation for intensity modulated radiation therapy 
X672 Preparation for total body irradiation 
X673 Preparation for hemi body irradiation 
X674 Preparation for simple radiotherapy with imaging and dosimetry 
X675 Preparation for simple radiotherapy with imaging and simple calculation 
X676 Preparation for superficial radiotherapy with simple calculation 
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X677 Preparation for complex conformal radiotherapy 
X678 Other specified preparation for external beam radiotherapy 
X679 Unspecified preparation for external beam radiotherapy 
Y921 Technical support for preparation for radiotherapy 
Y928 Other specified support for preparation for radiotherapy 
Y929 Unspecified support for preparation for radiotherapy 
Radiotherapy delivery 
Y902 Radiotherapy NEC 
X651 Delivery of a fraction of total body irradiation 
X652 Delivery of a fraction of intracavitary radiotherapy 
X653 Delivery of a fraction of interstitial radiotherapy 
X654 Delivery of a fraction of external beam radiotherapy NEC 
X658 Other specified radiotherapy delivery 
X659 Unspecified radiotherapy delivery 
Radiotherapy type 
Y911 Megavoltage treatment for complex radiotherapy 
Y912 Megavoltage treatment for simple radiotherapy 
Y913 Superficial or orthovoltage treatment for radiotherapy 
Y914 Megavoltage treatment for adaptive radiotherapy 
Y915 Megavoltage treatment for hypofractionated stereotactic radiotherapy 
Y918 Other specified external beam radiotherapy 
Y919 Unspecified external beam radiotherapy 
Chemotherapy: Chemotherapy procurement 
X701 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 1 
X702 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 2 
X703 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 3 
X704 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 4 
X705 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 5 
X708 Other specified procurement of drugs for chemotherapy for neoplasm in Bands 1-5 
X709 Unspecified procurement of drugs for chemotherapy for neoplasm in Bands 1-5  
X711 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 6 
X712 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 7 
X713 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 8 
X714 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 9 
X715 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 10 
X718 Other specified procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
X719 Unspecified procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
Chemotherapy delivery 
X352 Intravenous chemotherapy 
X373 Intramuscular chemotherapy 
X384 Subcutaneous chemotherapy 
X721 Delivery of complex chemotherapy for neoplasm including prolonged infusional treatment at 
first attendance 
X722 Delivery of complex parenteral chemotherapy for neoplasm at first attendance 
X723 Delivery of simple parenteral chemotherapy for neoplasm at first attendance 
X724 Delivery of subsequent element of cycle of chemotherapy for neoplasm 
X728 Other specified delivery of chemotherapy for neoplasm 
X729 Unspecified delivery of chemotherapy for neoplasm 
X731 Delivery of exclusively oral chemotherapy for neoplasm 
X738 Other specified delivery of oral chemotherapy for neoplasm 
X739 Unspecified delivery of oral chemotherapy for neoplasm 
X748 Other specified other chemotherapy drugs 
X749 Unspecified other chemotherapy drugs 




Table 91: The codes used to identify the events to calculate time to correct treatment (TTCT) from 
the routine data. 
8.3.2 Data quality event coding 
Code Value 
Cystoscopy (all) 
M451 Diagnostic endoscopic examination of bladder and biopsy of lesion of bladder NEC 
M452 Diagnostic endoscopic examination of bladder and biopsy of lesion of prostate NEC 
M453 Diagnostic endoscopic examination of bladder and biopsy of lesion of bladder using rigid cystoscope 
M454 Diagnostic endoscopic examination of bladder and biopsy of lesion of prostate using rigid cystoscope 
M455 Diagnostic endoscopic examination of bladder using rigid cystoscope 
M458 Other specified diagnostic endoscopic examination of bladder 
M459 Unspecified diagnostic endoscopic examination of bladder 
M421 Endoscopic resection of lesion of bladder 
M422 Endoscopic cauterisation of lesion of bladder 
M423 Endoscopic destruction of lesion of bladder NEC 
M428 Other specified endoscopic extirpation of lesion of bladder 
M429 Unspecified endoscopic extirpation of lesion of bladder 
M411* Open extirpation of lesion of bladder 
M448 Other specified other therapeutic endoscopic operations on bladder 
BCG 
M494 Introduction of therapeutic substance into bladder 
M495 Injection of therapeutic substance into bladder wall 
E952 Administration of Bacillus Calmette-Guerin vaccine 
X448 Other specified administration of vaccine 
X449 Unspecified administration of vaccine 
M479 Unspecified urethral catheterisation of bladder (only in combination with the below) 
M479 + X721 Delivery of complex chemotherapy for neoplasm including prolonged infusional treatment at first attendance 
M479 + X722 Delivery of complex parenteral chemotherapy for neoplasm at first attendance 
M479 + X723 Delivery of simple parenteral chemotherapy for neoplasm at first attendance 
M479 + X724 Delivery of subsequent element of cycle of chemotherapy for neoplasm 
M479 + X728 Other specified delivery of chemotherapy for neoplasm 
M479 + X729 Unspecified delivery of chemotherapy for neoplasm 
M479 + X748 Other specified other chemotherapy drugs 
M479 + X749 Unspecified other chemotherapy drugs 
Surgery to bladder 
M341 Cystoprostatectomy 
M342 Cystourethrectomy 
M343 Cystectomy NEC 
M344 Simple cystectomy 
M348 Other specified total excision of bladder 
M349 Unspecified total excision of bladder 
M358 Other specified partial excision of bladder 
M359 Unspecified partial excision of bladder 
M418 Other specified other open operations on bladder 
M419 Unspecified other open operations on bladder 
M488 Other specified operations on bladder 
M489 Unspecified operations on bladder 
M498 Other specified other operations on bladder 
M499 Unspecified other operations on bladder 
X141 Total exenteration of pelvis 
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X142 Anterior exenteration of pelvis 
X148 Other specified clearance of pelvis 
X149 Unspecified clearance of pelvis 
Radiotherapy 
Radiotherapy planning 
X671 Preparation for intensity modulated radiation therapy 
X672 Preparation for total body irradiation 
X673 Preparation for hemi body irradiation 
X674 Preparation for simple radiotherapy with imaging and dosimetry 
X675 Preparation for simple radiotherapy with imaging and simple calculation 
X676 Preparation for superficial radiotherapy with simple calculation 
X677 Preparation for complex conformal radiotherapy 
X678 Other specified preparation for external beam radiotherapy 
X679 Unspecified preparation for external beam radiotherapy 
Y921 Technical support for preparation for radiotherapy 
Y928 Other specified support for preparation for radiotherapy 
Y929 Unspecified support for preparation for radiotherapy 
Radiotherapy delivery 
Y902 Radiotherapy NEC 
X651* Delivery of a fraction of total body irradiation 
X652* Delivery of a fraction of intracavitary radiotherapy 
X653* Delivery of a fraction of interstitial radiotherapy 
X654 Delivery of a fraction of external beam radiotherapy NEC 
X658 Other specified radiotherapy delivery 
X659 Unspecified radiotherapy delivery 
Radiotherapy type 
Y911 Megavoltage treatment for complex radiotherapy 
Y912 Megavoltage treatment for simple radiotherapy 
Y913 Superficial or orthovoltage treatment for radiotherapy 
Y914 Megavoltage treatment for adaptive radiotherapy 
Y915 Megavoltage treatment for hypofractionated stereotactic radiotherapy 
Y918 Other specified external beam radiotherapy 
Y919 Unspecified external beam radiotherapy 
Chemotherapy 
Chemotherapy procurement 
X701 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 1 
X702 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 2 
X703 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 3 
X704 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 4 
X705 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 5 
X708 Other specified procurement of drugs for chemotherapy for neoplasm in Bands 1-5 
X709 Unspecified procurement of drugs for chemotherapy for neoplasm in Bands 1-5 
X711 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 6 
X712 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 7 
X713 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 8 
X714 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 9 
X715 Procurement of drugs for chemotherapy for neoplasm for regimens in Band 10 
X718 Other specified procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
X719 Unspecified procurement of drugs for chemotherapy for neoplasm in Bands 6-10 
Chemotherapy delivery 
X352 Intravenous chemotherapy 
X373* Intramuscular chemotherapy 
X384* Subcutaneous chemotherapy 
X721 Delivery of complex chemotherapy for neoplasm including prolonged infusional treatment at first attendance 
X722 Delivery of complex parenteral chemotherapy for neoplasm at first attendance 
X723 Delivery of simple parenteral chemotherapy for neoplasm at first attendance 
X724 Delivery of subsequent element of cycle of chemotherapy for neoplasm 
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X728 Other specified delivery of chemotherapy for neoplasm 
X729 Unspecified delivery of chemotherapy for neoplasm 
X731* Delivery of exclusively oral chemotherapy for neoplasm 
X738* Other specified delivery of oral chemotherapy for neoplasm 
X739* Unspecified delivery of oral chemotherapy for neoplasm 
X748 Other specified other chemotherapy drugs 
X749 Unspecified other chemotherapy drugs 
Y123* Electrochemotherapy to lesion of organ NOC 
Chemotherapy (other) 
X358 Other specified other intravenous injection 
X292 Continuous intravenous infusion of therapeutic substance NEC 
X293* Continuous subcutaneous infusion of therapeutic substance NEC 
X298 Other specified continuous Infusion of therapeutic substance 
X299 Unspecified continuous Infusion of therapeutic substance 
X281 Intermittent intravenous infusion of therapeutic substance 
X282* Intermittent subcutaneous infusion of therapeutic substance 
X288 Other specified intermittent infusion of therapeutic substance 
X289 Unspecified intermittent infusion of therapeutic substance 
X308 Other specified injection of therapeutic substance 
X309 Unspecified injection of therapeutic substance 
X391* Oral administration of therapeutic substance 
X398* Other specified other route of administration of therapeutic substance 
X399* Unspecified other route of administration of therapeutic substance 
X353* Intravenous immunotherapy 
X374* Intramuscular immunotherapy 
X385* Subcutaneous immunotherapy 
Last follow-up censor event (attended inpatient or outpatient event) 
101 Urology 
370 Medical oncology 
800 Clinical oncology 
 
Table 92: Codes identified by the algorithm to detect events for the data quality validation.  
(* included to identify miscoded procedures). 
 
 
A: Word count tables, figures, captions: 16,927 
B: Appendix word count: 4,595 
C: Reference word count: 6,224 
D: Total word count: 92,931 
 
Final word count (exclusive of appendices, figures/tables, captions and references but 
inclusive of all pre-text, in-text reference numbering and caption cross-references) 
D – (A + B + C) = 92,931 – (16,927 + 4,595 + 6,224 = 27,746): 65,185 
 
 
